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ABSTRACT 
Cordelia Johnson Barrick: MODELING THE CONSEQUENCES OF EPIDERMAL 
GROWTH FACTOR RECEPTOR INHIBITION ON CARDIAC DEVELOPMENT, 
FUNCTION, AND HOMEOSTASIS  
(Under the direction of David Threadgill) 
The epidermal growth factor receptor (EGFR/ERBB1) is the prototypical and first discovered 
member of the ERBB family of receptor tyrosine kinases. As transmembrane receptors, their 
primary function is to translate extracellular signals into cellular response. Signaling is 
initiated through binding by members of the EGF ligand family, which induces receptor 
homodimerization or heterodimerization with other ERBB receptors (ERBB2, ERBB3 or 
ERBB4). Activation of downstream cytoplasmic signaling pathways occurs, leading to 
alterations in biological responses such as cellular proliferation, survival, motility, and 
adhesion. As EGFR is expressed in most developing and adult tissues, misregulation or 
dysfunction of EGFR activity severely impacts embryonic viability, tissue maintenance and 
multiple disease processes.  Since EGFR was first proposed as a cancer drug target over 
twenty years ago, substantial research has defined a central role for aberrant ERBB signaling 
in cancer and led to the design of targeted therapies that effectively inhibit receptor activity.  
However, significant cardiotoxicity was observed in clinical trials targeting the closely 
related ERBB2 receptor, necessitating further studies on the role of ERBB signaling in 
cardiac development and function. Genetic ablation of any of the ERBB receptors, select 
ligands, or ligand-processing enzymes results in severe congenital cardiac defects, often 
causing embryonic lethality. Direct stimulation of ERBB2/ERBB4 heterodimers by the 
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ligand neuregulin-1 (NRG1) supports cardiomyocyte survival, while GPCR mediated 
transactivation of EGFR likely plays a significant role in cardiac hypertrophy and 
hypertension. These discoveries have fostered interest in novel therapies targeting the EGFR 
signaling pathway for the treatment of several common cardiovascular diseases. However, 
the effects of chronic EGFR inhibition on cardiovascular homeostasis have not been 
evaluated. Through the use of mouse models, we demonstrated that genetic or 
pharmaceutical repression of EGFR signaling significantly altered cardiac function and 
homeostasis. Since the cardiac phenotype of mice harboring a hypomorphic mutation in Egfr 
was strongly dependent on genetic background, we broadly localized quantitative trait loci 
(QTL) which modulate the cardiac phenotype. These studies should be useful in predicting 
degenerative cardiac changes associated with EGFR inhibition which may be overlooked in 
short term clinical trials, and may advance understanding of the role of EGFR in cardiac 
development and function.  
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CHAPTER 1 
THE ROLES OF EGFR/ERBB1 SIGNALING IN CARDIAC DEVELOPMENT AND 
DISEASE 
Abstract 
The epidermal growth factor receptor (EGFR/ERBB1) is the prototypical and first 
discovered member of the ERBB family of receptor tyrosine kinases. As transmembrane 
receptors, their primary function is to translate extracellular signals into cellular response. 
Signaling is initiated through by members of the EGF ligand family, which induces receptor 
homodimerization or heterodimerization with other ERBB receptors (ERBB2, ERBB3 or 
ERBB4). Activation of downstream cytoplasmic signaling pathways occurs, leading to 
alterations in biological responses such as cellular proliferation, survival, motility, and 
adhesion. As EGFR is expressed in most developing and adult tissues, misregulation or 
dysfunction of EGFR activity severely impacts embryonic viability, tissue maintenance and 
multiple disease processes.  Since EGFR was first proposed as a cancer drug target over 
twenty years ago, substantial research has defined a central role for aberrant ERBB signaling 
in cancer and led to the design of targeted therapies that effectively inhibit receptor activity.  
However, a major side effect on cardiac function was observed, necessitating further studies 
on the role of ERBB signaling in cardiac development and function. Genetic ablation of any 
of the ERBB receptors, select ligands, or ligand-processing enzymes results in severe 
congenital cardiac defects, often causing embryonic lethality. Direct stimulation of 
ERBB2/ERBB4 heterodimers by the ligand neuregulin-1 (NRG1) supports cardiomyocyte 
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survival, while GPCR mediated transactivation of EGFR likely plays a significant role in 
cardiac hypertrophy and hypertension. These discoveries have fostered interest in novel 
therapies targeting the EGFR signaling pathway for the treatment of common cardiovascular 
diseases. However, the effects of chronic EGFR inhibition on cardiovascular homeostasis 
have not been evaluated. Here, we review current research in ERBB signaling in cardiac 
development and disease, with particular emphasis on EGFR signaling. Through the use of 
mouse models, we demonstrate that genetic or pharmaceutical reduction of EGFR activity 
results in significant alterations in cardiac development and homeostasis; moreover the 
severity of these alterations is modified by genetic background. Genetic mapping studies also 
identify loci conferring susceptibility to EGFR-related degenerative cardiac pathology. 
Together, these studies should be useful in predicting degenerative cardiac changes 
associated with EGFR inhibition which may be overlooked in short term clinical trials.  
Introduction 
The EGFR (HER1) is the prototypical and first discovered member of the 
ERBB/HER family of membrane receptors, which also includes ERBB2/HER2, 
ERBB3/HER3 and ERBB4/HER4 [2].  These receptor tyrosine kinases have a conserved 
molecular structure with an extracellular, cysteine-rich ligand-binding domain, a single 
alpha-helix transmembrane domain and an intracellular domain with tyrosine kinase (TK) 
activity in the carboxy-terminal tail (except for ERBB3/ HER3) [3]. Ligand binding by 
members of the epidermal growth factor (EGF) family induces homodimerization or 
heterodimerization with other ERBB receptors, resulting in tyrosine kinase activity [4]. 
Subsequently, autophosphorylation or transphosphorylation of tyrosine residues in the 
carboxy-terminal tail directs binding for adaptor proteins and signaling molecules [5]. The 
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net result of intracellular signaling cascades is altered biological processes, including 
proliferation, differentiation, motility and survival [3]. 
The ERBB signaling pathway is complex and strongly associated with other central 
intracellular and extracellular signaling pathways [6, 7]. In addition to EGF [8], there are ten 
additional known ligands which bind to ERBB homo and heterodimers with differing degrees 
of preference, including transforming growth factor-α (TGF-α) [9], amphiregulin (AREG) 
[10, 11], diphtheria toxin receptor/ heparin-binding, EGF-like growth factor (HB-EGF/DTR) 
[12], betacellulin (BTC) [13, 14], epiregulin (EREG) [15], epigen (EPG) [16], and 
neuregulins (NRG1-4) [17-19].  As illustrated in Figure 1-1, EGF, TGF-α, and AR show 
specificity to EGFR, and HB-EGF/DTR, EPR and BTC bind to both EGFR and ERBB4. 
NRG1 and NRG2 bind to both ERBB3 and ERBB4, while NRG3 and NRG4 are specific to 
the ERBB4 receptor. Adding to the complexity, ERBB2 has no known ligand but enhances 
and stabilizes dimerization with other ERBBs, while ERBB3 is catalytically inactive [20-23].  
Receptor homodimer or heterodimer combinations induce phosphorylation of unique tyrosine 
sites which in turn serve as docking sites for specific SH-2 adaptor proteins that initiate 
intracellular signaling cascades. The Ras- and Shc-activated mitogen-activated protein kinase 
(MAPK) pathway is a target of all ERBB receptors, while the PI(3)K-activated AKT and 
p70S6K/p85S6K pathways are downstream of only some ERBB dimers [7].  Activation of 
signaling networks translates in the nucleus into distinct transcriptional programs involving 
the proto-oncogenes FOS, JUN and MYC, and several transcription factors, including SP1 and 
EGR1.  An additional control of biological outcomes is signal duration. The kinetics of signal 
termination is dependent upon ligand-mediated receptor endocytosis and receptor 
composition [7]. 
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Cross activation by other receptor families also contributes to ERBB signaling 
intricacy. For example, members of the G protein coupled receptor superfamily (GPCR) 
transactivate EGFR via metalloproteinase activation and subsequent cleavage and 
extracellular release of EGF-like ligands [24]. This is thought to be how GPCR agonists, 
such as angiotensin II (ANG-II), endothelin-1 (ET-1) and thrombin elicit growth effects via 
activation of the MAPK pathway, circumventing the lack of intrinsic tyrosine kinase activity 
of their cognate receptors [25, 26]. Recently, it was proposed that in the heart, ERBB2 forms 
a heterocomplex with GPCRs in a ligand-dependent fashion, leading to a direct activation of 
MAPK signaling [27]. 
ERBB signaling in cardiac development, function and homeostasis. Gene targeting 
studies in mice demonstrate that all four ERBB receptors, select ligands and ligand-
processing enzymes are required for normal cardiac development (summarized in Table 1-1).  
Mice lacking Erbb2, Erbb4, and Nrg1 all die around 10.5 days post-coitus (dpc) primarily 
due to defects in cardiomyocyte development [28-30]. While Erbb3 -/- mice have normal 
cardiomyocyte development,  defective cardiac valve formation and function results in 
embryonic lethality by 13.5 dpc [31]. Mice nullzygous for Egfr show strain-dependent 
lethality varying from early pre-implantation to three weeks after birth [32-34].  On the CD-1 
background, which supports survival to term, Egfr null mice have cardiac valve enlargement 
in addition to severe neurological and gastrointestinal defects [35, 36].  Of the ten known 
ligands, only genetic ablation of Nrg1 or Dtr/Hb-egf affects cardiovascular development. The 
precursor, membrane-bound form of DTR is cleaved by members of the “α disintegrin and 
metalloprotease” [37] family of convertases, resulting in the shedding of soluble HB-
EGF/DTR which can bind and activate EGFR and ERBB4 homodimers as well as ERBB2/3 
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heterodimers. Dtr/Hb-egf -/- mice exhibit severe defects in heart chamber and valve formation 
[35, 38], while mice lacking members of the ADAM family (tumor necrosis factor-alpha 
converting enzyme (TACE) or ADAM19) show similar valve phenotypes [1, 35]. 
Homozygous deletion of other ligands individually, or even combined Egf/Areg/Tgf-
α deletion, does not result in embryonic lethality or cardiovascular defects, suggesting 
significant signaling pathway redundancy in development [39, 40]. Cumulatively, these 
knock-out models suggest distinct, chronological roles of ERBB receptors and ligands during 
cardiovascular development, with NRG-1-ERBB2/4 signaling being of central importance in 
cardiomyocyte development and maturation, while DTR/HB-EGF and/or NRG-1 activation 
of EGFR, ERBB3 (and possibly ERBB2) being central to normal cardiac valve development.  
In order to define these roles in context, a brief outline of cardiac development follows. 
Outline of heart development: 
A. Cardiac crest formation. At approximately 7 days post-coitus (dpc) in the mouse, 
cardiac progenitor cells derived from the mesoderm and neural crest migrate towards the 
anterior and anterio-lateral portion of the embryo to form the “cardiac crescent” or 
primary heart field. Specification of the myocardial and endocardial cell lineages occurs 
during this stage (Figure 2A) [41]. 
B. Formation of the primitive heart tube. By 8.0 dpc in the mouse, the cardiac crescent 
has fused at the ventral midline to form a heart tube, consisting of an incomplete outer 
layer of myocardium and an inner lining of endocardial cells separated by an extensive 
extracellular matrix (ECM) referred to as the cardiac jelly (Figure 1-2B). At this stage, 
the forming heart is centrally located within the embryo and is bilaterally symmetrical. 
Marking studies have shown that the base of the tube is destined to give rise to the atria, 
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the middle region will give rise to a common ventricle, and the conus truncus, with 
contributions from a secondary heart field, will give rise to the outflow tract of the heart 
[41]. 
C. Cardiac looping. A crucial remodeling process of the heart tube known as cardiac 
looping occurs during 8.5-10.5 dpc in the mouse (Figure 1-2C). This positions the atrial 
region of the tube posterior to the common ventricle, setting the stage for the formation 
and maturation of the four chambers as well as establishment of separate pulmonary and 
systemic circulation (Figure 1-2C). 
D.  Cardiac maturation. Maturation of the heart occurs in multiple stages: (1) formation 
of trabeculated myocardium, (2) formation of endocardial cushions (ECC), which 
contribute to septation of the heart and cardiac valves and (3) compaction of the spongy 
myocardium coinciding with establishment of the coronary circulation. Ventricular 
trabeculation, whereby myocardial cells are activated by endocardium-derived signals to 
proliferate and invade the interior of the cardiac chambers, begins soon after right 
forward looping of the heart tube (Figure 1-2D). This process serves primarily as a 
means to increase myocardial oxygenation in the absence of coronary circulation and is 
necessary for circulation in the early stages of cardiac morphogenesis. Coinciding with 
ventricular septation, trabeculae start to compact at their base adjacent to the outer 
compact myocardium, adding to its thickness (beginning at Figure 1-2E). In the mouse, 
this process is fairly rapid, occurring between 13 and 14 dpc with the establishment of 
coronary circulation.[42]Non-compaction of the myocardium, even in small localized 
regions of the ventricular wall, results in serious functional consequences and is 
associated with heart failure and sudden cardiac death [43]. 
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E. Cardiac valve development. Formation of the endocardial cushion (ECC) tissues is 
extremely important for cardiac morphogenesis, as they provide the “glue” for virtually 
all of the septal structures in the heart [42]. Dysmorphogenesis of the ECC or failure of 
proper fusion are generally thought to play a major role in the etiology of congenital 
heart defects [43]. ECC formation is characterized by endothelial-mesenchymal 
transdifferentiation (EMT), where a subset of endocardial cells in the cushion-forming 
regions delaminates and invades the cardiac jelly shortly after cardiac looping (Figure 1-
3A). These cells proliferate and complete their differentiation into mesenchymal cells, 
forming cushions that subsequently give rise to the septa of the four-chambered heart as 
well as the cardiac valves. ECC formation is complete by 12.5 dpc in the mouse, and is 
followed by a valvular remodeling stage in which cell proliferation ceases and apoptosis 
increases, together remodeling the cushions into slender valve leaflets by 15.5 dpc. In 
normal mouse and human cardiac valve development, cell proliferation is significant 
during cushion development, decreases significantly during late embryonic development 
and early postnatal life (coinciding with valve remodeling), and is undetectable in adult 
valves [44]. 
Proportional valve growth after birth is largely attributable to increased ECM 
production. Stratification of the ECM into three overlapping layers also begins in valve 
remodeling stages but is not complete until postnatal life. In aortic valves, the arterial 
aspect of the cusp (fibrosa) is composed predominantly of collagen fibers; the central 
aspect (spongiosa) consists largely of loosely arranged proteoglycans; while the 
ventricular aspect (ventricularis) contains elastin fibers [44]. Defective stratification and 
8 
 
degeneration of these layers is a pathological characteristic of congenital and acquired 
aortic stenosis (AS) which has profound consequences on valve function.  
ERBB signaling and cardiac development. ERBB signaling is particularly important in 
mid-to late gestational cardiac processes, particularly in cardiomyocyte trabeculation and 
cardiac valve development, both of which depend upon reciprocal signaling between 
endocardial cells, ECM and cardiomyocytes to regulate cellular proliferation, differentiation 
and invasion.  As mentioned previously, mice lacking ERBB2, ERBB4, and NRG1 die 
around 10.5 dpc, primarily due to reduced blood flow resulting from a lack of ventricular 
trabeculae [28-30].  In wild-type 9.5/10.5 dpc embryos, ERBB2 and ERBB4 expression is 
specific to developing cardiomyocytes, whereas NRG is localized to the endocardium.  
Although ERBB2 is the preferred dimerization partner for ERBB3 and ERBB4 upon NRG 
stimulation, ventricular trabeculation is relatively normal in Erbb3-/- mice [31]. Since neither 
ERBB2 nor ERBB4 can compensate for the loss of the other receptor in the heart, cardiac 
NRG-1 signaling likely requires ERBB2/4 heterodimers.   Moreover, genetic rescue of 
Erbb2-/- and Erbb4-/- embryos by myocardial expression of Erbb2 or Erbb4 cDNA under the 
control of cardiac specific promoters circumvents cardiac defects and embryonic lethality 
[45, 46]. These data are consistent with a paracrine model whereby NRG1 is released by 
endocardial cells, diffuses through the cardiac jelly and activates ERBB2/4 receptors 
localized on cardiomyocytes, thus triggering proliferation and invasion to form ventricular 
trabeculae. 
During cardiac development, ERBB3 expression appears to be restricted to 
endocardial cushion mesenchyme [30]. Embryos lacking ERBB3 have thinned ECC 
completely lacking mesenchymal cells. These defects lead to significant blood reflux and 
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lethality at 13.5 dpc due to inability to sustain cardiac function [31]. While ERBB3 on its 
own lacks biological activity, NRG-1 activation of ERBB2/3 heterodimers generates a potent 
signal [47]. Although not as severe as the Erbb3 -/- phenotype, Nrg1-/- or Erbb2 -/-embryos 
also have underdeveloped ECC at 10.5 dpc, suggesting that NRG1-ERBB2/3 signaling plays 
a role in early stages of cellular proliferation and differentiation in ECC formation.  Recent 
work has uncovered additional modulators of ERBB3 activity in this developmental context. 
The extracellular matrix component hyaluronic acid appears to regulate ERBB2/3 signaling 
during cushion formation, while the transcription factors GATA binding protein 4 (GATA-4) 
and SRY (sex determining region Y)-box 9 (SOX9) are upstream mediators of ERBB3 
expression in differentiated mesenchymal cells [48-50]. 
EGFR signaling and cardiac development. Mice lacking EGFR, its ligand DTR/HB-EGF 
or the convertases TACE or ADAM19,  have enlarged, hyperplastic cardiac valves [1, 35, 36, 
38]. While these mutant embryos exhibit enlargement of all four cardiac valves, embryos 
homozygous for the hypomorphic waved-2 mutation have hyperplastic semilunar (SL, i.e. 
aortic and pulmonic) valves, suggesting there is greater requirement for EGFR signaling in 
SL valve development [35, 36]. Exposure to EGFR inhibitors or knockdown of Egfr 
expression in developing zebrafish results in a narrowed outflow tract, ventricular and atrial 
enlargement, and decreased circulation, suggesting that the cardiac phenotype resulting from 
disrupted EGFR signaling is conserved across species [51]. 
  Cardiac cushions form normally in Dtr/Hb-egf -/-embryos, but are only modestly 
condensed during remodeling stages (12.5-14.5 dpc) and thus remain significantly enlarged 
compared to wild-type controls by 15.5 dpc [35].  Aberrant mesenchymal cell proliferation, 
rather than decreased apoptosis, appears responsible for this phenotype. Egfr-/-  and Tace -/- 
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embryos have similarly enlarged, hyperplastic valves at 15.5 dpc, suggesting that impaired 
remodeling also underlies valve enlargement in these mutants [35].    During the valve 
remodeling stage in wild-type embryos,  and TACE expression is detected throughout the 
heart but enriched in cardiac cushions while DTR/HB-EGF is expressed exclusively by the 
endocardial cells lining the developing valves, but not in differentiated mesenchymal cells 
[35, 38]. Additionally, mice with Dtr knocked-out in endothelial and smooth muscle cell 
lineages, or homozygous for an uncleavable form of DTR/HB-EGF, have a similar valve 
phenotype [52, 53]. Together, this strongly suggests a paracrine model where DTR is 
processed and released from the endocardial cells by TACE or ADAM19, diffuses through 
the extracellular matrix, and activates EGFR on invading, differentiating cells to negatively 
regulate proliferation.   
Several findings suggest that signaling through EGFR may counterbalance bone 
morphogenic protein (BMP) signaling to suppress mesenchymal cell proliferation. Genetic 
studies using knockout mouse models established that endocardial outflow track cushion 
growth is largely controlled by the amount of BMP signaling, with diminished and excessive 
signaling correlating to hypo and hyperplastic cushions, respectively [54, 55]. Since the 
enlarged valves of Dtr/Hb-egf -/- embryos have dramatic increases in activated BMP 
signaling effectors SMAD1/5/8 and since EGFR downregulates BMP signaling by 
inactivating SMAD1 in vitro, EGFR activation by TACE-derived soluble DTR may normally 
limit BMP signaling during the transition from cushion formation/growth to valve 
remodeling [46]. Potential binding partners for EGFR in this process include ERBB3 or 
ERBB4 since both are expressed in remodeling valves. Since Erbb4 -/- embryos rescued by 
cardiomyocyte specific ERBB4 expression do not have enlarged valves, while Erbb3 -/- 
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embryos have defective cushion formation, ERBB3 seems a likely heterodimer candidate in 
DTR/EGFR signaling during valve remodeling. 
More recently, phospholipase C epsilon (PLCε), a phosphoinositide-specific 
phospholipase C, was proposed as a downstream effector of EGFR signaling in valve 
remodeling [56]. Mice homozygous for a targeted, inactivating mutation in Plcε (Plcε ΔX/ΔX) 
have hyperplastic semilunar valves, ventricular dilation, aortic stenosis and aortic 
regurgitation. Increased SMAD1/5/8 activity is detected in the remodeling valves of Plcε 
ΔX/ΔX 15.5 dpc embryos. The authors conclude that PLCε may play an important role in 
EGFR-mediated negative regulation of the SMAD1/5/8 activation at a late stage of valve 
remodeling [56]. 
 ERBB signaling in cardiac disease. A role for ERBB signaling in adult cardiac 
homeostasis and heart disease is also emerging. Three of the four receptors (EGFR, ERBB2 
and ERBB4) remain expressed in the adult human and rodent heart; among these ERBB4 
appears to be the most abundant [57-60]. The expression and activity of ERBB2 and ERBB4 
receptors is depressed in clinical and experimentally induced heart failure [61-63] and 
signaling via NRG-1/ERBB2/4 activation is critical for neonatal and adult cardiomyocyte 
survival and growth [57, 64-67]. The importance of this signaling pathway in cardiac 
homeostasis was not fully appreciated until the unexpected cardiotoxicity reported in breast 
cancer clinical trials using trastuzmab (Herceptin, Genetech San Francisco, CA), a 
humanized monoclonal antibody designed to repress ERBB2 activity by blocking the ligand 
binding site [66, 68-70]. While approximately 8% of patients had cardiac changes with 
trastuzmab monotherapy, 30% of patients receiving combinatorial therapy with 
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anthracycline, a commonly used chemotherapeutic drug, developed dilated cardiomyopathy.  
Mouse models with ventricular specific deletion of Erbb2 or Erbb4 have normal cardiac 
development, but progressive postnatal degeneration that mimics the cardiotoxicity observed 
in clinical trials [71-73]. Erbb2 conditional knock out (CKO) mice have up to 70% reduction 
of cardiomyocyte ERBB2 expression, with no alterations in ERBB4 expression. These mice 
develop ventricular dilation, reactivation of embryonic gene expression, increased 
normalized heart weight, and depressed cardiac contractility.  Erbb4 CKO mice have almost 
80%  reduction in ventricular ERBB4 protein levels, no alterations in ERBB2 protein levels, 
and cardiac phenotypes that match Erbb2 CKO mice as well as significant mortality by one 
year of age [73].  Although the authors do not report cardiomyocyte apoptosis in Errb2 or 
Erbb4 CKO hearts, isolated cardiomyocytes from Erbb2 CKO mice display increased 
sensitivity to the anthracycline doxorubicin, consistent with the enhanced cardiotoxicity 
observed with concurrent trastuzmab therapy [72]. In addition, overexpression of the anti-
apoptotic gene Bcl2/1 partially rescues ventricular dilation and contractility in Erbb2 CKO 
mice, suggesting decreased cell survival contributes to cardiac dysfunction.  
Consistent with these results, mice lacking one copy of Nrg1 (Nrg1+/-) have decreased 
survival due to heart failure when exposed to doxorubicin [74].  Cardiomyocyte anti-
apoptotic ERBB signaling involves activation of the serine/threonin kinase AKT, which 
attenuates apoptosis by phosphorylating, and thus inactivating, a variety of pro-apoptotic 
proteins.   Doxorubicin-treated Nrg1 +/- mice have significantly decreased levels of 
phosphorylated ERBB2, AKT, and ERK-1/2 compared to similarly exposed wild type 
controls [74].  Conversely, short term intravenous administration of a recombinant NRG1 
peptide fragment substantially improves cardiac function and survival in multiple cardiac 
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injury models (infarct-, viral-, anthracyline, and pacing models) in rodents and dogs [64].  
Consequently, there is interest in exploiting this pathway as a novel therapy for heart failure 
or as means to prevent chemotherapy-associated cardiotoxicity [75]. 
EGFR signaling in cardiac disease. Signaling through the EGFR has been shown to 
modulate pathological processes underlying common cardiovascular diseases, including 
cardiomyocyte apoptosis and hypertrophy, fibrosis and hypertension [26, 37, 76-79].  In vitro 
studies of isolated cardiomyocytes demonstrate that exposure to EGF increases 
cardiomyocyte contractile frequency [80], while EGF or DTR/HB-EGF induce hypertrophy 
and cardiac fibroblast proliferation [81] [82-84]. On a molecular level, these changes are 
accompanied by increased protein synthesis, MAPK activation and increased transcription of 
early response genes, suggesting that ligand-dependant EGFR activation can directly 
influence cardiac remodeling.  
Several GPCR agonists, such as angiotensin II (ANGII), endothelin-1 (ET-1) and 
thrombin, provoke cardiomyocyte hypertrophy, vascular smooth muscle proliferation, 
vasoconstriction and fibrosis [26, 78, 85-91]. Since GPCRs lack intrinsic tyrosine kinase 
activity, recent work proposes that these receptors “hijack” EGFR activity via activating 
metalloproteases which cleave membrane-bound ligands, and in this manner access 
downstream EGFR-dependent mitogenic pathways [24, 26, 92].  Cardiomyocyte hypertrophy 
induced by over stimulation of the renin-angiotensin (RAS) depends upon GPCR/EGFR 
transactivation [25]. Physiological actions of ANGII are mediated via the angiotensin type 1 
(AT1R) and angiotensin type 2 (AT2R) GPCRs, which are expressed in cardiomyocytes. In 
isolated neonatal cardiomyocytes, overexpression of AT1R stimulates robust hypertrophy 
accompanied by activation of MAPK, induction of the immediate-early response genes and 
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re-expression of atrial natriuretic peptide (ANP) [93].  These responses are blocked in vitro 
by AG-1478, an EGFR inhibitor, or KB-R7785, which inhibits the metalloprotease ADAM12 
[93, 94]. Since treatment with KB-R7785 blocks processing of DTR/HB-EGF and attenuates 
pressure-overload induced hypertrophy in vivo, disruption of GPCR/EGFR transactivation at 
this junction has been proposed as a novel therapy for left ventricular hypertrophy [94]. 
EGFR activation is also cardioprotective against the effects of sustained β-adrenergic 
stimulation and acute stress [79, 95].   Intermale fighting (IF) and restraint-and-cold (4°C) 
exposure (RCE) are two mouse models of intense acute stress. Following IF, but not RCE, 
plasma EGF concentrations increase up to 1,000-fold.  Cardiac necrotic lesions and elevated 
plasma activity of creatine kinase (CK, a biomarker for cardiac injury) are seen with RCE, 
but not IF [79]. Administration of AG-1478 (25mg/kg ip) prior to IF leads to increased 
plasma activities of CK and other biomarkers, while administration of endogenous EGF 
significantly reduces biomarker activity in RCE mice compared to vehicle treated controls. 
Co-administration of AG-1478 and EGF eliminates the cardioprotective effect in RCE mice, 
providing additional evidence that EGFR activation may protect the heart against stress-
induced injury. Activation of EGFR generates a potent survival signal in cardiomyocytes and 
other cell types [37]; conversely, EGFR inhibition enhances apoptosis in normal and 
cancerous epithelial cells [96] and in regenerating tissue [97, 98]. Since prolonged β-
adrenergic stimulation is known to trigger cardiomyocyte apoptosis, these studies suggest 
that chronic EGFR inhibition may exacerbate some types of heart disease. 
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Conclusions 
The EGFR/ERBB1 signaling pathway is complex, intricately intertwined with many 
extracellular and intracellular signaling pathways, and required for normal development and 
homeostasis of most tissues. Genetically engineered mouse models have advanced our 
understanding of ERBB receptor function in cardiac development and predicted 
cardiotoxicity arising from ERBB2/HER2 targeted therapy. The current use of EGFR 
inhibitors for cancer treatment and proposal of novel therapies repressing EGFR activity are 
proposed for cardiovascular diseases necessitates a better understanding of roles of this 
signaling pathway in cardiac development, function and disease.  
Mouse models with genetically reduced EGFR activity resulting from the waved-2 
hypomorphic allele (Egfr wa2) have assisted in defining the role of EGFR in carcinogenesis; 
moreover, phenotypes of Egfr wa2/wa2 mice mimic common side effects observed with EGFR-
targeted therapy [99, 100]. Despite extensive use of this mouse model, congenital valve 
defects and AS were discovered rather recently. Previous studies revealed the severity and 
penetrance of phenotypes associated with EGFR activity are highly dependent upon genetic 
background. To determine if genetic modifiers play a similar role in EGFR-related cardiac 
phenotypes, we backcrossed the mutation onto the commonly used C57BL/6J (B6) and 
129S1/SvImJ (129S1) inbred strains, creating Egfr wa2 congenic lines and an F1 Egfr wa2 
population. Because we found impressive genetic-background-dependent differences in 
cardiac phenotypes associated with congenitally enlarged aortic valves, we designed 
experiments investigating cardiac response to similar afterload in B6, 129S1 and F1 wild-type 
mice. In order to partition EGFR-related congenital defects from effects on cardiac 
homeostasis, we conducted toxicity studies where adult wild-type mice were chronically 
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exposed to EGFR small molecule inhibitors. Finally, to broadly localize genetic modifiers 
which confer susceptibility to EGFR-related cardiac hypertrophy and failure, we conducted 
preliminary genetic mapping experiments. Together, these studies should be useful in 
predicting degenerative cardiac changes associated with EGFR inhibition which may be 
overlooked in short term clinical trials.  
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Figure 1-1. ERBB ligand binding specificity is depicted for the four ERBB receptors. 
Epidermal growth factor (EGF), transforming growth factor alpha (TGF-a), amphiregulin 
(AREG), epiregulin (EREG), betacellulin (BTC), epigen (EPG), and neuregulins 1-4 (NRG1-
4). 
 
 Figure 1-1.  ERBB ligand binding specificity is depicted for the four ERBB receptors. 
Representative ligands are epidermal growth factor (EGF), transforming growth factor alpha 
(TGFα), amphiregulin (AR), epiregulin (EPR), betacellulin (BTC), epigen (EPG), and 
neuregulins 1-4 (NRG1-4). ERBB2 has no known ligand, while ERBB3 has an inactive 
catalytic domain. 
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Table 1-1. Phenotypes resulting from genetic ablation of ERBB receptors, ERBB ligands or 
ligand processing enzymes. 
ERBB receptor Survival Embryonic timepoint 
Cardiovascular 
defect Other defects References 
ERBB1/EGFR Genetic background dependent 
Embryonic, 
perinatal or 
postnatal lethality 
Semilunar valve 
enlargement 
Placental defects 
Eye, pulmonary, skin, 
kidney, brain, liver, 
GI tract 
[32-34] 
HER2/ERBB2 Embryonic lethal E 10.5 Trabeculation defects Nervous system [28] 
HER3/ERBB3 Embryonic lethal E13.5 Hypoplastic cardiac cushions 
Nervous system 
Stomach 
pancreas 
[31, 101] 
HER4/ERBB4 Embryonic lethal E 10.5 Trabeculation defects Nervous system [29] 
EGF ligand Survival Embryonic timepoint 
Cardiovascular 
defect Other defects References 
EGF Normal N/A None reported None [39] 
Amphiregulin (AR) Normal N/A None reported Mammary gland [39] 
TGF-a Normal N/A None reported Skin, eye [102] 
EGF/AR/TGF-a Normal N/A None reported 
Mammary gland, 
growth, 
small intestine 
[39, 40] 
HB-EGF/DTR Peri/postnatal N/A 
Cardiac dilatation 
Valve enlargement 
Skin,  pulmonary, eye [35, 38, 103] 
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EGF ligand 
Survival Embryonic timepoint 
Cardiovascular 
defect Other defects References 
Betacellulin (BTC) Normal N/A None reported None reported [35] 
Epiregulin (ER) Normal N/A None reported Intestinal damage [104] 
Neuregulin (NRG)-1 Embryonic lethal E 10 
Trabeculation 
defects 
Cardiac conduction 
Nervous system [30] 
NRG-2 Normal N/A None reported Growth, reproduction [105] 
Ligand processing Survival Embryonic timepoint 
Cardiovascular 
defect Other defects References 
ADAM17(TACE ) 
Processing of : 
NRG1 and 2, HB-
EGF, TGFα and AR 
Perinatal/postnatal 
[39] 
N/A 
SL and AV valve 
enlargement 
VSD 
Pulmonary [35, 106] 
ADAM19 
Processing of: 
HB-EGF, NRG1, AR 
Perinatal/postnatal N/A 
SL and AV valve 
enlargement 
VSD 
Overriding aorta 
Vasculature defects 
None reported [1] 
    ADAM17/19 Embryonic lethality > E14.5 
Trabeculation 
SL and AV valve 
None reported [106] 
20 
 
Figure 1-2. Developmental stages of heart development. A. Specification of precardiac 
mesoderm and formation of cardiac crescent. B. Fusing of the cardiac mesoderm to form 
linear heart tube. C. Right forward lopping of the heart tube and determination of segments 
giving rise to cardiac chambers and cardiac valves. D. Cardiac looping leads to formation of 
cardiac chambers and outflow tract. An example of an E12.5 embryonic heart is shown 
below (E). F. Later stages of cardiac maturation include remodeling of cardiac cushions to 
form mature valves as well as thickening of the ventricular chamber walls. An example of an 
E14.5 embryonic heart is shown below (G). A, Atria; V, ventricle; CT, conus truncus; SV, 
sinus venous; RA, right atrium; LA, left atrium. Figures adapted from [107, 108]. 
E.                               G. 
A.Cardiac crescent     B. Linear heart tube     C.  Cardiac looping                D.  Cardiac chambers form   E. Cardiac maturation 
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Figure 1-3. Developmental stages of cardiac valve development. A. Formation of the 
endocardial cushions begins when a subpopulation of endocardial cells is activated by signals 
released by  the myocardium to delaminate and invade the underlying cardiac jelly. B. These 
cells differentiate, migrate towards the myocardium and proliferate. C. During remodeling of 
the endocardial cushions, decreased proliferation and increased apoptosis results in mature 
slender valve leaflets. Stratification of the extracellular matrix also occurs.  Molecules within 
the ECM and released from endocardial cells are thought to mediate this process. Figures 
adapted from [107, 108]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.  Cardiac cushion forms                    B. Cells migrate, differentiate, proliferate       C.  Valves remodel          D.  Mature valve leaflet      
invading endocardial cell 
Cardiac jelly  
Myocardium 
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 CHAPTER 2
CARDIAC RESPONSE TO PRESSURE OVERLOAD IN 129S1/SVIMJ AND C57BL/6J 
MICE: TEMPORAL AND BACKGROUND DEPENDENT DEVELOPMENT OF 
CONCENTRIC LEFT VENTRICULAR HYPERTROPHY 
 
Abstract 
 
Left ventricular hypertrophy (LVH), a risk factor for cardiovascular morbidity and 
mortality, is commonly caused by essential hypertension (EH). Three geometric patterns of LVH 
can be induced by hypertension: concentric remodeling, concentric hypertrophy, and eccentric 
hypertrophy. Clinical studies suggest that different underlying etiologies, genetic modifiers, and 
risk of mortality are associated with LVH geometric patterns. Since pressure-overload induced 
LVH can be modeled experimentally using transverse aortic constriction and since C57BL/6J 
(B6) and 129S1/SvImJ (129S1) strains, which have different baseline cardiovascular phenotypes, 
are commonly used, we conducted serial echocardiographic studies to assess cardiac function up 
to eight weeks post-TAC in male B6, 129S1, and B6129S1F1 (F1) mice. B6 mice had earlier 
onset and more pronounced impairment in contractile function, with corresponding LV and RV 
dilatation, fibrosis, change in expression of hypertrophy marker, and increased liver weights at 
five weeks post-TAC. These observations suggest that B6 mice had eccentric hypertrophy with 
systolic dysfunction and right-sided heart failure. By contrast, we found that 129S1 and F1 mice 
delayed transition to decompensated heart failure, with 129S1 mice exhibiting preserved systolic 
function until eight weeks post-TAC, and relatively mild alterations in histology and markers of 
hypertrophy at five weeks post-surgery. Consistent with concentric hypertrophy, our results 
show that these strains manifest different cardiac responses to pressure overload in a time-
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dependent manner and that genetic susceptibility to initial concentric hypertrophy is dominant to 
eccentric hypertrophy. These results also imply that genetic background differences can 
complicate interpretation of TAC studies when using mixed genetic backgrounds. 
Introduction 
Left ventricular hypertrophy (LVH), or increased LV mass, is associated with many 
cardiovascular disorders and is recognized as an independent risk factor for cardiac-related 
morbidity and mortality [1-6].  Although it can be associated with mechanical stress, growth 
factors, catecholamines, cytokines and primary genetic abnormalities, a principle determinant of 
LVH is systemic hypertension. Of the nearly one in three adult Americans who have essential 
hypertension (EH), 20-60% will have evidence of LVH [7]. Moreover, the beneficial effects of 
reversing LVH with anti-hypertensive therapy have been well documented in clinical trials [8-
10]. 
Three patterns of LVH are observed in patients with EH and can be classified according 
to LV mass index (LVMI) and relative wall thickness (RWT, or ratio of diastolic LV posterior 
wall thickness to LV chamber cavity radius): concentric hypertrophy, characterized by an 
increase in both LVMI and RWT, eccentric hypertrophy, characterized by an increase in LVMI 
with normal RWT, and concentric remodeling, characterized by normal LVMI in the setting of 
an increased RWT.  Additionally, some individuals maintain normal LV geometry in the face of 
EH [11].  The geometric pattern of LVH appears to be closely related to LV function and patient 
prognosis, and may be a better predictor of outcome than traditional cardiovascular risk factors 
[12, 13].  LV geometry and LV mass are highly variable among patients with comparable 
systolic blood pressure, environmental and other known predisposing factors, suggesting a 
significant heritable susceptibility to specific geometric patterns of LVH. Recent estimates 
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attribute as much as 60% of the blood pressure (BP)-independent variation in cardiac mass to 
genetic factors; moreover, a significant correlation exists between adjusted relative risk for 
concentric LVH and elevated LVMI with race and ethnic background, suggesting the presence of 
genetic modifiers conferring differential susceptibility to pressure-overload induced LV 
remodeling and LVH [14-18]. Recent studies identifying polymorphisms in genes encoding 
ghrelin, angiotensin converting enzyme, bradykinin B2 receptor, and in genes involved with 
carnitine transport as candidate modifiers of LV remodeling and LVM, further support a strong 
genetic link [19-26]. 
  Surgical transverse aortic constriction [27] in mice causes chronic LV pressure overload, 
progressive LVH remodeling and subsequent cardiac failure, providing an experimental model 
for human cardiac response to systemic hypertension [28-31]. Since its development, the TAC 
model has been used extensively on genetically engineered mice to investigate the role of 
specific genes during the development of LVH and cardiac failure in vivo.  However, there is 
considerable variation in the degree of hypertrophy, LV geometry, and time to heart failure in 
this experimental model [32].  Since many studies use engineered mouse models maintained on 
outbred or mixed genetic backgrounds, genetic variability may contribute to observed phenotypic 
variability [27, 33-35], including cardiac response to TAC.  
C57BL/6J (B6) and 129S1/SvImJ (129S1) inbred mouse strains are some of the most 
widely used strains to generate genetically engineered mice [36-38], with many subsequent 
analyses being done on a mixed B6 and 129
 
genetic background. Since B6 and 129S1 mice have 
different baseline cardiovascular phenotypes [39, 40] and dissimilar response to various 
cardiovascular stressors [41, 42], it is likely that varied combinations of B6 and 129S1 alleles 
will cause divergent cardiac responses to chronic pressure overload.   
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Although several studies have investigated the B6 response to TAC, no comparative 
studies exist using 129S1 and B6129S1F1 (F1) mice. Because of the strain-based variation in 
baseline cardiac phenotypes, we hypothesized that the cardiac response to TAC would also vary 
by genetic background, and that strain-specific genetic modifiers may be a source of variability 
in previous studies on LVH, LV geometry, and cardiac failure. Furthermore, inter-strain 
variability in response to TAC may provide experimental models for different geometric patterns 
of LVH response to hypertension observed in humans. Therefore to identify potential strain-
specific differences in response to TAC, we quantified the effects of pressure overload induced 
by TAC on cardiac morphology, histology, hypertrophy-associated gene expression, and LV 
function in B6, 129S1 and F1 male mice.  We found these strains manifest very different cardiac 
responses to pressure overload, suggesting that genetic background modifiers are important 
determinants of the response to pressure overload, possibly complicating interpretation of TAC 
studies using genetically-engineered mice on mixed genetic backgrounds. Our results also 
identify the 129S1 strain as a model for concentric LVH and indicate that concentric LVH is 
dominant to the eccentric LVH observed in B6 mice. These models will be useful in determining 
how similar cardiac insults can result in very different responses among individuals and for the 
identification of therapeutic strategies for specific geometric patterns of LVH. The results also 
emphasize the importance of using proper genetic controls for studies investigating gene function 
using engineered mouse model
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Materials and Methods 
Animals. Mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Ten-week 
old 129S1/SvImJ (129S1), C57BL/6J (B6), and B6129S1F1 (F1) males were acclimated to 
the local environment for one week, which included housing in ventilated cages with HEPA-
filtered air and Purina 5058 rodent chow provided ad libitum.  
Aortic banding. Pressure overload of the left ventricle was induced by transverse aortic 
constriction [27] of nine mice each from B6, 129S1, and F1 genetic backgrounds, as 
described [29].  The aorta was ligated between the innominate and left common carotid 
arteries by tying a 7-0 silk suture around a tapered 27-gauge needle placed on top of the 
aorta.  33The tapered needle was removed, leaving the suture to produce a defined stenosis of 
the vessel. The skin was closed with separate sutures (6-0 silk) and buprenorphine was 
administered for analgesia. To estimate the load produced by TAC, Doppler velocities were 
measured in the right and left carotid arteries before and after ligation using a hand-held 20 
mHz Doppler probe (Indus Instruments, Houston, Texas).  Work by others has demonstrated 
that the RCA/LCA peak velocity ratio significantly correlates with heart weight after TAC 
and with peak jet across the banding site and can thus be used to estimate the pressure drop 
across the banding site (24). Peak systolic gradients post-TAC were similar among the 
genetic backgrounds (44±10 mmHg, B6 versus 40±12 mmHg, F1 versus 48 ±12 mmHg, 
129S1). Six mice of each genetic background received a sham operation in which the aortic 
arch was isolated and a band was twined around the aorta, but not ligated, and subsequently 
removed. Surgery was also performed on a smaller cohort of mice from each genetic 
background (n = 2-3 sham, 3-5 TAC) to assess cardiac function past eight weeks. 
Echocardiography. Transthoracic echocardiography (TTE) was performed at baseline and at 
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five weeks post-TAC using a 30 mHz probe and the Vevo 660 Ultrasonograph 
(VisualSonics, Toronto, Canada). Mice were lightly anaesthetized with 1-1.5% isofluorane, 
maintaining heart rate at 400-450 beats per minute, and a topical depilatory agent applied, 
before placing in the left lateral decubitus position under a heat lamp to maintain body 
temperature at 37°C. The heart was imaged in the 2D mode in the parasternal long-axis view.  
From this view, an M-mode cursor was positioned perpendicular to the interventricular 
septum and posterior wall of the LV at the level of the papillary muscles. Diastolic and 
systolic LV wall thickness, LV end-diastolic dimensions (LVDD), and LV end-systolic 
chamber dimensions (LVSD) were measured. All measurements were done from leading 
edge to leading edge according to the American Society of Echocardiography guidelines [43]. 
Two dimensional short and long axis views of the left ventricle were obtained. M-mode 
tracings were recorded and used to determine LV end-diastolic diameter (LVED,d), LV end 
systolic diameter (LVED,s), LV posterior wall thickness diastole (LVPWTh,d), and LV 
posterior wall thickness systole (LVPWTh,s), over three cardiac cycles. LV fractional 
shortening was calculated using the formula % FS= (LVED,d-LVED,s)/(LVED,d). LV mass 
was calculated according to uncorrected cube assumptions with some modifications using the 
equation:  
LV mass [44] = 1.055[(LVED,d + LVPWTh,d + LVIVSTh, d)3  (LVED,d)3] [45], where 
1.055 is the gravity of myocardium, LVPWTh,d is diastolic posterior wall thickness, and 
LVIVSTh,d is diastolic ventricular septal thickness.  Stroke volume [46] was estimated by the 
formula SV=(LV, volume d- LV volume,s), and was multiplied by mean HR to estimate cardiac 
output (CO). Percent ejection fraction (%EF) was calculated using the formula %EF= (LV 
volume, d-LV volume s)/(LV volume d). Relative wall thickness (RWT) was approximated using the 
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formula RWT=(LVPWTh,d+LVIVSTh,d)/(LVED,d), where LVIVSTh,d indicates diastolic 
intraventricular septal wall thickness.  Serial TTE under anesthesia was performed on a 
smaller cohort of mice at additional time points (0, 2, 4, 5, 6, and 8 weeks post-surgery; n = 
2-3 sham, 3-5 TAC). Conscious TTE was also performed on a smaller cohort of mice (n = 3 
sham, 5 TAC) at 5 weeks post-TAC. All measurements were made by an independent 
observer with no knowledge of treatment or genetic background. 
Histology.  Mice were weighed, and hearts, lungs, liver, and kidneys were dissected five 
weeks after TAC (n = 6) or sham surgery (n = 4) from mice of each genetic background, 
rinsed in PBS and weighed. Hearts were cut in cross-section just below the level of the 
papillary muscle. The top half of the heart was formalin-fixed and embedded in paraffin.  
Sections (5 μm) were prepared at 200 μm intervals. The sections were stained with 
hematoxylin and eosin (H&E) for examination of gross appearance, while Masson’s 
Trichrome [47] or Periodic Acid-Schiff (PAS-H) counterstained with hematoxylin (PAS-H) 
was employed in order to facilitate quantification of fibrosis and cardiomyocyte size, 
respectively. Cardiomyocyte hypertrophy was assessed by measuring cross-sectional area of 
100 cardiomyocytes per PAS-H stained section in ten randomly selected fields having nearly 
circular capillary profiles and centered nuclei in the left ventricular free wall. Cardiac fibrosis 
was determined by calculating the percent of MT stained area of interstitial fibrosis per total 
area of cardiac tissue. Inflammatory cells were detected using the pan rat anti-mouse 
monoclonal IgG macrophage/monocyte marker MCA519G (clone number MOMA-2) 
(Accurate Chemical, Westbury, New York) followed by biotinylated goat anti-rat IgG 
(Jackson ImmunoResearch, West Grove, Pennsylvania) with visualization using the ABC 
Elite kit (Vector, Burlingame, California). Positively stained cells per cross-section were 
 36 
 
manually counted in three sections per heart. Histological images were analyzed using Nova 
Prime 6.75.10 software (BioQuant Image Analysis, San Diego, California). Blinded 
measurements were made by two independent observers. 
Gene expression. Total RNA was extracted from the lower half of the LV using TRIzol 
(Invitrogen, Carlsbad, California). After DNAse treatment, 500 ng of total RNA was reverse 
transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City , 
California). The expression of α-myosin heavy chain (Myh6), β-myosin heavy chain (Myh7), 
atrial nautriuretic peptide (Nppa), brain nautriuretic peptide (Nppb), and medium chain acyl 
dehydrogenase (Acadm) was determined by real-time quantitaive PCR (qPCR) using Taqman 
Univeral Master Mix and Assays-on Demand primers and probes (Applied Biosystems, 
Foster City, California). β-actin (Actb) was used as an internal control for the results 
presented here; similar results were obtained using beta glucuronidase, (Gusb) as an internal 
control. There were no significant differences by genetic background or treatment in Actb 
expression levels. Reactions were run on a Stratagene MX3000P machine with analysis 
software. Threshold cycles [48] were determined by an in-program algorithm assigning a 
fluorescence baseline based on readings prior to exponential amplification. Fold change in 
expression was calculated using the 2-ΔΔCT method [49] using Actb as the endogenous 
control.  Results are represented as mean fold changes relative to B6 sham LV expression. 
Statistical analysis. All results were expressed as mean ± standard error of the mean [50]. 
Statistical analysis was performed using Statview version 5 (SAS Institute, Cary, North 
Carolina). The Kolmogorov-Smirnov test was used to test for normal distribution. Statistical 
significance within genetic backgrounds was determined using the two-tailed unpaired 
Student’s t-test or nonparametric Mann-Whitney test, while a two-way ANOVA or the 
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Kruskal-Wallis test was used to determine statistical significance within treatment groups. A 
p-value of less than 0.05 was considered significant.  
 
Results 
Previous studies suggest that many cardiovascular phenotypes vary by genetic 
background. Consequently, strain-specific genetic modifiers may have been a source of 
variability in previous studies using engineered models of LVH, LV geometry, and cardiac 
failure. To evaluate and characterize genetic background-specific responses, the effects of 
pressure overload induced by TAC were used to identify experimental models for different 
geometric patterns of LVH response to hypertension that is observed in humans.  
Baseline strain-specific differences in cardiovascular phenotypes. Sham treated B6 and 
129S1 control mice had natural baseline variation in cardiac morphology (Figure 2-1, A-D). 
Sections taken through the hearts showed that B6 hearts were rounded at the apex, with a 
larger LV diameter, while 129S1 hearts were longer and narrower with a thicker septal wall 
and with a smaller LV diameter.   Histologic analysis indicated that the 129S1 hearts had 
more tightly packed cardiomyocytes in the septal and free LV wall (Figure 2-1, B compared 
to D). The hearts of F1 sham mice were similar to those of 129S1 mice in morphology and 
cardiomyocyte density (data not shown).  
These baseline differences among the strains were also observed by transthoracic 
echocardiography (TTE).  129S1 mice had the smallest left ventricular end diastolic diameter 
(LVED,d) and left ventricular end systolic diameter (LVED,s), but longer LV length than B6 
mice (Figure 2-1G  and Table 2-1). Baseline calculated values of percent fractional 
shortening [51] and percent ejection fraction (%EF) were significantly lower in F1 mice 
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compared to 129S1 and B6 mice, while LVvol, d and LVvol, s were smaller in 129S1 mice 
compared to B6 and F1 mice suggesting intrinsic strain-dependent variation in cardiac 
contractility and left ventricular geometry (Table 2-1 and Table 2-2).   
Differences in body and organ weights across the strains were also observed (Table 2-
3).  129S1 sham mice were lighter, and had smaller wet organ weights compared to B6 and 
F1 mice. However when normalized to body weight, there was no significant difference in 
organ weights by genetic background.  There was also no significant difference in mean 
aortic diameter measured at the level of the aortic root at systole or diastole by genetic 
background at baseline.   As previously reported, 129S1 mice had higher systolic blood 
pressures as compared to B6 mice (122 ± 5 mmHg versus 116 ± 3 mmHg; Table 2-4).   
Pressure overload induces strain-specific differences in cardiac function. Because it is 
possible that baseline differences could impact cardiovascular pathophysiological responses, 
we subjected B6, 129S1 and F1 hybrid mice to TAC to identify strain-dependent cardiac 
responses to elevated pressure overload (Figure 2-1E and F).  No significant differences in 
heart rate were detected at baseline or after treatment or by genetic background. Following 
TAC, peak systolic gradients across the left and right carotid arteries were similar in B6, F1, 
and 129S1 mice (43.5 ± 10, 40± 12, and 48 ±12 mmHg, respectively), indicating a similar 
initial pressure gradient.  Approximately 20% of B6 mice died between one-to-three weeks 
post-TAC, similar to published mortality rates for this strain, with only 40% of B6 TAC mice 
surviving to eight weeks post-surgery [31].  No mortality occurred in 129S1, F1, or sham 
mice followed up to eight weeks post-TAC.  
To determine whether the increased mortality in B6 mice could reflect more severe 
LV dysfunction, changes in LV geometry and function were non-invasively measured by 
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TTE.  Five weeks post-TAC, B6 mice had LV chamber dilatation, reduced %FS, and reduced 
%EF, with no significant change in RWT as compared to sham B6 mice (Table 2-1), 
consistent with eccentric hypertrophy and depressed systolic function. Both 129S1 and F1 
mice developed concentric hypertrophy five weeks post-TAC, as marked by significantly 
reduced chamber size, increased wall thickness, increased RWT, and increased %FS and 
%EF compared to controls (Table 2-1 and 2-2).  Although LV wall posterior wall thickness 
(LVPWTh) increased in all three genetic backgrounds with chronic pressure overload, 129S1 
TAC mice manifested the greatest percent increase in LVPWTh compared to sham-operated 
controls (Table 2-1). In contrast, calculated LV mass also increased in all TAC mice 
compared to sham-operated mice, but a significantly greater increase was observed in B6 
TAC mice compared to other genetic backgrounds (% increase LV mass over baseline 
89.9±14.9, B6 versus 66.3±16.3, F1 versus 56.1±7.1, 129S1; p < 0.05).   Sections taken 
through the hearts confirmed that B6 TAC mice developed a dilated cardiomyopathy with 
RV enlargement, whereas 129S1 TAC mice had concentric hypertrophy (Figure 2-1, E and 
F).  Interestingly, measurements of mean aortic diameter proximal to the constriction site 
taken five weeks post-surgery were significantly greater in B6 TAC mice compared to shams 
as well as compared to F1 and 129S1 TAC mice, suggesting possible strain differences in the 
aortic response to load (Table 2-2).  
Initial assessment of LV geometry and function by TTE was performed on mice 
anethestized with inhaled isoflurane, which in published studies has been found to have mild 
effects on cardiac function and has been proposed to be the best anesthetic for repeated 
measurement in the same animal [52-57]. To exclude the possibility that differences we were 
observing in the cardiac geometry and function in B6, F1, and 129S1 mice by TTE could be 
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ascribed to differential strain susceptibility to anesthesia, we performed conscious 
echocardiographic and compared the results to those obtained under isoflurane.  TTE on 
conscious mice yielded similar patterns to those observed with isoflurane anesthetized 
animals with 129S1 and F1 TAC mice having reduced LVED,d, LVED,s and increased %FS 
and %EF consistent with concentric hypertrophy, while B6 TAC mice had increased 
LVED,d, LVED,s and reduced %FS and %EF consistent with LV dilatation (Table 2-5).   
 Five weeks post-TAC, significant strain differences were observed in body weight 
(BW), organ weights and organ:BW ratios (Table 2-3).   Pressure overload significantly 
increased heart weight (HW), and HW:BW on all three genetic backgrounds relative to 
controls. However, wet lung weight and Lu:BW were significantly increased in F1 and 129S1 
TAC mice (p < 0.02 versus shams), while wet liver weight (LiW) was significantly higher in 
TAC B6 mice (p < 0.03 versus shams), but when corrected for BW did not reach significance 
(p < 0.06 versus shams). There were no differences in wet kidney weight (KiW) or Ki:BW 
between banded and sham mice (data not shown). When wet organ weights were expressed 
as percent increase over sham mice, B6 TAC mice had the largest relative increase in HW 
and LiW whereas 129S1 mice had the largest relative increase in LuW.  Since B6 mice also 
have evidence of RV dilatation (Figure 2-1, E) it is likely they manifest passive liver 
congestion and right-sided heart failure in response to chronic pressure overload, whereas 
129S1 mice have significant pulmonary congestion. 
B6 mice have heightened cellular responses to pressure overload. Cardiomyocyte 
hypertrophy was assessed by histomorphometry in mice from all three genetic backgrounds. 
Changes in cardiomyocyte size varied with background, approximately doubling in B6 TAC 
hearts, while only increasing 1.6 fold in F1 TAC hearts and 1.3-fold in 129S1 TAC hearts 
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relative to sham controls (Figure 2-2, A). Within the TAC group, B6 cardiomyocytes had the 
largest cross-sectional area (Figure 2-2, B and C).   
The hypertrophic response to pathological stimuli often involves fibrosis [58]. 
Quantitative analysis of Masson’s Trichrome stained sections, in which collagen stains a 
bright blue color, indicated increased interstitial fibrosis (IS) in B6 and 129S1 TAC mice 
compared to shams (Figure 2-3, A). B6 TAC mice had significantly greater IS fibrosis than 
respective TAC mice on other genetic backgrounds (Figure 2-3, C and E).  Additionally, only 
B6 TAC mice tended to have extensive perivascular fibrosis (Figure 2-3, B and D). B6 TAC 
mice also had inflammatory infiltrate found in regions of fibrosis (Figure 2-4, A). 
Comparably fewer inflammatory cells were detected in the hearts of sham mice on all genetic 
backgrounds as well as F1 and 129S1 TAC mice (Figure 2-4, C), and were not associated 
with fibrosis (Figure 2-4, B). 
Strain-specific hypertrophic response is supported by expression of molecular markers. 
Pressure overload and other cardiac stressors typically initiate induction of the fetal 
hypertrophic gene program, which is associated with pathological ventricular remodeling 
[59]. The expression of atrial natriuretic peptide (Nppa/ANP), brain natriuretic peptide 
(Nppa/BNP), medium chain acyl dehydrogenase (Acadm/MCAD), α-myosin heavy chain 
(Myh6/α−MHC) and β-myosin heavy chain (Myh7/β-MHC), signature markers for cardiac 
hypertrophy, was measured by qPCR using LV total RNA (Figure 2-5). The re-expression of 
ventricular Nppb and Nppa, both cardioprotective hormones, is recognized as a marker for 
the induction of the embryonic gene program in ventricular hypertrophy [60]. Although Nppa 
and Nppb expression was elevated in the LV of mice on all backgrounds after TAC relative 
to sham-treated mice of the same background, only LV from B6 and F1 mice showed 
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significant changes (Figure 2-5, A and B). Interestingly, B6 mice (both sham and TAC) had 
nearly 3-fold greater Nppb LV expression in the LV as compared to F1 and 129S1 mice in 
respective treatment groups.  
In failing mouse and human hearts, a shift in myosin heavy chain isoform expression 
from the adult form (Myh6) to the fetal form (Myh7) can occur, and a change in the ratio of 
these isoforms is associated with pathological hypertrophy. Pressure overload of C57BL/6J X 
SJL/J mice was previously reported to suppress expression of Myh6 by more than 50% after 
ten weeks of banding [61]. We also found decreased Myh6 expression (by approximately 
75%) while Mhy7 expression was dramatically increased in B6 TAC LVs compared to 
controls (Figure 2-5, C and D). Milder alterations in the expression of these markers were 
also observed in F1 mice. Additionally, within the TAC cohort, B6 mice had significantly 
lower Myh6 expression and higher Myh7 expression than F1 and 129S1 mice (p < 0.05). 
 During the transition to heart failure, the chief myocardial energy source switches 
from fatty acid beta-oxidation to glycolysis indicating a reversion to the fetal energy 
substrate preference pattern. Expression of Acadm, coding for a rate limiting fatty acid beta-
oxidation enzyme, is reported to be down-regulated during the progression from cardiac 
hypertrophy to failure [62]. Consistent with this expression, Acadm expression was 
significantly decreased in B6 TAC mice compared to shams as well as compared to other 
TAC mice (Figure 2-5 E; p < 0.05). Together with echocardiographic data, altered gene 
expression of these markers may reflect a transition in the B6 mice to decompensated heart 
failure.   
129S1 genetic modifiers delay transition to decompensated heart failure. To determine if 
the 129S1 mice would eventually progress to an eccentric, decompensated phenotype, 
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cardiac geometry and function was assessed serially by TTE for up to eight weeks post-TAC 
in all three strains (n = 3-4 TAC, 2-3 sham; Figure 2-6 A-E).   By week eight post-surgery, 
LVED,d, LVED,s and LV posterior wall thickness were significantly increased and %FS was 
significantly decreased in all TAC mice relative to respective sham controls, demonstrating 
that pressure overload ultimately leads to dilatation and decreased systolic function 
irrespective of genetic background.  However, there was both a blunting and a temporal delay 
in transition to decompensated heart failure in 129S1 and F1 mice.  Interestingly, both the 
129S1 and the B6 mice went through an initial stage characterized by pronounced concentric 
hypertrophy.  In contrast the B6 TAC mice developed characteristics of decompensated heart 
failure by five weeks; the F1 and 129S1 TAC mice did not have significant evidence of LV 
dilation or systolic dysfunction until week six and eight weeks post-TAC, respectively. Even 
after eight weeks, surviving B6 TAC mice retained the largest percent increase in LV 
diameter and greatest reduction in %FS relative to baseline values. Together, this data 
suggests that the 129S1 strain harbors protective genetic modifers that enables prolonged 
compensation to chronic pressure overload.  
Discussion 
B6 and 129 strains are known to differ in baseline cardiovascular phenotypes such as 
blood pressure, morphological traits (i.e. atrial and ventricular size), heart rate variability, 
and cardiac metabolism, as well as in cardiac response to stressors [39-42]. Extending these 
findings, we present evidence that B6, and 129S1 mice manifest different cardiac phenotypes 
in response to TAC; moreover, genetic background influences the ability to maintain cardiac 
function in the face of prolonged cardiac stress as modeled by TAC-induced pressure 
overload.  
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While B6 and 129S1 genetic backgrounds have a hypertrophic response, as indicated 
by increased heart weight and cardiomyocyte area over controls, they differ significantly in 
LV function over time, LVH geometric pattern and pathological LV remodeling. By five 
weeks post-surgery, B6 TAC mice have depressed contractile function, LV dilatation 
proportional to LV wall thickness, extensive fibrosis associated with inflammatory infiltrate, 
and significantly altered expression of classic hypertrophy markers. B6 mice also have the 
largest increase in liver weights and RV dilatation, suggesting passive liver congestion.  
Collectively, these observations suggest that B6 mice have LV remodeling consistent with 
eccentric hypertrophy (heart mass increases, but RWT does not change), accompanied by 
systolic dysfunction and right-sided heart failure. Although 129S1 TAC mice eventually 
progress to a “decompensated” phenotype, this transition is significantly delayed compared 
to B6 TAC mice. At five weeks post-surgery, 129S1 mice have a phenotype characteristic of 
concentric hypertrophy in response to TAC, with increased cardiac mass, RWT, and 
decreased LVED,d. Systolic function, estimated by FS and EF is also enhanced, evidence of 
an increased contractile status, while CO is significantly decreased, probably due to reduced 
LV chamber size and stroke volume. Additionally, 129S1 mice have more pronounced 
increases in lung volumes after pressure overload suggesting pulmonary congestion, possibly 
due to elevated LVED pressure. These findings are consistent of clinical features observed in 
patients with diastolic dysfunction in the setting of concentric LVH. In response to TAC, F1 
mice have a cardiac phenotype intermediate to B6 and 129S1 parental strains in many 
parameters, but appear to be protected from early systolic dysfunction and cardiac fibrosis, 
responding similarly to parental 129S1 mice. This result implies that 129S1 genetic modifiers 
may protect against the more severe pathologic changes seen in the hearts of B6 mice in 
 45 
 
response to TAC at earlier timepoints as well as delay transition to decompensated heart 
failure. This protective effect is significant, as, when all studies were combined, 
approximately 20% of all B6 TAC mice died by three weeks post-TAC, with approximately 
60% dying by eight weeks post-TAC. By contrast, no mortality was observed in 129S1 or F1 
TAC mice.   
Our echocardiographic and morphologic data are comparable to prior studies 
investigating B6 response to pressure overload at similar time points [31, 61, 63].  Less data 
is available for 129S1 mice, and no studies have reported a direct comparison between these 
widely used strains.   Schmitt et al. [50] performed TAC on wild-type 129SvEv mice 
(substrain not specified) as controls for co-isogenic mice carrying a mutation in alpha cardiac 
myosin heavy chain (Myh403/+).  Interestingly, they report that TAC-treated 129SvEv mice 
had significantly thickened LV walls, reduced LV diameter, and were able to maintain 
normal contractile function for over 30 weeks post-banding [50].  Data from our lab and 
others demonstrate that, compared to B6 mice, 129S1 mice have a higher baseline systolic 
pressure at baseline and in response to cardiovascular stressors [39, 64-66]. Although there 
are no publications directly comparing B6 to 129S1 blood pressure response after TAC, 
comparison of independently published values suggest that 129SvEv mice likely continue to 
maintain higher systolic pressures than B6 post-TAC (10, 22). Thus, 129S1 TAC mice 
chronically maintain systolic function despite slightly higher afterload than B6 TAC mice.  
Our data, together with reports in the literature, consistently indicates that the B6 and 
129S1 strains differ greatly in their ability to adapt to acute pressure overload. As many TAC 
studies use transgenic mice that have not been backcrossed to congenicity, it is possible that a 
combination of B6 and 129S1 modifiers would influence the response to pressure overload, 
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contributing to variability.  Thus, the significance of an individual gene effect on pressure-
overload induced LVH and remodeling could be masked or diluted by unidentified genetic 
modifiers in studies that do not adequately control for genetic background. Moreover, many 
published studies examine the cardiac response to TAC from four-to-six weeks post-surgery, 
timepoints where our studies would predict there would be more pronounced differences in 
response. 
We also found significant differences in gene expression, fibrosis, organ weights and 
cardiac morphology among control, sham-treated mice, underscoring the inherent 
cardiovascular differences of the parental strains. Similarly, the phenotype of transgenic mice 
overexpressing the sarcoplasmic reticulum Ca2+-binding protein calsequestrin (Casq1) are 
highly strain-specific, showing wide variability when mice carrying the transgene are crossed 
to different inbred mouse strains [67-70]. In contrast to our results using the TAC model, 
which showed a dominant 129S1 modifier protecting against dilated cardiomyopathy, 
reciprocal backcrosses between DBA/2 and B6 mice revealed that the B6 background 
contributes a dominant susceptibility allele to the cardiomyopathic phenotype in the Casq1 
transgene model, leading to dramatically reduced survival. Thus, the same genetic insult may 
be significantly modified by genetic background, leading to variable cardiovascular 
compensation, even in the absence of additional stimuli.  
Clinical studies suggest that screening for LVH geometric pattern in patients with EH 
may have prognostic value in stratifying patients based on CV risk.  Yet, relatively little is 
known about the natural history of LV geometric remodeling in human hypertension; for 
example, whether the remodeling patterns are temporal stages in the development of the 
hypertensive heart from normal geometry through compensated hypertrophy to dilation and 
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heart failure or if every pattern is genetically or hemodynamically predisposed. A recent 
study followed changes in LVM and LV geometry in 100 hypertensive patients for five years 
and concluded that LV geometry is a rather conservative entity, as transformation from one 
pattern to another was rarely observed, even in untreated hypertensive patients. In particular, 
concentric LVH was fairly stable, without transformation to dilatation over the course of the 
study; however, the development of eccentric hypertrophy in patients with normal baseline 
geometry was observed [71]. This suggests that independent determinants of LV geometry 
exist despite similar arterial hypertension.   
In light of the unique patterns of LV remodeling in humans, continued exploration 
and comparison of inbred strain-specific responses to pressure overload will lead to better 
pre-clinical models for partitioning LVH by LV geometry. These mouse models will provide 
tools to investigate changes in LV remodeling and LV geometry over time, to decipher 
genetic networks that may contribute to different LV geometric patterns, and to compare 
benefits of pharmaceutical intervention based on LV geometry subtype. It is now clear
 
that 
similar genes and signaling pathways regulate the development
 
of the heart and vasculature, 
as well as cardiovascular response to stressors, in mice and humans. Molecular genetics
 
will 
play an important role in discovering novel methods of diagnosing and treating patients with 
cardiovascular diseases [2, 28, 37], and mouse models for defined subsets of patients will be 
essential for pre-clinical therapeutic studies. Ultimately, these studies will contribute to 
understanding why some patients with chronic pressure overload manifest concentric LVH 
whereas others progress to LV dilatation and systolic dysfunction.  
As exemplified in our studies, the selection of appropriate genetic background 
controls is essential when performing gene function studies using engineered mouse models 
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to study response to TAC to ensure interpretable results. Although the vast majority of 
mutations are produced in 129 embryonic stem cells before generating chimeras, the 
resulting chimeras are typically bred to B6 mice to produce F1 hybrids followed by 
intercrossing of the offspring to generate homozygous mutants on a mixed B6 and 129 
genetic backgrounds for analysis. Frequently, viable homozygous mutant mice are 
maintained as closed colonies for study. Our results show that F1 hybrids from B6 and 129S1 
are not appropriate controls for either these experiments since the F1 response to TAC will 
not reflect either the B6 or 129 strains. If mutations are maintained as a closed breeding 
colony, there are no appropriate controls for genetic background since the composition of the 
background will be variable and unpredictable, and the genetic background effects described 
here may incorrectly be associated with the mutation under study. Rather, the only adequate 
controls are littermates with an equivalently random distribution of the B6 and 129 genomes. 
However, because of the strong genetic background influence on response to TAC-induced 
pressure overload, significantly larger groups of mice will be required due to high intra-group 
variation. 
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Figure 2-1. B6 and 129S1 male mice have innate differences in cardiac morphology.  (A-F) 
Representative H&E staining of cardiac sections from B6 and 129S1 sham (A-C) and TAC 
(E and F) heart five weeks post-surgery (A,C, E and F, magnification, 1.6x; B and D, 
magnification, 10x. Bar = 100μm). (G) Representative M-mode tracings taken from the 
short-axis five-weeks post surgery from B6 and 129S1 mice.  LVED,d, LV end diastolic 
diameter, LVED,s, LV end systolic diameter, LVPWTh, d, LV posterior wall thickness 
diastole, LVPWTh,s , LV posterior wall thickness systole. 
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Table 2-1. Echocardiographic analysis in baseline, sham, and banded mice. LVED,d, LV end diastolic diameter; LVED, s, LV end 
systolic diameter; LVPWTh, d, LV posterior wall thickness diastole; LVPWTh, s, LV posterior wall thickness systole; FS, fractional 
shortening; RWT, relative wall thickness, LV vol, d; diastolic LV volume, LV vol, s; systolic LV volume, SV; stroke volume, AoD, d; 
diastolic aortic diameter, AoD, s; systolic aortic diameter, LV length, d; diastolic LV length  P-values are shown from comparisons 
between strains using the non-parametric Kruskal-Wallis test. Echocardiographic measurements are represented as average ± SEM. *p 
< 0.05 vs F1 mice; dp < 0.01 vs F1 mice. 
 
Treatment: Baseline SHAM TAC 
Genetic 
Background: B6 F1 129S1 B6 F1 129S1 B6 F1 129 
N 15 15 15 6 6 6 9 9 9 
HR (BPM) 487.09±10 451±15 482±11 495±16 473±10 448±15 509±18 473±13 460±16 
LVED,d(mm) 3.80±0.07 3.80±0.06b 3.56±0.05b,d 3.85±0.10 3.95±0.10 3.53±0.12 4.11±0.13 3.48±0.09a** 2.87±0.23b,d** 
LVEDS(mm) 2.27±0.09 2.51±0.07a 1.98±0.05a,d 2.24±0.08 2.42±0.17 2.05±0.19 2.85±0.14** 1.78±0.15a* 1.06±0.15b,c* 
LVPWTh, d(mm) 0.62±0.03 0.72±0.06 0.65±0.03 0.62±0.04 0.76±0.10 0.71±0.07 0.85±0.07* 0.97±0.13 1.06±0.09c
LVPWTh, s(mm) 1.11±0.05 0.82±0.06 0.98±0.05 0.91±0.05 0.84±0.14 1.08±0.09 1.36±0.11** 1.39±0.15* 1.70±0.14* 
RWT 0.38±0.02 0.36±0.01a 0.46±0.02b,d 0.49±0.06 0.39±0.02 0.43±0.06 0.51±0.02* 0.54±0.04** 0.82±0.05b,d** 
%FS 40.41±1.57 33.91±1.16b 44.14±1.34d 41.85±1.99 38.86±3.21 38.48±3.44 29.92±2.17** 48.63±4.18b 59.73±4.88b** 
LV vol, d(μl) 62.20±2.67 62.16±2.43b 53.27±1.86b,d 64.18±4.06 68.19±4.27 50.44±5.40 75.61±6.17 50.48±3.05** 34.67±3.14b** 
LV vol, s(μl) 18.25±1.82 22.86±1.50 12.61±0.87d 17.09±1.53 21.18±3.93 14.31±3.50 31.74±3.72** 10.22±1.72b** 3.70±1.16b,d** 
%EF 71.42±1.93 63.36±1.55a 76.32±1.43d 73.24±2.30 69.42±4.26 72.20±4.44 58.44±3.21* 79.55±3.44b 89.55±6.37b
SV(μl) 43.90±1.40 39.30±1.60b 40.7±1.60d 47.10±3.60 47.00±2.80 36.1±3.40 42.90±3.70 40.30±2.80b 27.5±3.60b
CO(μl/min) 21.41±0.64 21.00±2.30 19.10±0.97 22.3±1.72 22.22±1.47 17.58±1.31 18.00±1.03 19.70±1.31 14.69±0.01a,d* 
LV MASS (mg) 82.35±3.01 86.27±4.14 84.82±4.75 89.81±9.86 95.73±9.30 87.04±9.92 150.53±15.72* 137.45±7.99* 120.49±19.11 
AoD, d (n=3)(mm) 1.10±0.10 1.33±0.12 1.25±0.07 1.16±0.08 1.35± 0.11 1.28± 0.07 1.62±0.02* 1.47±0.03 1.35±0.09 
AoD, s (n=3) (mm) 1.28±0.07 1.39±0.10 1.38±0.10 1.37± 0.05 1.44± 0.11 1.46± 0.06 1.73±0.04* 1.52±0.04 1.53±0.07 
LV Length, d 
(n=3)(mm) 6.67±0.15 6.75±0.15 7.15±0.09 6.6±0.12 6.94±0.10 7.30±0.07 7.0±0.19 7.74±0.24* 7.86±0.09* 
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Table 2-2. Percent change in echocardiographic parameters compared to baseline five weeks post surgery. HR, heart rate; 
LVED, d, LV end diastolic diameter; LVED, s, LV end systolic diameter; LVPW, d, LV posterior wall thickness diastole; 
LVPW, s, LV posterior wall thickness systole; %FS, fractional shortening; % EF, percent ejection fraction. P-values are shown 
from comparisons between TAC and sham-operated animals using the 2-tailed unpaired Student’s t-test.  P-values are shown 
from comparison within strains using two-way ANOVA. Measurements are represented as average percent change over 
baseline ± SEM. *p < 0.05 or **p < 0.01 vs sham controls; ns, not significant. ap < 0.01 vs B6 TAC; bp < 0.05 vs F1 TAC; cp < 
0.01 vs F1 TAC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment: SHAM ANOVA TAC ANOVA Genetic Background: B6 F1 129S1 B6 F1 129S1 
N 6 6 6 p < 9 9 9 p < 
HR 495±16 473±10 448±11 ns 509±18 473±13 460±16       ns 
LVED, d (%) -0.1±2.2 4.5±1.9 4.7±2.6 ns 9.9±3.9b* -7.9±2.3** -21.0±2.5a,b** 0.01 
LVED, s (%) -2.1±4.9 -1.2±5.9 10.1±12.2 ns 28.3±6.6c** -28.8±4.9** -48.9±4.3a** 0.01 
LVPWTh, d (%) -0.6±9.1 21.6±10.2 0.7±16.8 ns 41.5±10.8* 31.9±10.7 77.1±18.7b* ns 
LVPWTh, s (%) -14.3±5.7 7.1±12.9 3.7±14.4 ns 20.9±8.1b** 69.4±16.5* 83.2±10.2a** 0.01 
%FS (%) 5.1±7.6 11.9±9.1 -1.4±4.1 ns -32.5±9.1c* 46.4±14.2 23.7±12.5a** 0.01 
%EF (%) 3.2±5.0 7.7±6.0 -5.7±6.3 ns -18.2±2.8c** 26.6±6.8 6.6±11.6a,b** 0.01 
CO (%) 7.4±7.6 4.1±2.52 2.4±3.7 ns -19.3±3.9** -17.1±7.7* -18.7±5.5** ns 
LV Mass (%) -2.1±3.5 9.4±5.7 4.6±5.5 ns 89.9±14.9** 66.3±16.3* 56.1±7.1** ns 
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Table 2-3.  Comparison of organ weights between SHAM and TAC treated mice. BW, body weight; HW, heart weight; LuW, lung 
weight; LiW, liver weight; H:BW, heart:body weight; Lu:BW, lung:body weight; Li:BW (liver;body weight) . Percent increase 
denotes percent increase over sham-operated animals.  P-values are shown from comparisons between TAC and sham-operated 
animals using the Mann-Whitney rank sum test.  Comparisons between strains were made using the non-parametric Kruskal-Wallis 
test. Organ weight measurements are represented as average ± SEM. *p < 0.05 or **p < 0.01 vs sham of the same genetic background. 
ns, not significant. Within treatment group: ap < 0.05 vs B6 mice; bp < 0.01 vs B6 mice; cp < 0.05 vs F1 mice; dp < 0.01 vs F1 
Treatment: SHAM ANOVA TAC ANOVA % Increase Genetic Background: B6 F1 129S1 B6 F1 129S1 B6 F1 129S1 
N 4 4 4 p < 6 6 6 p <    
BW (g) 31.10±0.42 30.58±1.20 27.63±0.85a,c 0.05 30.50 ±0.33 30.50±1.18 26.06± 0.65a,c 0.05 -5.64 -2.11 -7.38 
HW (mg) 164.00±5.14 153.63±5.58 131.48±3.14a,c 0.05 224.83±14.74* 181±13.46* 159.00±7.18a,c** 0.05 37.51 17.84 21.37 
LuW (mg) 157.00±6.56 159.80±6.72 131.95±3.43a,c 0.05 175.53±5.25 172.00±6.22** 154.00±5.46b,d** 0.01 12.03 7.33 16.77 
LiW (g) 1.41±0.13 1.35±0.43 1.07±0.05a,c 0.05 1.66±0.22* 1.28±0 12 1.06±0.04 ns 18.02 -4.97 -1.70 
H:BW(mg:g) 5.25±0.30 5.05±0.30 4.76±0.08 ns 7.36±0.42** 6.39±0.37* 6.13±0.29a,c** 0.05 40.19 26.53 28.78 
Lu:BW(mg:g) 5.44±0.30 5.24±0.24 4.79±0.19 ns 5.76±0.05 6.07±0.19* 5.90±0.09** ns 5.88 15.84 23.17 
Li:BW(mg:g) 45.18±4.54 44.20±0.84 38.87±0.91 ns 54.67±0.11 45.09±2.48 40.56±1.32b,d 0.01 21.00 2.01 4.17 
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Table 2-4. Blood pressure measurements in conscious ten week-old male mice.  
SYS=systolic pressure, DIAS=diastolic pressure, MAP=mean arterial pressure. 
Parameters were not significantly different by genetic background. 
 
 
 
Genetic  
Background SYS (mmHg) DIAS(mmHg) MAP HR (BPM) 
B6 (n=7) 116±3 85±2 101±2 702±5 
129S1 (n=6) 122±5 87±19 108±7 676±18 
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Table 2-5. Percent change over baseline in echocardiographic parameters five weeks post-
surgery in conscious mice. HR; heart rate, LVED,d, LV end diastolic diameter; LVED,s, LV 
end systolic diameter; LVPW,d, LV posterior wall thickness diastole; LVPW, s, LV posterior 
wall thickness systole; %FS, percent fractional shortening; %EF percent ejection fraction; CO; 
cardiac output, LV Mass; left ventricular mass. P-values are shown from comparisons between 
TAC and sham-operated animals using the 2-tailed unpaired Student’s t-test. P-values are 
shown from comparisons within treatment group by genetic background using two way 
ANOVA. No differences were detected between baseline and sham-operated animals of the 
same strain for any parameters. No differences were detected in heart rate by treatment or strain.  
Echocardiographic measurements are represented as average percent change over baseline ± 
SEM. *p < 0.05 or **p < 0.01 vs sham controls; ap < 0.05 vs B6 mice (within treatment group). 
         
Genetic Background: B6 F1 129S1 ANOVA 
p < 
B6 F1 129S1 ANOVA 
p < N 3 3 3 3 5 5 Treatment: SHAM TAC    
HR (BPM) 631±27 621±14.5 611±4 ns 612±10 614±17 635±9 ns 
LVED,d (mm) 2.1±0.8 0.7±1.0 7.8±0.1 ns 10.2±5.8* -12.1±7.6* -9.4±2.4a** 0.01 
LVED,s (mm) -7.4±1.2 0.7±1.0 6.9±1.9 ns 31.1±15.4** -27.9±3.1a* -25.4±8.0a* 0.01 
LVPWTh, d (mm) 11.7±5.5 -6.2±0.7 6.2±0.2 ns 34.9±16.2 56.7±25.9* 50.3±11.3* ns 
LVPWTh, s (mm) -0.2±4.3 6.7±8.3 2.5±7.5 ns 6.7±8.8 28.2±16.1 15.3±7.8 ns 
%FS 6.5±1.90 -13.0±16.4 0.5±1.1 ns -12.9±7.4* 18.0±4.5a 9.8±4.8a 0.01 
%EF 2.6±0.9 6.9±1.9 0.5±0.4 ns -7.1±4.2* 8.9±1.7a* 3.1±1.5a 0.01 
CO (μl/min) 3.2±1.0 3.6±0.9 2.3±1.7 ns 12.0±6.8 -18.5±10.4 -30.8±4.3a** 0.05 
LV Mass (mg) 4.4±1.6 7.1±9.1 14.2±4.0 ns 47.3±3.7 52.8±17.7 32.8±9.5 ns 
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Figure 2-2. Comparison of mean cardiomyocyte area across treatment group and genetic 
background. A. Cardiomyocyte size was significantly increased in TAC mice relative to mice 
receiving sham surgery on all genetic backgrounds (p < 0.05 versus sham controls). Within 
the TAC treatment group, the hearts of B6 mice had the greatest increase in cardiomyocyte 
area (p < 0.0001 versus F1 and 129S1 TAC). Representative histology of PAS-H stained 
cardiac sections from the LV septal wall of (B) B6 and (C) 129S1 TAC hearts. 
(Magnification, 20x. Bar = 50 μm). Cardiomyocyte area is represented as average ± SE. 
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Figure 2-3. Comparison of severity and location of cardiac fibrosis by treatment and genetic 
background. A. Interstitial fibrosis was significantly increased in B6 and 129S1 TAC mice 
compared to mice receiving sham surgery (p < 0.01 versus sham). B6 sham and TAC mice 
had more interstitial fibrosis as compared to F1 and 129S1 mice in their respective groups (p 
< 0.05 versus F1 and 129S1 shams; p < 0.01 versus F1 and 129S1 TAC). (B-E) Masson’s 
Trichrome stained sections demonstrated that B6 TAC mice have extensive perivascular 
fibrosis associated with intimal hyperplasia (arrow in B) as well as interstitial fibrosis (C). By 
comparison, 129S1 TAC mice had very little fibrosis (D and E) (B-E, magnification 20x, Bar 
= 50 μm). Percent interstitial fibrosis per mm 2 MT cardiac section is represented as average 
± SE.
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Figure 2-4. Inflammatory infiltrate is associated with fibrosis in B6 TAC hearts. (A and B) 
Staining for the pan macrophage/monocyte marker MOMA-2 revealed inflammatory 
infiltrate in regions of perivascular and interstitial fibrosis in B6 TAC hearts (A, brown 
staining at arrows), while little to no infiltrate was detected in fibrotic regions of F1 (not 
shown) or 129 TAC hearts (B) (A and B, magnification 40x, Bar = 25 μm). (C) A low 
number of positively staining cells were detected in the hearts of all sham mice as well as F1 
and 129S1 TAC hearts. Mean cell count is per mm2 of tissue and is represented as average ± 
SEM. 
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Figure 2-5. Comparison of relative expression of cardiac hypertrophy markers in LV by 
treatment and genetic background. (A-E) Expression of Nppa (ANP), Nppb (BNP) and Myh7 
(β-MHC) were all significantly increased in B6 and F1 TAC mice (p < 0.05 versus sham 
controls), while Myh6 (α-MHC) and Acadm (MCAD) were significantly decreased in B6 
TAC mice (p < 0.05 versus sham controls). Additionally there were significant differences in 
the gene expression of some markers (Nppa, Nppb, Acadm) among the sham groups. Fold 
change is relative to mean B6 sham values and is expressed as average ± SE. 
Expression of Acadm in LV
B6 F1 129
0
1
2
SHAM
TAC
Genetic Background
* 
* 
 Expression of Myh6 in LV
B6 F1 129
0
1
2 SHAM
TAC
Genetic background
Expression of Myh7 in LV
B6 F1 129
0
1
2
3
4
5
6
7
8
SHAM
TAC
Genetic Background
* 
*
* 
*
Expression of Nppa in LV
B6 F1 129
0
1
2
3
4
5
6
7
SHAM
TAC
Genetic Background
Expression of Nppb in LV
B6 F1 129
0.0
0.5
1.0
1.5
2.0
2.5 SHAM
TAC
Genetic background
*
* 
D 
* 
A B 
C 
E 
Myh6 Myh7 
Nppa Nppb 
Acadm 
 59 
 
Figure 2-6. 129S1 genetic modifiers delay transition to decompensated heart failure. 
Temporal echocardiographic analysis of B6, F1 and 129S1 TAC mice post-surgery. Percent 
change in (A) LVED,d, (B) LVED,s, (C) LVPWTh, d, (D) LVPWTh,S and (E) % FS over 
time. LVED,d, LV end diastolic diameter; LVED,s, LV end systolic diameter; LVPWTh, d, 
LV posterior wall thickness diastole; % FS, percent fractional shortening. Echocardiographic 
measurements are represented as average percent change over baseline ± SE. n = 3-5 mice 
per group. *p < 0.05 or **p < 0.01 versus sham controls. 
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                                                               CHAPTER 3 
EPIDERMAL GROWTH FACTOR RECEPTOR IS REQUIRED TO PREVENT 
LEFT VENTRICULAR HYPERTROPHY, CARDIAC FAILURE AND CALCIFIC 
VALVULAR AORTIC STENOSIS IN C57BL/6J BUT NOT 129S1/SVIMJ MICE 
 
Abstract 
Mice homozygous for the hypomorphic Egfrwa2 allele of epidermal growth factor receptor 
have semilunar valve hyperplasia and aortic stenosis on a hybrid genetic background. Since 
previous studies demonstrated that genetic background significantly modifies other 
phenotypes associated with reduced or absent EGFR activity, we created C57BL/6J and 
129S1/SvImJ-Egfrwa2 congenic lines to investigate the effect of genetic background on the 
development of aortic stenosis and cardiac function. Egfrwa2/wa2 mice on both genetic 
backgrounds have obvious congenital valve defects at birth, with similar levels of aortic 
valve hyperplasia. However, by three months of age, C57BL/6J-Egfrwa2/wa2 mice had 
significantly thicker aortic cusps and elevated transvalvular gradients compared to 
heterozygous controls and age-matched Egfrwa2 homozygous mice on either 129S1/SvImJ or 
B6.129 F1 backgrounds. Additionally, only C57BL/6J-Egfrwa2/wa2 mice developed severe left 
ventricular hypertrophy and progressive cardiac failure. Histological analysis revealed 
cellular changes in cardiac valves unique to C57BL/6J-Egfrwa2/wa2 mice including increased 
cellular proliferation, ectopic cartilage formation, extensive calcification and inflammatory 
infiltrate, which mimic changes seen in human calcific aortic stenosis. Despite having 
congenital aortic stenosis, 129S1/SvImJ and B6.129 F1-Egfrwa2/wa2 mice had normal 
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lifespans, no evidence of left ventricular hypertrophy and maintained normal systolic 
function. These results suggest that a threshold exists for aortic valve function before a 
significant pressure gradient develops triggering a hypertrophic response and that the 
129S1/SvImJ background dominantly protects against calcific aortic stenosis in Egfrwa2 mice.  
Introduction 
Valvular aortic stenosis (AS), in which calcification and fibrosis of the aortic valve leaflets 
obstruct left ventricular outflow, is the most common indication for valve replacement 
surgery in the US [1]. Since valvular calcific lesions progress slowly over several decades 
before causing clinically relevant AS, prevalence is highest in the elderly [2-5]. In the US, 
the number of persons greater than 65 years of age is projected to more than double by 2030; 
consequently, calcific AS is predicted to become an increasing health burden [6, 7]. The only 
treatment for severe calcific AS is valve replacement surgery as there are no medical 
treatments proven to prevent or delay the disease process in the aortic valve leaflets [1]. 
While several risk factors have been associated with increased prevalence and/or progression 
of AS, growing evidence suggests genetic factors also modify susceptibility to congenital and 
calcific valvular disease [8-15]. Moreover, genetic factors may predispose to both 
developmental defects such as bicuspid aortic valve and valvular calcification [16]. Even 
though the incidence of AS in increasing, there is a paucity of useful experimental models for 
development of AS caused by calcific valves, as most mouse models with valve defects 
arising from gene disruptions have a drastically shortened life span and/or do not have 
isolated valve defects [17-22]. 
Mice homozygous for the Egfrwa2 hypomorph mutation in the epidermal growth 
factor receptor (Egfr) gene develop semilunar valve thickening and AS on mixed genetic 
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backgrounds [23]. Egfrwa2 mutant mice are otherwise normal despite having up to a 90% 
reduction in EGFR tyrosine kinase activity [24]. Similar to Egfrwa2 homozygosity, deficiency 
for EGFR results in semilunar valve thickening on a mixed genetic background [23], but also 
results in genetic background-dependent pre- or peri-natal lethality [25, 26].  
To elucidate whether genetic modifiers alter AS severity when EGFR signaling is 
perturbed, we created congenic lines by backcrossing the Egfrwa2 allele onto the commonly 
used C57BL/6J (B6) and 129S1/SvImJ (129S1) strains that have different responses to 
pressure-induced cardiac overload (see Chapter 2). All Egfrwa2/wa2 mice have significantly 
thickened aortic valves compared to heterozygous littermates, yet they differ dramatically by 
genetic background in the severity of valvular abnormalities, development of left ventricular 
hypertrophy (LVH) and progression to cardiac failure. Phenotypic analysis of Egfrwa2 
homozygous mice shows that the 129S1 strain harbors dominant and protective genetic 
modifiers that prevent progression to calcific aortic stenosis and cardiac failure in the context 
of reduced EGFR activity. 
 
Materials and Methods 
Generation of congenic lines 
Stock B6EiC3H-a/A-Egfrwa2 Wnt3avt   mice were obtained from The Jackson Laboratory (Bar 
Harbor, Maine). The Egfrwa2 allele was backcrossed to the 129S1 and B6 inbred strains. After 
ten generations, animals carrying the Egfrwa2 allele were freely incrossed. Segregation and 
loss of the Wnt3avt mutation, which resides approximately 20 cM distal to Egfr on 
chromosome 11 and which is maintained in cis with Egfrwa2 in the progenitor stocks, was 
verified by PCR genotyping. An F1 population was created by outcrossing B6-Egfrwa2/+ 
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females to 129S1-Egfrwa2/wa2 males. Homozygous pups were identified by their curly whisker 
phenotype and confirmed by PCR genotyping as previously described [27]. Adult Egfrwa2 
homozygous mice and wild-type controls were housed and analyzed in same-sex littermate 
pairs to allow for paired statistical comparisons. 
Cardiovascular and molecular phenotyping.  
Echocardiography. Transthoracic echocardiography (TTE) was performed using a 30 mHz 
probe and the Vevo 660 Ultrasonograph (VisualSonics) as previously described (see 
Materials and Methods in Chapter 2). Doppler tracings were obtained at the level of the 
aortic root and mean maximum velocities were obtained over three cardiac cycles. Pressure 
gradients were calculated from the modified Bernoulli equation P=4(v)2 where v= maximum 
transvalvular velocity in cm/s. 
Blood pressure measurements. Systolic blood pressure was measured in conscious mice 
using a Blood Pressure Analysis tail cuff from Hatteras Systems, Inc (Apex, NC) [28]. 
Arterial cannulation and ventricular pressure measurements. Mice were anesthesized 
with 50-80 mg of pentobarbital, IP, and intubated. Mouse body temperature was monitored 
with a rectal probe and maintained at 37 ±1 degree C throughout the surgical procedure with 
a variable output halogen lamp. The mouse was positioned on a “mouse pad” (THM-100 
board, Indus Instruments, Houston, Texas) that contains EKG electrodes and a built in 
surface mounted semi-conductor temperature sensor that distributes heat through surface 
mounted resistors providing control of body temperature. All procedures were done 
aseptically. Surgery was performed with the aid of a OPMI-DFC surgical stereomicroscope 
(Carl Zeiss, Dublin, California). An approximate 1 cm midline neck incision from the lower 
mandible to the sternum was made. The right common carotid artery was exposed and 
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isolated by blunt dissection of the thin layer around the trachea. A secure suture was placed 
around the distal end of the artery and a loose suture is placed around the proximal end of the 
artery. A small vascular clip was placed on the proximal end to minimize bleeding. A 1-2 
mm incision near the distal end of the artery was made and the incision extended 
longitudinally. After removal of the clip, a 1.4 French catheter (Millar Instruments, Houston, 
Texas) was quickly advanced beyond the proximal suture. The catheter was then advanced 
retrograde down the ascending aorta and pressure readings were obtained. Since enlarged 
aortic valves prevented advancement of the catheter into the LV, a bilateral subcoastal 
incision was performed on the skin and extended into the abdominal cavity. The diaphragm 
was incised and the pericardium was removed. A small incision with a 11.0 scapel was made 
on the LV apex and a 1.4 French catheter was advanced beyond the proximal electrodes. The 
shape of the PV loops was used to determine the optimal placement of the catheter within the 
LV. 
Histology.  After the mice were weighed, the hearts, lungs, liver, and kidneys were dissected, 
rinsed in PBS and weighed individually. Hearts were cut in cross-section just below the level 
of the papillary muscle. For assessment of cardiomyocyte size and fibrosis, the top half of the 
heart was fixed in neutral buffered formalin and embedded in paraffin wax.  Sections of 5 μm 
thickness were prepared at 200 μm intervals. The sections were stained with hematoxylin and 
eosin (H&E) for examination of gross appearance, while Masson’s Trichrome (MT) or 
Periodic Acid-Schiff counterstained with hematoxylin (PAS-H) was employed in order to 
facilitate quantification of fibrosis, valve size, and cardiomyocyte size. Cardiomyocyte 
hypertrophy was assessed by measuring cross-sectional area of 100 cardiomyocytes per PAS-
H stained section in ten randomly selected fields having nearly circular capillary profiles and 
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centered nuclei in the left ventricular free wall. Histological images were analyzed using 
Nova Prime 6.75.10 software (BioQuant Image Analysis, San Diego, California). For 
measurement of cardiac valve size, morphology and immunohistological analysis, serial 
sagittal sections were collected from at least four littermate pairs on each genetic 
background. Aortic cusp diameter was only measured from sections where the aortic outflow 
tract and aortic walls were clearly visible and in similar orientation.  Immunostaining of the 
valves for demonstration of cellular proliferation and bone matrix protein expression was 
performed on paraffin-embedded tissues using a streptavidin-biotin method following 
manufacturer’s instructions (DakoCytomation, Universal LSAB™+, AP, K0678, K0689, 
Carpentaria, California). Proliferating nuclear cell antigen (PCNA), a DNA polymerase, and 
phospho ERK1/2 were used as markers for cellular proliferation (Cell Signaling, Danvers, 
Massachusetts) while osteopontin was detected using anti-osteopontin (Abcam, Cambridge, 
Massachusetts). Alizarin Red S and Von Kossa’s method were used as markers for 
calcification, (http://www.medlib.med.utah.edu/WebPath/HISTHTML/MANUALS; [29]  
while Movat’s pentachrome stain was used to assess extracellular matrix (ECM) 
composition. DAPI and the pan rat anti-mouse monoclonal IgG macrophage/monocyte 
marker MCA519G (clone number MOMA-2) (Accurate Chemical, Westbury, New York) 
followed by a Cy3-labeled goat anti- rat secondary (Jackson ImmunoResearch, West Grove, 
Pennsylvania) was used to detect inflammatory cells within the aortic valves. 
Gene expression. Total RNA was extracted from the lower half of the LV using TRIzol 
(Invitrogen, Carlsbad, California). After DNAse treatment, 500 ng of total RNA was reverse 
transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City , 
California). The expression of α-myosin heavy chain (Myh6), β-myosin heavy chain (Myh7), 
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atrial nautriuretic peptide (Nppa), brain nautriuretic peptide (Nppb), and medium chain acyl 
dehydrogenase (Acadm) was determined by real-time quantitaive PCR (qPCR) using Taqman 
Univeral Master Mix and Assays-on Demand primers and probes (Applied Biosystems, 
Foster City , California). β-actin (Actb) was used as an internal control. Results are 
represented as mean fold changes relative to Egfr wa2/+ expression. Reactions were run on a 
Stratagene MX3000P machine with analysis software. Threshold cycles [30] were 
determined by an in-program algorithm that assigned a fluorescence baseline based on 
readings prior to exponential amplification. Fold change in expression was calculated using 
the 2-δδCT method [31] using the gene β-actin as an endogenous control.  
In vivo phosphorylation assays. Neonatal pups (PD7) were injected subcutaneously with 
5μg/g body weight of EGF (R&D Systems,Minneapolis, Minnesota) in PBS. After 10 min, 
liver and heart were harvested, frozen in liquid nitrogen, and stored at -80°C. The frozen 
tissues were sonicated in 5–10 volumes (5–10 ml/g tissue) of lysis buffer consisting of 20 
mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 10 
μg/ml of leupeptin, 10 μg/ml of aprotinin, 1 mM sodium vanadate, and 10 mM β-
glycerophosphate at 4°C. The tissue lysates were cleared by centrifugation for 10 min at 4°C 
and protein concentrations were determined by the Bradford assay (Bio-Rad, Hercules, 
California). An equal amount of protein lysate (15 μg for liver or 30 μg for heart) was 
separated by denaturing 7.5% sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to PVDF membranes (Bio-Rad, Hercules, California). Protein 
blots were incubated overnight at 4°C with EGFR ab-17 polyclonal rabbit antibody (RB-
1417-P1, LABVISION/Neomarker, Freemont, California), polyclonal rabbit phospho-EGFR 
(Tyr1086) antibody (36-9700, Zymed, San Fransico, California), or polyclonal rabbit 
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phospho-p44/42 MAP Kinase (Thr202/Tyr204) antibody (Cell Signaling, Danvers, 
Massachusetts) followed by incubation goat anti-rabbit horseradish peroxidase conjugated 
antibody (1858413, Pierce, Rockford, Illinois) and detected with an enhanced 
chemiluminesence system (AmershamPharmacia/GE Healthcare).  
Characterization of congenital cardiac defects. Noon on the day that copulation plugs 
were observed was designated as 0.5 days post-coitus (dpc). Pregnant females were 
euthanized by CO2 asphyxiation and embryos were dissected from the uterine horns on the 
morning of 12.5 through 18.5 dpc into PBS. The placenta and extra-embryonic tissues were 
separated from the embryo by mechanical dissection and a tail biopsy was collected for DNA 
extraction to determine the genotype.   Embryos were fixed in neutral buffered formalin for 
histological analysis and paraffin embedded.   Sections of 5 μm thickness were 
deparaffinized, rehydrated in a graded series of ethanols, and counterstained with 
hematoxylin and eosin (H&E) for morphological characterization.  
Statistical analysis. Data is presented as mean +/- standard deviation (SE). The 
nonparametric Wilcoxon rank sum test or the two sided student’s t-test was used for 
statistical analysis, pairing data from littermates. The Kruskal-Wallis test or analysis of 
variance [20] was used to detect significance by genotype or genetic background. Statistical 
analyses were performed using StatView (SAS, Cary, NC). A p < 0.05 was considered 
statistically significant.  
Results 
Survival of mice with reduced EGFR activity. Although B6-Egfrwa2/wa2 mice were born 
close to the expected Mendelian ratios from B6-Egfrwa2/+ female by B6-Egfrwa2/wa2 male 
matings (43%, n = 8 litters, 43 pups), at weaning less than 30% of surviving mice were 
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homozygous for the Egfrwa2 allele as compared to 44.44% and 46.15% from similar crosses 
on F1 and 129S1 backgrounds, respectively (n = 4 and 9 litters; 27 and 39 mice, 
respectively). Between weaning and six months of age, an additional 15% of B6-Egfrwa2/wa2 
mice died. Thus, by one year of age, approximately 50% of B6-Egfrwa2/wa2 mice had died as 
compared to less than 10% of B6-Egfrwa2/+ littermates (Figure 3-1 A; n = 50 mice of each 
genotype, p < 0.001). A pronounced sex difference in survival was observed as 
approximately 40% of B6-Egfrwa2/wa2 male mice but only one female B6-Egfrwa2/wa2 mouse 
(10%) died prior to three months of age. Sudden death was a common complication resulting 
from minor stressors such as handling or ear notching, and necropsies of these mice showed 
massive enlargement of their hearts (Figure 3-1 B) as well as increased liver and lung 
weights, all characteristics of congestive heart failure. Normalized for body weight, the B6-
Egfrwa2/wa2 heart and lung weights were significantly larger when compared to B6-Egfrwa2/+ 
littermates (n = 16 sibling pairs, p < 0.001; Figure 3- 1C and Table 3-1).  There were no 
significant differences in survival or normalized heart or lung weights in inbred 129S1 (n = 
18 sibling pairs) or hybrid F1 (n = 9 sibling pairs) wildtype versus Egfrwa2/wa2 mice even at 15 
months of age. 
EGFR expression and signaling activity. To determine whether differences in expression 
from the Egfrwa2 allele contributed to background-dependent lethality, lysates were prepared 
from liver and hearts of one week old Egfrwa2/wa2 and Egfrwa2/+ littermates. Western blot 
analyses demonstrated that EGFR of similar size is produced in the hearts and livers of 
controls and Egfrwa2/wa2 mice (Figure 3- 2, A and B). Although there were strain- and organ-
specific differences in total EGFR protein, no significant differences in EGFR protein levels 
were observed among Egfr wa2/wa2 mice. To verify equivalent levels of EGFR signaling, 
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ligand-induced EGFR activity was measured in one-week-old pups by dosing with EGF (5 
mg/g body weight) and quantifying the level of phosphorylated EGFR and ERK1/2 by 
western blot analyses. Similar to previous reports [26] phosphorylated EGFR was below the 
limits of detection in heart lysates of all mice, but was significantly decreased in liver lysates 
of Egfrwa2/wa2 mice compared to their respective controls (ANOVA, p < 0.01). 
Phosphorylated ERK1/2 levels were also significantly decreased in heart lysates of 
Egfrwa2/wa2 mice on all genetic backgrounds and in liver lysates of B6 and 129S1-Egfr wa2/wa2 
mice compared to heterozygous controls, consistent with depressed activation of downstream 
EGFR signaling pathways (ANOVA,  p < 0.01). Quantitative PCR analysis of Egfr verified 
equivalent transcript levels in hearts of three-month-old Egfr wa2/wa2 mice across all 
backgrounds, although Egfrwa2/wa2 mice had consistently higher levels of Egfr transcripts than 
wildtype (Figure 3-2 C).  
Pathological, molecular and functional effects. Since a large proportion of B6-Egfrwa2/wa2 
deaths occurred prior to weaning, we compared cardiac development at mid (13.5 dpc - 15.5 
dpc) and late (18.5 dpc – postnatal day (PD) 1) gestational windows by genotype and genetic 
background. Consistent with previous reports, thickened semilunar valves were observed in 
Egfrwa2/wa2 embryos on all genetic backgrounds from 15.5 dpc to PD1, highlighting a 
requirement for normal EGFR activity for valvular remodeling (Figure 3-3 A).  However, 
additional congenital cardiac defects like decreased trabeculation, ventricular septal defects, 
thinned chamber walls and enlarged hearts, unique to B6-Egfrwa2/wa2 mice, were detected at 
earlier time points (12.5 dpc - 13.5 dpc;) and likely contribute to the observed postnatal 
deaths (Figure 3-3 B).  
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Cardiomyocyte size, as measured by mean cross-sectional area, was enlarged by 
approximately two-fold in PD1 B6-Egfrwa2/wa2 mice and by almost three-fold in adult B6-
Egfrwa2/wa2 mice as compared to heterozygous littermates (Figure 3-1 A; n = 8 sibling pairs, p 
< 0.01). By 12 weeks of age, B6-Egfrwa2/wa2 mice demonstrated dilated left ventricles and 
thickened septal and chamber walls (Figure 3-1 B). No difference in cardiomyocyte size was 
detected among 129S1 or F1-Egfrwa2/wa2 and heterozygous littermates, even at 15 months of 
age (data not shown). Hyperchromasia and karyomegaly, hallmarks of cardiac hypertrophy, 
were observed in histological sections from adult B6-Egfrwa2/wa2 hearts (Figure 3-4 B). 
Additionally, multifocal lesions with vacuolar degeneration, inflammatory infiltrate, and 
necrosis were observed in the hearts of moribund B6-Egfrwa2/wa2 mice. These pathological 
changes were accompanied by extensive interstitial fibrosis localized primarily to the apex 
and subendocardial regions of the heart (Figure 3-4 B). Consistent with previous reports [23], 
histological examination of other tissues that were severely affected in Egfr null mice (brain, 
liver, lung, kidney, gastrointestinal tract) revealed no significant morphological defects in 
Egfrwa2/wa2 mice.  
The re-expression of a fetal gene program, which occurs in response to a variety of 
stimuli, is a consistent and sensitive marker of cardiac hypertrophy in humans and laboratory 
animals. The expression of the atrial and brain nautriuretic peptide genes (Nppb and Nppa, 
the products of which induce vasodilation and sodium excretion) and the gene for the fetal 
isoform of myosin heavy chain (Myh7) were significantly or suggestively upregulated in B6-
Egfrwa2/wa2 left ventricles compared to wildtype (mean fold transcript increases in B6-
Egfrwa2/wa2 vs. Egfrwa2/+ hearts: Nppb, 65 ± 7.5, p < 0.07, Nppa, 50 ± 2.5, p < 0.05, Myh7, 20 
± 2.5, p < 0.05; 4 sibling pairs; data not shown). Consistent with altered cardiac metabolism, 
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expression of the medium chain acyl dehydrogenase gene (Acadm) was reduced by 
approximately 50% in B6-Egfrwa2/wa2 LV (data not shown). In agreement with histological 
measurements, there were no significant differences in expression of these markers in the LV 
among 129S1 or F1-Egfrwa2/wa2 and heterozygous littermates.  
Cardiovascular function was evaluated by transthoracic echocardiography (TTE) in 
three-to-five month old sex matched littermates on all three genetic backgrounds (Figure 3-3 
C; Table 3-2). Compared to their sex matched B6-Egfrwa2/+ littermates, B6-Egfrwa2/wa2 mice 
had larger left ventricles and reduced fractional shortening (FS, a measure of ventricular 
systolic function) consistent with dilation of the LV and a thickened chamber wall.  By 
contrast, 129S1-Egfrwa2/wa2 mice had smaller left ventricular end diameter diastole (LVED,d) 
and left ventricular end diameter systole (LVED,s) measurements with thinner chamber walls 
compared to 129S1-Egfrwa2/+ littermate controls, matching their proportionately smaller heart 
and body size; there was no significant difference in FS among 129S1 or F1-Egfrwa2/wa2 and 
heterozygous littermates. Additionally, there were no significant differences by genetic 
background or genotype in systolic blood pressures as assessed by the tail cuff method 
(conscious mice) or by aortic catheterization (anesthetized mice) (Table 3-3), suggesting that 
differences in systolic pressures did not contribute to differences in cardiac hypertrophy. 
Taken together, histopathological and echocardiographic analysis indicated that B6-
Egfrwa2/wa2 mice displayed increased chamber size, myofiber hypertrophy, and decreased 
fractional shortening, signs of severe cardiac dysfunction.  
Development of calcific aortic stenosis. Since analysis of congenic Egfrwa2 embryos 
suggested defects in cardiac valve remodeling, we suspected there also might be differences 
in postnatal valve function and degeneration, modulated by genetic modifiers of cardiac 
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valve homeostasis, function and subsequent severity of the AS leading to background-
dependent differences in cardiac hypertrophy, dysfunction and survival. While aortic valve 
cusp thickness, estimated by cusp diameter, was significantly increased in Egfrwa2 
homozygous mice compared to heterozygous controls on all three genetic backgrounds 
(Figure 3-4 A), B6-Egfrwa2/wa2 mice had the thickest cusps (Figure 3-5 B; B6, n = 8 sibling 
pairs, p < 0.001; F1, n = 4 sibling pairs, p < 0.01; 129S1, n = 6 sibling pairs, p < 0.01). 
Moreover a positive linear relationship exists between aortic valve thickness and heart weight 
in B6-Egfrwa2/wa2 mice (Figure 3-5 C, R2=0.77), suggesting an inverse relationship between 
hypertrophy and aortic systolic opening. Inclusion of B6 Egfr wa2/+ mice increased the 
correlation coefficient (R2=0.91), however no such relationship was observed by genotype or 
genetic background in F1 or 129S1 mice. 
Doppler tracings taken at the level of the aortic root confirmed elevated average peak 
velocities in Egfrwa2/wa2 mice compared to age and sex matched littermate controls (Figure 3-
6 A; Table 3-2). However, aliasing, an artifact that occurs in pulsed wave Doppler peak 
velocities above the threshold for the VisualSonics instrument (i.e. greater than 4 m/s), was 
evident in tracings from many B6-Egfrwa2/wa2 mice. Thus, the gradients calculated from peak 
Doppler velocities may under represent the true peak velocities in the most severely affected 
B6-Egfrwa2/wa2 mice. Cardiac catheterization confirmed higher left ventricular end systolic 
pressures (PSP) in all Egfrwa2/wa2 mice examined compared to littermate controls (Table 3-2). 
Although the catheter cannot simultaneously monitor LV and aortic PSP, peak-to-peak 
gradients could be calculated by measuring aortic PSP and then inserting the catheter into the 
LV to measure PSP. B6-Egfrwa2 mice consistently exhibited the largest pressure gradients, 
indicating severe AS. Transvalvular gradients in B6 Egfr wa2/wa2 mice showed a positive 
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linear relationship with aortic valve thickness (Figure 3-6 B; R2 = 0.89), suggesting that in 
this mouse model as in human patients, there may be a physiological threshold for AS which 
must be reached before significant pressure gradients and cardiac disease symptoms appear. 
Further examination of the thickened aortic valves demonstrated distinct genetic 
background differences in cellular morphology and differentiation. Gross dissection revealed 
that the cardiac valves of severely affected B6-Egfrwa2/wa2 mice had pronounced, dense 
pigmentation around the aortic and mitral valve cusps (Figure 3-7 A). Cardiac valves of B6-
Egfrwa2/+ mice had mild or no discoloration, while 129S1 and F1-Egfrwa2 mice of both 
genotypes were unaffected (data not shown). Because melanocytes have been reported in 
cardiac valves from wildtype B6 mice, we crossed B6-Egfrwa2 mice to albino B6-Tyrc-2J mice 
to verify the pigmentation was due to melanocytes. The cardiac valves of B6-Tyrc-2J 
Egfrwa2/wa2 mice, although similarly thickened, were not discolored, demonstrating that the 
cardiac valves of B6-Egfrwa2/wa2 mice have increased resident melanocyte populations.  
Recent evidence from clinical and experimental models supports the hypothesis that 
calcific AS is an active disease process with many similarities to atherosclerosis [5, 14, 32-
46]. Studies of diseased valves have shown cusp and leaflet thickening, inflammatory 
infiltrate, collagen fiber disorganization, increased valvular interstitial cell (VIC) 
proliferation, and calcification. Calcification contributes to lesion rigidity, worsening 
obstruction to left ventricular outflow and correlates clinically both with more rapid disease 
and worse outcomes [35]. Because histomorphological evidence of ectopic cartilage 
formation was seen in hematoxylin and eosin stained aortic valves of adult B6-Egfrwa2/wa2 
mice, we performed further immunohistochemical analysis using markers for cellular 
proliferation (PCNA, pERK1/2), extracellular matrix composition (ECM) composition 
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(Movat’s pentachrome), macrophage infiltration (MOMA-2), calcification (Alizarin Red S 
and von Kossa), and mature osteoblasts (osteopontin). B6-Egfrwa2/wa2 valves had evidence of 
cellular proliferation and MAPK activation (Figure 3-7 B and C) and altered ECM 
composition (Figure 3-8 A); the intense teal color with Movat’s pentachrome that was unique 
to B6-Egfrwa2/wa2 valves indicates close proximity of glycosaminoglycans and collagen. B6-
Egfrwa2/wa2 valves also contained osteoblasts, were calcified and had evidence of 
inflammatory infiltrate (Figure 3-8 B -D). A low level of positive staining for calcification 
was also observed in the cardiac valves of some B6-Egfrwa2/+ while 129S1 and F1-Egfrwa2/wa2 
valves showed no evidence of positive staining for any markers (data not shown). Neither 
calcification nor altered ECM composition was detected in the valves of embryonic or 
neonatal B6-Egfrwa2/wa2 mice (see Figure 3-3). Taken together, these data suggest that 
modifiers on the B6 genetic background sustain continued post-natal proliferation and 
differentiation of valvular interstitial cells residing in the cardiac valves. In the environment 
of congenitally malformed aortic valves, these differences become critical to cardiac function 
as what is already a grossly enlarged valve becomes stiff and dysfunctional in the B6-
Egfrwa2/wa2 mice 
Discussion 
Egfrwa2 mutant mice on a mixed genetic background have semilunar valve thickening and 
mild to moderate AS that is enhanced when combined with a mutation in Ptpn11 [23]. Since 
previous studies established that phenotypes resulting from reduced or ablated EGFR activity 
are highly dependent upon genetic background [25, 47], we generated and examined B6 and 
129S1-Egfrwa2 congenic lines and their F1 hybrids. Similar to findings in other organ systems, 
genetic background significantly modifies the cardiovascular phenotype in the Egfrwa2 mouse 
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model of AS (Figure 3-9), although there are no detectable background-dependent 
differences in residual EGFR activity. B6-Egfrwa2/wa2 mice have significantly decreased 
survival secondary to congestive heart failure. In contrast, mice homozygous for the Egfrwa2 
mutation on the 129S1 inbred or F1 backgrounds have normal life spans and cardiac function 
with no histological or molecular evidence of LVH, implying the presence of dominant 
129S1 protective modifiers. Although aortic valves are thickened in Egfrwa/wa2 mice on all 
genetic backgrounds relative to littermate controls, aortic valves of adult B6-Egfrwa2/wa2 mice 
are significantly more thickened as compared to Egfrwa2 homozygous mice on other genetic 
backgrounds. Moreover, aortic valve thickness is highly correlated with cardiac weight and 
physiologically significant pressure gradients in Egfrwa2 mutant mice. We also found 
degenerative cellular changes unique to B6-Egfrwa2/wa2 cardiac valves, such as increased VIC 
proliferation and differentiation, altered ECM composition, calcification and inflammation.  
In humans, significant hemodynamic or clinical changes are rare in AS until the valve 
orifice has narrowed to approximately one-third of normal [48, 49]. Studies using a 
hypercholesterolemic mouse model of AS showed that an almost identical threshold of 
decreased aortic valve orifice must be achieved before significant hemodynamically-induced 
transvalvular gradients and pathophysiological responses are detected in mice [50]. Our 
morphometric, immunohistochemical and hemodynamic analysis also support a threshold 
effect in the Egfrwa2 model of AS, whereby congenitally thickened aortic valves of B6-
Egfrwa2/wa2 mice become progressively larger and stiffer than those of 129S1 or F1-Egfrwa2/wa2 
mice, leading to a critical reduction in systolic valve area, valve flexibility and elevated 
pressure gradients. Because 129S1 and F1-Egfrwa2/wa2 valves do not reach the critical 
threshold, LV compensatory mechanisms are not triggered, even in aged mice. Thus, the 
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striking differences in Egfr-associated cardiac hypertrophy and mortality between genetic 
backgrounds are most likely secondary to genetic modifiers influencing cardiac valve 
development and homeostasis. Although delayed relative to B6, 129S1 mice will eventually 
develop LVH in the presences of elevated aortic pressure gradients induced by minimally 
invasive aortic banding (MIAB) (Chapter 2), further supporting that the dominant protective 
129S1 modifier(s) prevent the degenerative valvular changes that lead to LVH and 
congestive heart failure. However, since 129S1-Egfrwa2wa2 mice have congenitally thickened 
semilunar valves and mild pressure gradients across the aortic valve (8-10 mmHg), yet do not 
develop LVH or cardiac dysfunction, 129S1 protective modifiers may also directly sustain 
normal cardiomyocyte development, survival and function.  
Genetic studies using knockout mouse models established that endocardial outflow 
track cushion growth is largely controlled by the amount of BMP signaling, with diminished 
and excessive signaling correlating to hypo and hyperplastic cushions, respectively [51, 52]. 
Defective cardiac valvulogenesis in mice lacking Dtr (coding for the EGFR ligand HB-EGF), 
Egfr or Adam17 (coding for a metalloprotease required to process mature EGFR ligands) 
results from abnormal valvular mesenchymal cell proliferation, while Erbb3 deficient 
embryos have hypoplastic cushions completely lacking mesenchymal cells. Since the 
thickened valves of Dtr null embryos showed dramatic increases in activated BMP signaling 
effectors SMAD1/5/8 [17, 53] and since EGFR has been shown to downregulate BMP 
signaling by inactivating SMAD1 in vitro, Jackson et al. postulated that EGFR activation by 
TACE-derived soluble DTR normally limits BMP signaling during the transition from 
cushion formation/growth to valve remodeling [17]. Although we did not find overt genetic 
background-dependent differences in cardiac valve size from 15.5 dpc through PD1 
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Egfrwa2/wa2 mice, modifiers may have affected the balance of these signaling pathways post-
natally. Cellular changes in adult B6-Egfrwa2/wa2 semilunar valves mimic those seen in 
degenerative aortic stenosis [36, 42, 43, 46, 54, 55], suggesting that EGFR activity is also 
required to repress abnormal growth and differentiation in mature aortic valves. Several 
mediators of BMP signaling like TGFβ1, BMP2 and BMP4 are detected in aortic valve 
lesions and promote differentiation of isolated valvular interstitial cells to osteoblast-like 
cells [56]; osteoblasts express EGFR, while EGF stimulates osteoblast proliferation in vitro. 
Additionally, primary osteoblast cultures isolated from Egfrtm1Mag/tm1Mag null mice have 
reduced proliferation, but increased differentiation and ability to form bone nodules relative 
to controls [57]. Thus, attenuation of EGFR signaling predisposes to congenital defects and 
promotes a calcifying cell phenotype in mature valves on a B6 background. 
Accumulating evidence from epidemiologic, clinical and animal studies supports the 
hypothesis that calcific AS and atherosclerosis have common cardiovascular risk factors and 
pathological processes [34-36, 39, 44, 58, 59]. B6 and 129S1 inbred mouse strains are known 
to differ markedly in plasma HDL-cholesterol concentrations and susceptibility to 
atherosclerosis after high-fat diet consumption, with B6 mice having lower HDL levels and 
increased fatty streak aortic lesion formation [60]. Recently, it was shown that B6 mice 
chronically fed a high fat/high carbohydrate diet acquire aortic valve abnormalities, with 
decreased corrected valve orifice area, histological evidence of calcification and 
inflammation, and increased mean aortic outflow tract peak systolic velocities [61]. Since we 
detected similar pathological changes in the cardiac valves of adult B6-Egfrwa2/wa2 mice and 
wild-type B6 mice subjected to surgically induced pressure overload (C.J.B and D.W.T, 
unpublished observations), we speculate that the B6 background is predisposed to valve 
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disease that can be triggered by a variety of insults. Moreover, the predisposition of B6 mice 
to atherosclerosis and calcific AS may be mediated by common mechanisms.   
The B6 genetic background is also susceptible to developmental defects that probably 
contribute to early postnatal lethality in the presence of reduced EGFR activity. Decreased 
trabeculation, ventricular septal defects, thinned chamber walls and enlarged hearts were 
observed in B6-Egfrwa2/wa2 embryos at 12.5 dpc, prior to detection of obvious valve defects. 
Similar but more severe cardiac phenotypes were reported with targeted disruption of the 
neuregulin 1 (Nrg1) gene or of either of the two neuregulin receptor genes (Erbb2  or Erbb4) 
resulting in death by mid-gestation [62-64]. Nrg1, Erbb2 and Erbb4 remain expressed in 
postnatal and adult ventricular myocytes, and signaling through the ERBB axis is crucial for 
adult cardiomyocyte survival and cardiac function [65-69]. Additionally, Erbb2 and Erbb4 
are downregulated at both the message and protein levels in experimental and clinical studies 
of heart failure, supporting a role for disabled ERBB receptor signaling in the transition from 
compensatory hypertrophy to failure [70, 71]. EGFR has been biochemically linked to the 
ERBB signal axis through NRG1, which can bind to and activate EGFR heterodimers with 
ERBB3 and ERBB4. 
Most models of aortic valve deformities caused by gene disruptions have a drastically 
shortened life span and/or do not have isolated valve defects [17-22]. Consequently, it has 
been difficult to conduct detailed phenotypic analysis. Herein, we have extensively 
phenotyped two Egfrwa2 congenic lines that are susceptible or resistant to valvular 
degeneration with subsequent development of LVH and cardiac failure, despite having 
similar congenital valvular disease. Humans with acquired or congenital AS have 
considerable variability in onset of symptoms, cardiac response and function, and disease 
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progression. A subset of patients with AS remain asymptomatic despite rapid disease 
development and have a heightened risk of sudden death. Thus far, the only reliable predictor 
for these high risk patients is age and the extent of valvular calcification [72]. The 
development of therapeutic approaches that will halt or retard valve calcification should be 
aided by the Egfrwa2 model of AS. Finally, many cancers are now being managed as chronic 
rather than terminal diseases, and since targeted inhibition of EGFR activity is becoming a 
widely used cancer therapeutic, our results suggest that a subset of patients with congenital 
valve defects or predisposed to valvular defects may be at risk for developing drug-induced 
valvulopathy with prolonged EGFR inhibition. 
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Figure 3-1. Survival curve, gross and histological comparison of hearts in B6 Egfr wa2 
littermates and comparison of normalized heart weights in Egfr wa2 littermates. A. Survival 
curve of B6 Egfr wa2 littermates (n=50 mice, p<0.001). B. Gross and histological comparison 
of hearts from three-month-old B6 Egfr wa2 littermates. C. Comparison of normalized heart 
weights by genotype and genetic background in three-to-five month old Egfr wa2 littermates 
(N= 16, 13 and 17 sibling pairs, ***p<0.001).
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Table 3-1. Organ weights from three-to five month old Egfr wa2 littermates. Comparison by 
genotype *p<0.05, **p<0.01,***p<0.001. 
 
 
Genetic Background B6 F1                   129S1 
Genotype wa2/+ wa2/wa2 wa2/+ wa2/wa2 wa2/+ wa2/wa2 
N 16 16 9 9 18 18 
BW (g) 26.45±0.96 26.80±1.11 24.94±0.72 25.24±0.90 27.17±1.17 23.14±1.04* 
HW 141.83±3.50 330.15±24.36*** 124.27±4.23 134.11±4.14 148.31±4.94 136.26±4.60 
H:BW 5.42±0.16 12.33±0.82*** 4.98±0.07 5.34±0.18 5.56±0.23 5.99±0.21 
N 6 6 6 6 8 8 
LuW 149.63±1.84 173.25±2.75*** 141.4±15.34 157.67±3.43 141.96±8.62 129.4±3.5 
LiW 1244.62±30.65 1354.08±63.45 971.00±20.42 1086.67±52.33 981.20±31.93 758.78±46.97.00** 
Lu:BW 5.88±0.27 6.72±0.22* 5.44±0.58 5.47±0.40 5.33±0.50 6.02±0.31 
Li:BW 48.61±0.91 52.57 ±1.54* 37.43±1.45 37.53±2.72 36.65±2.27 35.06±2.16 
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Figure 3-2.  Western blot and densitometry analysis of total EGFR and  
phospho-ERK1/2 from B6 and 129S1 Egfr wa2  littermates A. Western blot and densitometry 
analysis of total EGFR and phospho-ERK1/2 (heart lysates) from B6 and 129S1 Egfr wa2 
littermates. B. Western blot and densitometry analysis of total and phospho-EGFR and 
phospho-ERK1/2 (liver lysates) from B6 and 129S1 Egfr wa2 littermates. All values are 
normalized to the β-actin loading control. Values represent the means from at least 3 
samples. C. EGFR transcript levels in total RNA extracted from hearts of adult Egfr wa2 
littermates. Fold change is relative to B6 Egfr wa2/+ samples. *p<0.05, **p<0.01 relative to 
Egfr wa2/+ littermates. 
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Figure 3-3. Comparison of congenital cardiac defects in B6 and 129 Egfr wa2 embryos. A. 
Endocardial cushions which give rise to the cardiac valves are similar in size and ECM 
composition in B6 and 129 Egfr wa2/wa2 12.5-13.5 dpc embryos. Aortic valves from newborn 
Egfr wa2/wa2 mice on both genetic backgrounds also appear similarly affected. B. Additional 
cardiac defects were detected in B6 Egfr wa2/wa2 prior to valve defects which likely contribute 
to early post-natal lethality. A. Heart enlargement was detected as early as 12.5 dpc. 
Histological analysis of B6 Egfr wa2/wa2 embryos demonstrated that both left and right 
ventricular chambers were dilated at this point in development, with some embryos 
manifesting additional defects such as thinned chamber walls, hypotrabeculation, and 
ventricular septal defects (VSDs). (A and B, B6 Egfr wa2/wa2 compared to E and F, B6 Egfr 
wa2/+). At E12.5 cardiac cushions were similar in size in Egfr  wa2/wa2 mice on all genetic 
backgrounds. By PD1, B6 Egfr wa2/wa2 hearts had visibly enlarged cardiac chambers, with 
loosely packed cardiomyocytes, and increased apoptosis, particularly in the intraventricular 
septal wall (Figure C, D, and E, B6 Egfr wa2/wa2 compared to B6 Egfr wa2/+ G, H and I; VSD= 
ventral septal defect, AVC= cardiac cushions contributing to aortic valve).  
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Figure 3-4. Comparison of cardiomyocyte size and cardiac fibrosis in B6 Egfr wa2   
littermates. A. Comparison of mean cardiomyocyte cross-sectional area in PD1 and 12 week-
old B6 Egfr wa2  littermates (N=3 and 8 sibling pairs, respectively, 300 cardiomyocytes 
measured per animal, **p<0.01). B. Representative Masson’s trichrome stained histological 
slices from the LV free wall of B6 Egfr wa2 littermates (20x magnification). C. Representative 
short-axis M-mode tracings from three month old B6 Egf wa2 littermates.
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Table 3-2. Measurements of cardiac function from three-to five month old Egfr wa2 
littermates. Comparison by genotype *p<0.05, **p<0.01,***p<0.001. 
 
Genetic 
Background 
 
B6 
 
F1 
 
129 
Genotype  wa2/+ wa2/wa2  wa2/+ wa2/wa2  wa2/+ wa2/wa2 
N 11 11 8 8 8 8 
LVED, d (mm) 3.52±0.06 4.88±0.15*** 3.79±0.07 3.73±0.05 3.72±0.05 3.31±0.09 
LVED, s (mm) 2.11±0.08 3.43±0.15*** 2.29±0.11 2.40±0.07 2.17±0.07 1.83±0.10 
LVPWTh, d (mm) 0.97±0.07 1.52±0.09*** 0.82±0.02 0.70±0.03* 0.84±0.04 0.74±0.05 
LVPWTh, s (mm) 1.34±0.08 2.16±0.10*** 1.09±0.02 1.02±0.05 1.19±0.04 1.14±0.08 
% FS 40.23±1.70 29.32±1.50*** 39.70±2.40 35.69±1.61 41.81±1.19 45.27±2.05 
RWT 0.56±0.05 0.63±0.05 0.44±0.01 0.38±0.02* 0.45±0.02 0.47±0.04 
HR (BPM) 437±14 430±9 461±15 425±12 470±17 445±13 
N 5 5 4 4 4 4 
Mean Peak AoVelocity 
(cm/s) 108±13 371±100
* 103±8.1 180±11 98±16 184±44 
N 5 15 4 4 7 12 
Pressure gradient 
(mmHg) 
(catheterization) 
-0.40±1.33 22.13±2.87** 3.5±3.01 11.35±5.54 -2.49±3.36 5.59±1.93* 
91 
 
 
Table 3-3.  Blood pressure measurements from three-to five month old Egfr wa2 littermates. 
No significant differences were detected in any parameters by genotype or genetic 
background. 
Genetic Background B6 129 
Genotype  wa2/+ wa2/wa2  wa2/+ wa2/wa2 
N 7 4 8 8 
SYS (mmHg) 119±9 125±7 125±11 133±30 
DIAS (mmHg) 90±16 108±11 94±17 106±16 
MAP (mmHg) 102±15 110±15 106±14 114±19 
HR (BPM) 757±40 734±24 683±42 708±14 
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Figure 3-5. Comparison of aortic cusp thickness and correlation of aortic cusp thickness and 
heart weight in Egfr wa2 littermates. A. Representative hemotoxylin and eosin stained sections 
of the thickest region of two cusps of the aortic valves from B6 and 129 Egfr wa2 littermates. 
B. Comparison of mean aortic valve cusp diameter by genotype and genetic background. 
(**p<0.01, *** p<0.001) C. Correlation between heart weight and mean cusp thickness by 
genotype and genetic background. 
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Figure 3-6. Representative Doppler tracings from B6 Egfr wa2 littermates and correlation 
between pressure gradients and mean cusp thickness in Egfr wa2littermates A. Representative 
Doppler tracings from three-month-old B6 Egfr wa2 littermates at the level of the aortic root. 
B. Correlation between peak systolic pressure (PSP) and mean aortic valve cusp diameter in 
B6 and 129 Egfr wa2 littermates. 
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Figure 3-7. Histological comparison of markers for cellular proliferation in aortic cusps from 
B6 and 129S1 Egfr wa2 littermates. A. Comparison of aortic and mitral valves at gross 
dissection between three-month-old B6 Tyrc-2J Egfr wa2 littermates. Cells in the aortic valves 
of B6 Egfr wa2/wa2 mice stain positive for PCNA (B) and pERK1/2 (C) (magnification= 20x 
and 40x, respectively).
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Figure 3-8. Histological comparison of markers for altered extracellular matrix composition, 
calcification and inflammation in aortic cusps from B6 and 129S1 Egfr wa2 littermates. A. 
Movat’s pentachrome stain reveals altered ECM composition in the aortic valves of B6 Egfr 
wa2/wa2 mice compared to B6 Egfr wa2/+ and 129 Egfr wa2 mice (magnification= 10x (first 
panel) and 40x (second and third panels)). Arrows point to cells within the aortic valves of 
B6 Egfr wa2/wa2 mice that stained positive for osteopontin (B, magnification=40x). 
Calcification (black staining) is detected in aortic valves of B6 Egfr wa2 littermates (C, 
magnification=20x). D. Inflammatory cells are detected in the aortic valves of some B6 Egfr 
wa2/wa2 mice (blue= DAPI stained nuclei, red= Cy3 labeled MOMA-2 positive cells, 
magnification= 20x).  
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Figure 3-9. Timeline comparing observed cardiac phenotypes in B6 and 129S1 Egfr wa2/wa2 
mice. 
E12.5 E15.5-PD1 PD7  PD21 12 wks*
Cardiac phenotypes:
Enlarged ventricles
Thinned chamber walls
VSD
Decreased trabeculation
Cardiomyocyte hypertrophy
Valve phenotypes:
Enlarged valves
Calcification/differentiation
Altered ECM composition
Aberrant VIC proliferation
Inflammatory infiltrate
Summary of Egfr wa2/wa2 cardiac phenotypes
= observed in129 Egfr wa2 /wa2 mice 
= observed in B6 Egfr wa2/wa 2 mice
= only 1 littermate pair analyzed
XXXXX=absence of phenotype in 129 Egfr wa 2/wa2 mice
XXXXX= only 1 littermate pair analyzed 
* Arrow starts at timepoint phenotype  was first observed
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXX
XXXXXXXXX
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CHAPTER 4 
CHRONIC REPRESSION OF EGFR ACTIVITY LEADS TO CARDIAC 
DYSFUNCTION IN C57BL/6J MICE 
 
Abstract 
Increased or constitutive signaling through EGFR/ERBB1 occurs in approximately one third 
of all human neoplasms and is associated with poor prognosis. EGFR targeted therapy using 
tyrosine kinase inhibitors (TKIs), which block receptor activity by binding to the ATP 
binding pocket of the kinase region, has impacted patient survival in several tumor types with 
oral administration. With these and other advances in drug discovery coupled with 
improvements in chemotherapy regimen and detection, the 10 year survivorship for many 
common cancers in the United States has substantially increased over the past two decades.  
Consequently, more individuals may be exposed to EGFR targeted therapies for longer 
duration. EGFR, as well as other ERBB family members, play key roles in cardiac 
development and homeostasis. However, the consequence of chronic suppression of EGFR 
activity on cardiac physiology is unknown. To address this question, we exposed 6-8 week 
old C57BL/6J (B6) mice to EKB-569, an irreversible TKI, or AG-1478, a reversible TKI, in 
chow for three months. Age and sex matched controls received the AIN-93G base diet.  Body 
weight was monitored over the course of the experiment, while cardiac function was 
evaluated at baseline and prior to sacrifice. Heart, lung, liver and kidney weights were 
collected at necropsy. Cardiac fibrosis and apoptosis were assessed using the Masson’s 
Trichrome and TUNEL assays while cardiomyocyte size was compared as an indicator of 
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cardiac hypertrophy. Real time PCR was used to evaluate gene expression of ERBB 
receptors and ligands (Egfr, Erbb2, Egf, Nrg1, and Dtr/Hb-egf), pro and anti-apoptotic genes 
(Bcl2/1, Bax, and Bad) and cardiac hypertrophy (Nppa and Nppb) in the LVs of AG-1478 
exposed mice compared to controls. In B6 female mice, chronic dietary exposure to both 
TKIs depressed body weight gain and caused significant changes in LV wall thickness and 
cardiac function compared to controls. No significant differences were observed in heart 
weight or cardiomyocyte size by treatment. Histological analysis revealed increased numbers 
of TUNEL positive cells in the hearts of TKI-exposed B6 female mice; however this 
difference was only significant in EKB-569 exposed mice compared to controls. Consistent 
with histological results, LV apoptotic gene expression was altered, with significant 
downregulation of the anti-apoptotic gene Bcl2/1. Interestingly, there were no significant 
differences in any of these endpoints in AG-1478 exposed male mice compared to controls. 
However, the LVs of AG-1478 exposed male mice had significant upregulation of Egf, 
Erbb2, and Nppb over controls. Taken together, these data suggest that chronic dietary 
exposure to TKIs may result in pathological and physiological changes in the heart. 
Additionally, gender may influence susceptibility to TKI mediated toxicity. 
Introduction 
The EGFR (HER1) is the prototypical and first discovered member of the HER 
family of membrane receptors, which also includes ERBB2/HER2, ERBB3/HER3 and 
ERBB4/HER4.  These receptors have a conserved molecular structure with an extracellular, 
cysteine-rich ligand-binding domain, a single alpha-helix transmembrane domain, and an 
intracellular domain with tyrosine kinase (TK) activity in the carboxy-terminal tail (except 
ERBB3) [1]. Ligand-binding induces EGFR homodimerization or heterodimerization with 
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other ERBB receptors and triggers tyrosine kinase catalytic activity.  Subsequently, 
autophosphorylation or transphosphorylation of tyrosine residues in the carboxy-terminal tail 
produces phosphotyrosine sites where adaptor and docking molecules bind [2]. The net result 
of intracellular signaling cascades is altered transcription of key molecules involved in a 
wide range of cellular processes, including proliferation, differentiation, motility, survival, 
angiogenesis and invasion.  
It has been estimated that increased or constitutive signaling through EGFR, occurs in 
approximately one third of all human neoplasms; moreover, aberrant signaling is associated 
with poor prognosis including non-responsiveness to traditional chemotherapy and decreased 
survival [3-5]. Since the EGFR was first proposed as a cancer drug target almost twenty 
years ago [6-8], advances in drug discovery have produced a plethora of inhibitors targeting 
specific regions of the receptor.  In particular, tyrosine kinase inhibitors (TKIs), which block 
EGFR activity by competing with adenosine triphosphate (ATP) for binding to the receptor's 
kinase pocket, have impacted patient survival in several tumor types with oral administration 
[9].  Two EGFR TKIs, [Gefitinib/Iressa, (AstraZeneca, Wilmington, Delaware) and 
Erlotinib/Tarceva, (OSI Pharmaceuticals, Uniondale, New York)], have received regulatory 
approval for use in cancer patients while several others are being evaluated in ongoing 
clinical trials as mono or combinatorial therapies [10, 11]. With the enormous strides that 
have been made in cancer therapy, and the resultant increases in life expectancy after 
diagnoses, certain cancers are now perceived and treated as chronic, rather than terminal, 
disease [12-16]. Although the side effects of targeted therapies like TKIs are considered mild 
compared to traditional chemotherapeutics, patients may now be exposed to these drugs for 
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years rather than months. However, the long-term physiological consequences of suppressed 
EGFR activity are unknown. 
A wealth of evidence has established that all four ERBB family members are 
essential to normal cardiovascular development [17-25]. A role for ERBB signaling in adult 
cardiac homeostasis is also emerging. Three of the four receptors (EGFR, ERBB2, and 
ERBB4) are detected in the adult human and rodent heart; among these ERBB4 appears to be 
the most abundant [26-29]. The expression and activity of ERBB2/4 receptors is depressed in 
clinical and experimentally induced heart failure [30-32] and signaling via NRG1/ERBB2/4 
activation is critical for adult cardiomyocyte survival [26, 33-35]. The importance of this 
signaling pathway in normal cardiac physiology was not fully recognized until the 
unexpected and lethal cardiomyopathy reported in breast cancer clinical trials using 
trastuzmab (Herceptin, Genetech San Francisco, CA), a humanized monoclonal antibody 
targeting ERBB2 [35-38]. Subsequently, mouse models with ventricular specific deletion of 
ERBB2 or ERBB4 were found to recapitulate the cardiac phenotype observed in clinical 
trials [39-41]. More recently, signaling through EGFR also was shown to impact 
cardiomyocyte hypertrophy and survival as well as provide cardioprotection against stress-
induced injury [42-46]. However, to date, no in vivo studies have specifically assessed the 
effects of chronically reduced EGFR activity (as might be expected with continuous drug 
exposure to TKIs) on adult cardiac function. To address this question, we used EKB-569 (6,7 
disubstituted 4-anilinoquinoline-3-carbonitrile, Wyeth Pharmaceuticals, Collegeville, 
Pennsylvania) a selective irreversible TKI currently in clinical trials [47, 48], and AG-1478 
(4-3-chloroamlino-6,7, dimethoxyquinazoline) a reversible TKI demonstrated to selectively 
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inhibit EGFR in various experimental systems [49-52], to assess the effects of chronic oral 
exposure to these drugs on cardiac function and pathology in C57BL/6J (B6) mice. 
Materials and Methods 
Animals and diet. B6 mice (6-8 weeks old) of both sexes were weighed, randomly 
distributed to treatment groups, and received either AIN-93G (Bioserve, Frenchtown, New 
York) control chow (controls, n=11 females and 4 males) or AIN chow containing the EGFR 
small molecule inhibitors EKB-569 (150 mg/kg of food, n=8, female) or AG-1478 (144 
mg/kg of food, n=6 females and 4 males) equivalent to 20 and 19.2 mg/kg/mouse/day. Mice 
were housed together for the duration of the studies, and were maintained on these diets ad 
libitum for 90 days, then sacrificed (all protocols approved by institutional animal care and 
use committee). Body weights were measured at baseline and at approximately 15 days, 30 
days, 60 days, and 90 days of treatment. 
Pharmacologic Treatment of Apc Min/+ mice. B6-ApcMin mice were obtained from The 
Jackson Laboratory (Jackson Laboratories, Bar Harbor, Maine). Mice were genotyped for 
ApcMin alleles as reported [53].  Starting at weaning, male and female Apc Min/+ littermates 
were fed either AG-1478 or control diets as described above ad libitum.  Animals euthanized 
at three months of age and gastrointestinal (GI) tracts were processed as described below. 
Macroadenoma Counts. The GI tract from pylorus to rectum was removed. Small intestine 
was cut into thirds, and the caecum and colon were separated. Segments were gently flushed 
with PBS to remove fecal material, cut longitudinally, splayed flat on Whatmann 3MM 
paper, and fixed overnight at 4°C in 4% paraformaldeyhyde. Polyp counts and diameter 
measurements were made under a dissection microscope with an in-scope micrometer, 
allowing detection of polyps >0.3 mm in diameter. 
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Echocardiography. Transthoracic echocardiography (TTE) was performed at baseline and 
prior to sacrifice using a 30 mHz probe and the Vevo 660 Ultrasonograph (VisualSonics, 
Toronto, Canada). Mice were lightly anaesthetized with 1-1.5% isofluorane and a topical 
depilatory agent applied, before placing in the left lateral decubitus position under a heat 
lamp to maintain body temperature at 37°C. Heart rate was maintained between 450-500 
BPM. Two dimensional short and long axis views of the left ventricle were obtained. M-
mode tracings were recorded and used to determine LV end-diastolic diameter (LVED,d), 
LV end systolic diameter (LVED,s), LV posterior wall thickness diastole (LVPWThD) and 
LV posterior wall thickness systole (LVPWThS) over three cardiac cycles. LV fractional 
shortening was calculated using the formula % FS= (LVED,d-LVED,s)/(LVED,s).  
Histology. At necropsy, hearts, lungs, liver, and kidneys were dissected from mice of each 
treatment group, rinsed in PBS and weighed. Hearts were cut in cross-section just below the 
level of the papillary muscle. For assessment of cardiomyocyte size, and fibrosis, the top half 
of the heart was formalin-fixed and embedded in paraffin.  Sections (5 μm ) were prepared at 
200 μm intervals. The sections were stained with hematoxylin and eosin (H&E) for 
examination of gross appearance, while Masson’s Trichrome (MT) was employed to 
facilitate visualization of fibrosis, aortic valve size and cardiomyocyte size. Cardiomyocyte 
hypertrophy was assessed by measuring cross-sectional area of 100 cardiomyocytes per PAS-
H stained section in ten randomly selected fields having nearly circular capillary profiles and 
centered nuclei in the left ventricular free wall. Histological images were analyzed using 
Nova Prime 6.75.10 software (BioQuant Image Analysis, San Diego, California). For 
measurement of cardiac valve size and calcification, serial sagittal sections (5 μm) were 
collected from each treatment group. Von Kossa’s method was used as a marker of 
108 
 
calcification.(http://www.medlib.med.utah.edu/WebPath/HISTHTML/MANUALS; [54]  
Gene expression. Total RNA was extracted from the lower half of the LV using TRIzol 
(Invitrogen, Carlsbad, California). After DNAse treatment, 500 ng of total RNA was reverse 
transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, 
California). The expression of classic hypertrophy markers [(atrial nautriuretic peptide 
(Nppa) and brain nautriuretic peptide (Nppb))], pro and anti-apoptotic members (Bcl2/1, Bax 
and Bad), and selected ERBB receptors and ligands (Egf, Nrg1, Dtr/Hb-Egf, Erbb1 and 
Erbb2) was determined by real-time quantitative PCR (qPCR) using Taqman Univeral 
Master Mix and Assays-on Demand primers and probes (Applied Biosystems, Foster City, 
California). Results are represented as mean fold changes relative control groups. Reactions 
were run on a Stratagene MX3000P machine with analysis software. Threshold cycles (CT) 
were determined by an in-program algorithm assigning a fluorescence baseline based on 
readings prior to exponential amplification. Fold change in expression was calculated using 
the 2-ΔΔcT method [55] using the gene β−actin as an endogenous control. Similar results were 
obtained using GusB as an endogenous control. 
In vivo phosphorylation assays. B6 mice maintained on the respective diets for 
approximately 90 days were injected subcutaneously with 5 μg/g body weight of EGF (R&D 
Systems, Minneapolis, Minnesota) in PBS. After 10 minutes, livers and hearts were 
harvested, frozen in liquid nitrogen, and stored at -80°C. The frozen tissues were sonicated in 
5–10 volumes (5–10 ml/g tissue) of lysis buffer consisting of 20 mM HEPES, pH 7.4, 150 
mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 10 μg/ml of leupeptin, 10 μg/ml of 
aprotinin, 1 mM sodium vanadate, and 10 mM β-glycerophosphate at 4°C. The tissue lysates 
were cleared by centrifugation for 10 min at 4°C and protein concentrations were determined 
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by the Bradford assay (Bio-Rad, Hercules, California). An equal amount of protein lysate (15 
μg, liver and 30 μg, heart) was separated by denaturing 7.5% sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes (Bio-
Rad, Hercules, California). Protein blots were incubated overnight at 4°C with EGFR ab-17 
polyclonal rabbit antibody (RB-1417-P1, LABVISION/Neomarker, Freemont, California), 
polyclonal rabbit phospho-EGFR (Tyr1086) antibody (36-9700, Zymed, San Fransico, 
California), or polyclonal rabbit phospho-p44/42 MAP Kinase (Thr202/Tyr204) antibody 
(Cell Signaling, Danvers, Massachusetts) followed by incubation goat anti-rabbit horseradish 
peroxidase conjugated antibody (#1858413, Pierce, Rockford, Illinois) and detected with an 
enhanced chemiluminesence system (Amersham Pharmacia/GE Healthcare). 
Statistical analysis. Data is presented as mean+/-SEM. Data from control groups was pooled 
where there was no significant difference between parameters. The Mann-Whitney or 
unpaired student’s t-test was used to compare data between respective treatment and control 
groups. The Kruskal-Wallis test or analysis of variance (ANOVA) was used to detect 
significance by treatment. All was performed using the StatView (SAS, Cary, North 
Carolina) program. A p<0.05 is considered statistically significant. 
 
Results 
Dietary exposure to AG-1478 is biologically effective. Previous reports using the Apc Min/+ 
mouse model of familial colorectal cancer demonstrated that dietary exposure to irreversible 
EGFR small molecule inhibitors EKB-785 or EKB-569 dramatically inhibited intestinal 
polyp formation [56, 57]. Although the reversible EGFR inhibitor AG-1478 has been used 
extensively and effectively with numerous in vitro and in vivo models of carcinogenesis, to 
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our knowledge it has not been used in this exposure regimen. To determine if dietary 
exposure to AG-1478 would elicit a significant biological response, recently weaned B6 Apc 
Min/+ littermates were fed chow containing AG-1478 (144 mg/kg; equivalent to approximately 
19.2 mg/kg/day, n=6) or base diet alone (n=6) ad libitum for 30 days after which their 
intestinal tracts were removed and the number of intestinal tumors counted under a dissecting 
microscope. AG-1478 was sufficient to reduce polyp number by 45% compared to controls 
(Table 4-1). This amount of protection was less than that reported for EKB-569 (at 20 
mg/kg/day, 87% reduction in polyp number), but almost identical to protection by EKI-785 
(at 40 mg/kg/day, 50% reduction in polyp number) under similar experimental conditions 
[56]. This preliminary experiment established the anti-tumor efficacy of AG-1478 in Apc 
Min/+ mice, and demonstrated that dietary delivery was an effective route. 
Dietary exposure to AG-1478 inhibits EGFR tyrosine kinase activity. Since 
pharmacokinetic studies in wild-type mice reported 3H AG-1478 tissue distribution to be 
highest in liver, which also has the highest EGFR expression levels and phosphorylated 
protein content, we examined protein levels of EGFR, ERK1/2 and their phosphorylated 
forms in liver lysates from wild-type B6 mice fed either control or AG-1478 diets to confirm 
that EGFR activity was being suppressed [49]. Mice were injected with rhEGF (5μg/g BW) 
prior to sacrifice. As seen in Figure 4-1, AG-1478 treatment reduced phospho-EGFR and 
phospho ERK1/2 protein levels in livers from wild-type B6 mice although EGFR total 
protein was similar to controls (Figure 4-1).  
Toxicology endpoints.  Female wild-type B6 mice chronically exposed to small molecule 
EGFR inhibitors exhibited depressed weight gain over the course of the experiment 
compared to controls (Figure 4-2). After 90 days of treatment, EKB-569 treated mice had lost 
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almost 6% of their starting body weight while their respective controls gained approximately 
16% over baseline body weights.  Although AG-1478 and respective control groups gained 
weight over the course of the experiment, drug treatment retarded weight gain (37.89±1.25 
controls, versus 29.08±7.20 AG-1478). Altered body weight suggested alterations in feeding 
behavior, energy expenditure or mild toxicity at these drug concentrations; however, there 
were no signs of dehydration, lethargy or ataxia in any treatment groups. 
There were no significant differences in wet heart, liver, or kidney weight by 
treatment groups. (Table 4-2 and data not shown). However, EKB-569 treated mice had 
increased wet lung weights (147.85±6.30 control versus 184.30±10.80 EKB-569, p<0.05), 
which remained significant when normalized for body weight (6.94±0.48 control versus 
9.67±0.28 EKB-569, p<0.05). Since interstitial lung disease has been reported in a subset of 
patients treated with the EGFR small molecule inhibitor gefitinib [58], we used MTC stain to 
visually inspect changes in collagen production in lungs from these mice. However, 
histological analysis did not reveal any obvious differences by treatment group. 
Cardiovascular function.  Chronic dietary exposure to EGFR small molecule inhibitors led 
to significantly altered cardiac function (assessed by TTE) although the severity varied by 
drug formula (Table 4-3). Both EGFR inhibitors caused increased left ventricular end 
diastolic and systolic dimensions and reduced contractility (as estimated by percent fractional 
shortening, %FS) compared to baseline values or control values, with EKB-569 having the 
greatest effect on LV wall thickness. Consistent with echocardiographic data, H&E stained 
cross sections taken at the level of the papillary muscle also showed morphological evidence 
of LV and septal wall thinning (Figure 4-3 A). 
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Cardiopathology and LV gene expression changes. Because significant alterations were 
seen in cardiac function with drug treatment, we conducted histological analysis of cardiac 
sections to investigate pathological endpoints such as cardiomyocyte hypertrophy, fibrosis, 
and apoptosis.  Consistent with heart weight data, there were no significant differences in 
mean cardiomyocyte area or in gene expression of the classic hypertrophy markers natriuretic 
peptide precursors A and B (Nppa, Nppb) in the LV by treatment (data not shown). There 
were also no significant differences in LV gene expression of selected Erbb family members 
and ligands (Erbb1, Erbb2, epidermal growth factor (Egf), neuregulin 1 (Nrg1), diphtheria 
toxin receptor/ heparin-binding EGF-like growth factor (Dtr/Hbegf), data not shown). 
Interstitial fibrosis, as demonstrated by Masson’s Trichrome stain, was observed in the LV 
walls of 25% (2/8) EKB-569 and 50% (3/6) of AG-1478 treated mice. Mild fibrosis was also 
observed in 20% (2/10) of controls (representative slices shown in Figure 4-3 A). 
Interestingly, both inhibitors increased the number of TUNEL-positive cardiac cells (Figure 
4-3 B and C) with apoptotic cells located in the LV walls, LV papillary muscle, and left atria 
(20.98±5.40 EKB-569 versus 16.64±3.87 AG-1478, and 6.43±1.95 Control, TUNEL positive 
cells/cm2, p<0.07).  Consistent with TUNEL assay, altered expression of apoptotic genes was 
observed in the LV of inhibitor-treated mice relative to controls (Figure 4-3 D). Specifically, 
expression of the anti-apoptotic gene Bcl2/1 was suppressed by approximately 50% (p<0.05) 
while pro-apoptotic genes Bad and Bax were non-significantly upregulated and 
downregulated, respectively. 
Since earlier evidence suggested that EGFR activity is critical for normal semilunar 
valve development [18], we investigated the effects of chronic exposure to EGFR inhibitors 
on morphological and histological changes in cardiac valves. Results from the initial cohort 
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using EKB-569 suggested that reduced EGFR activity might trigger excessive ECM 
production and calcification in adult valves. All EKB-569 treated mice (8/8) but less than 
half of the control mice (3/8) had evidence of cardiac valve calcification by von Kossa stain 
(examples shown in Figure 4-4 A), however, all B6 female mice from respective control and 
AG-1478 groups had some evidence of calcification. Interestingly, there was a significant 
dietary effect on mean valve thickness (AG-1478 (n=6) 0.15±0.01 μm versus EKB-569 (n=5) 
0.12±0.014μm versus Control (n=6) 0.95±0.02 μm, ANOVA p<0.04, Figure 4-4 B). For 
comparison, mean valve thickness for 16 week-old B6 male mice maintained on normal 
chow (NC) is also shown. Since the synthetic AIN-93G diet has higher fat content than 
regular chow (11%  AIN-93G versus 5% NC) and B6 mice are known to be prone to 
valvulopathy induced by high fat diet [59], it is possible that the effects of the small molecule 
inhibitors on valvular pathology were confounded by dietary fat content.  Thus, we are 
unable to draw conclusions about a correlation between chronic suppression of EGFR 
activity and valvulopathy. 
Gender specific effects of AG-1478. It is well established that gender dramatically 
influences physiological and pathological responses to xenobiotics. To determine if chronic 
EGFR inhibition affected males differently than females, a smaller cohort of 6-8 week old 
male B6 mice were fed AG-1478 or control diets (n=4 per group) under identical conditions. 
Male mice had no significant differences in body weight gain, organ weights or 
cardiovascular function after 90 days of treatment, nor significant differences in cardiac 
pathology (no evidence of fibrosis, cellular necrosis, or increased apoptosis).  Aortic valves 
appeared to be enlarged with AG-1478 treatment, but this did not reach significance (Figure 
4-5 A). There were no significant changes in cardiac expression of apoptotic genes (Bcl2/1, 
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Bax or Bad) by treatment groups. However, the hypertrophy marker Nppb was upregulated in 
the hearts of AG-1478 treated male mice, despite the fact that mean cardiomyocyte area was 
smaller. Erbb2 and Egf transcripts were also upregulated compared to controls (Figure 4-5 
B).  
Discussion 
To our knowledge, this is the first study to extensively evaluate cardiac function and 
pathology with chronic oral exposure to EGFR TKIs in healthy adult mice. Consistent with 
earlier reports using TKIs EKB-569 or EKI-785 [56], we demonstrated that dietary delivery 
of EGFR small molecule inhibitor AG-1478 effectively repressed EGFR-kinase activity and 
tumorigenesis in vivo. Employing AG-1478 and EKB-569, potent TKIs from different 
chemical classes, we found marked changes in weight gain and cardiac function in B6 female 
mice with chronic dietary exposure. Drug exposure also resulted in pathological changes in 
the heart. Most notably, the number of TUNEL positive cells was increased by 
approximately three-fold in the hearts of AG-1478 treated female B6 mice over controls, and 
was supported molecularly by significantly decreased expression of the anti-apoptotic gene 
Bcl2/1 in cardiac tissue from these animals compared to controls. We also found some 
histological evidence of pathological changes in cardiac valves of TKI-exposed mice, 
however, additional studies with larger numbers are needed to rule out possible confounding 
effects of the synthetic base diet.  
Results of our studies also imply that EKB-569 may be more toxic than AG-1478 in 
female mice. EKB-569 exposure resulted in body weight loss, compared to suppression of 
body weight gain with AG-1478 treatment. Interestingly, reports from Phase I clinical trials 
reported anorexia in ~ 20% of patients receiving intermittent doses of EKB-569 [48]. 
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Although AG-1478 caused greater depression in systolic function, hearts from EKB-569 
treated mice had thinner LV walls and significantly more TUNEL positive cells per square 
centimeter compared to controls.  Despite milder changes in cardiac contractility, wet lung 
weights were significantly increased with EKB-569 exposure.  Although we did not see 
evidence of increased fibrosis or pulmonary congestion, it is important to note that interstitial 
lung disease has been reported in a subset of patients receiving gefinitib in non-small cell 
lung cancer clinical trials [60-62].   
Although our observations are limited by small numbers, gender may influence response 
to TKIs, as we saw no differences in physiological and pathological parameters by treatment 
in male B6 mice that were significantly different in inhibitor-treated B6 female mice as 
compared to controls. We detected no significant differences by gender or treatment in 
cardiac EGFR expression, however, sexual dimorphism in basal EGF levels has been 
reported with male mice having higher protein levels in salivary glands [63] and higher 
transcript levels in pituitary glands [64] compared to females. Since we found that Egf, 
Erbb2, and Nppb transcripts were upregulated in the LV of male, but not female, AG-1478 
exposed mice relative to respective controls, it is possible that increased expression of these 
genes in the heart, coupled with higher circulating ligand levels, may compensate for reduced 
EGFR activity and contribute to the observed gender-specific effects. 
Differences between mode of inhibition, potency and selectivity between the two TKIs 
used in our experimental regimen may account for the discrepancy in toxicity. EKB-569 is an 
irreversible inhibitor, forming a covalent bond with the Cys 773 residue within the EGFR 
catalytic domain, while AG-1478 is a competitive inhibitor of ATP binding [47]. With 
irreversible inhibition, normal levels of EGFR activity are only recovered after gene 
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transcription and translation. Recent findings suggest irreversible inhibitors may prevent the 
acquired resistance seen in non-small cell lung cancer patients treated with competitive 
inhibitors such as gefitinib and erlontinib [65, 66]. While these properties are promising for 
cancer therapy, irreversible TKIs  may adversely affect cardiomyocyte function and survival, 
since EGFR transcript levels are normally very low in the adult mouse and human heart. The 
AG-1478 diet resulted in an approximately 45% reduction in polyp number, while at 
approximately the same concentration in identical base chow, EKB-569 caused about 87% 
reduction in polyp number in the Apc Min mouse model [56].  A single oral dose of EKB-569 
(10 mg/kg) was previously reported to rapidly inhibit EGFR kinase activity by 90% while 
multiple oral doses of AG-1478 (126 μM/kg) decreased phosphorylation of EGFR and 
ERK1/2 by approximately 60% and 50%, respectively, in xenograft studies [49].  This data 
suggests that EKB-569 is more potent than AG-1478 in these systems. 
Since ERBB2/HER2 and EGFR  have a high sequence homology in their catalytic 
domains [67-69], it is not surprising that many TKIs suppress activity of both receptors.  In 
cell free systems, AG-1478 showed higher selectivity for EGFR over ERBB2/HER2 (IC50, 3 
nM EGFR versus >100 μM   ERBB2/HER2) than EKB-569  (IC50, 0.08 μM EGFR versus 
1.23 μM for ERBB2/HER2) [9] [70].  In cell based assays using human carcinoma cell lines 
which overexpress EGFR (A431) or ERBB2/HER2 (SKBR3), the IC50 for EKB-569 was 
0.03 μg/mL and 0.007 μg/mL, respectively, consistent with effective inhibition of both 
receptors.  Mice with myocardium-specific gene targeting reducing myocardial Erbb2 
expression by 70% had a significant increase in cardiomyocyte apoptosis with anthracycline 
exposure [39]. Moreover, gene therapy with over-expression of Bcl2/1 partially rescued the 
dilated cardiomyopathy in these mice. Recent data also demonstrated similarly depressed 
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Bcl2/1 expression, cardiomyocyte apoptosis, and mitochondrial dysfunction in isolated 
cardiomyocytes with exposure to the anti-ERBB2 drug Herceptin (Trastumizab)[71]. Given 
the well documented roles of ERBB2 and ERBB4 signaling in cardiomyocyte survival, it is 
possible that greater cardiac cell death and LV dilatation observed with EKB-569 exposure 
reflects greater inhibition of ERBB2 and/or ERBB4 signaling, or other off-target effects.  
Consistent with growing literature underscoring the cardioprotective roles of ERBB 
signaling in vitro and in vivo, our studies suggest that prolonged exposure to TKIs targeting 
EGFR may compromise cardiac function. Recent analysis documents a major increase in the 
10 year survivorship for many common cancers in the US compared to the late 1980’s, thus 
more individuals may be exposed to TKIs and other chemotherapeutics for a longer duration 
[72]. Although overall, the side-effects of targeted therapies such as the TKIs are well-
tolerated compared to older chemotherapeutic drugs, these studies imply that, as with 
Herceptin therapy, cardiovascular function should be monitored with chronic exposure to 
these drugs.  
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Table 4-1.  Dietary exposure to AG1478 significantly reduces polyp count in ApcMin/+ mice. 
**p<0.01 
 
 
 
          Diet 
 
Na 
 
Polyp count        % control 
 
AG1478 
 
6 
 
23.7±5.8**                55.4% 
 
Control 
 
6 
 
53.1±14.8            100% 
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Figure 4-1. Immunoblot analysis of liver lysates from wild-type B6 mice exposed to the 
EGFR small molecule inhibitor AG-1478 in AIN 93G diet (AG-1478) or AIN 93G diet 
(Control) for three months. Mice were dosed with recombinant EGF (5 μg/kg) 10 minutes 
prior to sacrifice. 
Total EGFR 
 
pEGFR 
 
pERK1/2 
 
β-tubulin 
 Diet:     AG-1478  Control
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Figure 4- 2. Effects of dietary exposure to EGFR inhibitors on weight gain in B6 female 
mice. EKB-569 (A) or AG-1478 (B) exposure repressed weight gain in B6 female mice 
compared to controls. *p<0.05,**p<0.01, ***p<0.001 
 
*   *     
**  
                
*
***            ***                   *** 
     ***                  ***               *** 
B. AG-1478 Body weight                                            B. AG-1478 Percent Increase in BW over baseline 
A. EKB-569 Body weight                                            A EKB-569 Percent Increase in BW over baseline 
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Table 4- 2. Organ and body weights of EGFR inhibitor exposed mice compared to controls. 
*p<0.05,**p<0.01 compared to respective controls. BW, body weight, HW, heart weight, 
LuW, lung weight, H:BW, normalized heart weight, Lu:BW, normalized lung weight. 
 
Treatment N BW (g) HW [73] LuW [73] H:BW (mg:g) Lu:BW (mg:g) 
Control 8 22.04±0.40 121.93±6.0 147.85±10.80 5.74±0.31 6.94±0.48 
EKB-569 8 19.65±0.21** 112.61±5.73 184.25±10.85* 5.64±0.26 9.67±0.28* 
Control 3 24.67±0.33 155.3±10.33 174.00±14.60 6.31±0.47 7.05±0.57 
AG-1478 5 22.50±1.05 141.20±12.08 172.29±13.55 6.30±0.53 7.78±0.86 
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Table 4-3. Echocardiographic parameters measured at baseline and after approximately 90 
days on respective diets. *p<0.05, Inhibitor versus Baseline**p<0.01, Inhibitor versus 
Baseline £ p<0.05; Inhibitor versus Control, ¥ p<0.01; Inhibitor versus Control, δ p<0.05; 
EKB-569 versus AG-1478. LVED,d, left ventricular end diastolic diameter, LVPWTh,d, left 
ventricular posterior diastolic wall thickness, %FS, Percent fractional shortening, HR, heart 
rate.
Treatment N LVED,d LVPWTh,d %FS HR 
Baseline 16 3.40±0.07 0.70±0.08 39.80±2.38 455±20 
Control 6 3.35±0.08 0.81±0.07 42.42±5.53 467±15 
EKB-569 5 3.58±0.05*,£ 0.59±0.03£δ 36.24±2.10£ 444±30 
AG-1478 5 3.60±0.27£ 0.75±0.13 29.34±2.56,¥ 452±12 
ANOVA p< 0.05 0.01 ns ns 
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Figure 4-3. Pathological changes in the hearts of B6 mice chronically exposed to EGFR 
inhibitors. LV wall thinning and interstitial fibrosis (A) and increased apoptosis (B) were 
observed in the hearts of TKI exposed mice. C. Gene expression of proapoptotic and anti-
apoptotic genes. *p<0.05 
D. 
C. 
*
AG-1478 
Control
EKB-569
*
B. 
Control 
 
 
 
 
 
 
 EGFR inhibitor 
     A. 
 
AG-1478             EKB-569    Control 
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Figure 4-4. Valvular changes in the hearts of EGFR inhibitor-exposed B6 mice  
compared to mice fed normal chow. Valvular changes, such as calcification (detected by von 
Kossa stain, A) and increased aortic cusp thickness (B) were observed in the hearts of EGFR 
inhibitor-exposed B6 mice compared to mice fed normal chow (NC) or control (AIN-93G) 
chow. Arrows in A indicate positive staining for calcium deposition. NC= normal chow, 
*p<0.05. Bar= 100 μm. 
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 Figure 4-5. Mean thickness of aortic valves and relative fold changes in gene expression in 
the LV of B6 male mice chronically exposed to AG-1478 compared to controls. A. Mean 
thickness of aortic valves of B6 wild type mice fed normal chow (NC) control chow (AIN-
93G) or AG1478 chow. B. Relative fold changes in gene expression in the LV of B6 male 
mice chronically exposed to AG-1478 compared to controls. Nppa =nautriuretic peptide 
precursor A, Nppb= Natriuretic peptide precursor B, Egf=epidermal growth factor Erbb2= 
erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene 
homolog (avian), Dtr/Hb-egf= Diptheria toxin receptor/ heparin-binding epidermal growth 
factor. *p<0.05, **p<0.01. 
**
*          * 
         NC  Control           AG1478 
A. 
 
 
 
 
 
 
 
 
 
 
B. 
126 
 
 
References 
 
1. Wells, A., EGF receptor. Int J Biochem Cell Biol, 1999. 31(6): p. 637-43. 
 
2. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell, 2000. 103(2): p. 211-25. 
 
3. Salomon, D.S., et al., Epidermal growth factor-related peptides and their receptors in human 
malignancies. Crit Rev Oncol Hematol, 1995. 19(3): p. 183-232. 
 
4. Woodburn, J.R., The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol 
Ther, 1999. 82(2-3): p. 241-50. 
 
5. Nicholson, R.I., J.M. Gee, and M.E. Harper, EGFR and cancer prognosis. Eur J Cancer, 2001. 37 
Suppl 4: p. S9-15. 
 
6. Gill, G.N., et al., Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of 
epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists 
of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem, 1984. 259(12): p. 
7755-60. 
 
7. Masui, H., et al., Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth 
factor receptor monoclonal antibodies. Cancer Res, 1984. 44(3): p. 1002-7. 
 
8. Sato, J.D., et al., Biological effects in vitro of monoclonal antibodies to human epidermal growth 
factor receptors. Mol Biol Med, 1983. 1(5): p. 511-29. 
 
9. Jimeno, A. and M. Hidalgo, Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors. Biochim Biophys Acta, 2006. 1766(2): p. 217-29. 
 
10. Marshall, J., Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. 
Cancer, 2006. 107(6): p. 1207-18. 
 
11. Steeghs, N., J.W. Nortier, and H. Gelderblom, Small molecule tyrosine kinase inhibitors in the 
treatment of solid tumors: an update of recent developments. Ann Surg Oncol, 2007. 14(2): p. 942-53. 
 
12. Disis, M.L. and S. Rivkin, Future directions in the management of ovarian cancer. Hematol Oncol 
Clin North Am, 2003. 17(4): p. 1075-85. 
 
13. Snyderman, N., Cancer is no longer a death sentence. http://www.msnbc.msn.com/id/17760785/, 
2007. 
 
14. Michener, C.M. and J.L. Belinson, Modern management of recurrent ovarian carcinoma. A systematic 
approach to a chronic disease. Oncology (Williston Park), 2005. 19(10): p. 1277-85; discussion 1285, 
1288, 1293. 
 
15. Markman, M., Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol 
Oncol, 2006. 100(2): p. 229-30. 
 
16. Burton, A.W., et al., Chronic pain in the cancer survivor: a new frontier. Pain Med, 2007. 8(2): p. 189-
98. 
17. Lee, K.F., et al., Requirement for neuregulin receptor erbB2 in neural and cardiac development. 
Nature, 1995. 378(6555): p. 394-8. 
 
127 
 
18. Chen, B., et al., Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat 
Genet, 2000. 24(3): p. 296-9. 
 
19. Iwamoto, R. and E. Mekada, ErbB and HB-EGF signaling in heart development and function. Cell 
Struct Funct, 2006. 31(1): p. 1-14. 
 
20. Iwamoto, R., et al., Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart 
function. Proc Natl Acad Sci U S A, 2003. 100(6): p. 3221-6. 
 
21. Jackson, L.F., et al., Defective valvulogenesis in HB-EGF and TACE-null mice is associated with 
aberrant BMP signaling. Embo J, 2003. 22(11): p. 2704-16. 
 
22. Negro, A., B.K. Brar, and K.F. Lee, Essential roles of Her2/erbB2 in cardiac development and 
function. Recent Prog Horm Res, 2004. 59: p. 1-12. 
 
23. Erickson, S.L., et al., ErbB3 is required for normal cerebellar and cardiac development: a comparison 
with ErbB2-and heregulin-deficient mice. Development, 1997. 124(24): p. 4999-5011. 
 
24. Gassmann, M., et al., Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin 
receptor. Nature, 1995. 378(6555): p. 390-4. 
 
25. Goishi, K., et al., Inhibition of zebrafish epidermal growth factor receptor activity results in 
cardiovascular defects. Mech Dev, 2003. 120(7): p. 811-22. 
 
26. Zhao, Y.Y., et al., Neuregulins promote survival and growth of cardiac myocytes. Persistence of 
ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem, 1998. 273(17): 
p. 10261-9. 
 
27. Zhao, Y.Y., et al., Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar 
microdomains in cardiac myocytes. Circ Res, 1999. 84(12): p. 1380-7. 
 
28. Srinivasan, R., et al., Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and 
adult tissues and in a survey of nine solid tumour types. J Pathol, 1998. 185(3): p. 236-45. 
 
29. Fuchs, I.B., et al., Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of 
trastuzumab (Herceptin). Breast Cancer Res Treat, 2003. 82(1): p. 23-8. 
 
30. Uray, I.P., et al., Left ventricular unloading alters receptor tyrosine kinase expression in the failing 
human heart. J Heart Lung Transplant, 2002. 21(7): p. 771-82. 
 
31. Rohrbach, S., et al., Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed 
expression and attenuated activation. Basic Res Cardiol, 2005. 100(3): p. 240-9. 
 
32. Rohrbach, S., et al., Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential 
expression of erbB2 and erbB4 receptors. Circulation, 1999. 100(4): p. 407-12. 
 
33. Liu, X., et al., Neuregulin-1/erbB-activation improves cardiac function and survival in models of 
ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol, 2006. 48(7): p. 1438-47. 
 
34. Fukazawa, R., et al., Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis 
via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol, 2003. 35(12): p. 1473-9. 
 
35. Schneider, J.W., A.Y. Chang, and T.P. Rocco, Cardiotoxicity in signal transduction therapeutics: 
erbB2 antibodies and the heart. Semin Oncol, 2001. 28(5 Suppl 16): p. 18-26. 
 
128 
 
36. Schneider, J.W., A.Y. Chang, and A. Garratt, Trastuzumab cardiotoxicity: Speculations regarding 
pathophysiology and targets for further study. Semin Oncol, 2002. 29(3 Suppl 11): p. 22-8. 
 
37. Ewer, M.S., et al., Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, 
synergistic or sequential stress, or surveillance artifact? Semin Oncol, 1999. 26(4 Suppl 12): p. 96-
101. 
 
38. Schaller, G., et al., Therapy of metastatic breast cancer with humanized antibodies against the HER2 
receptor protein. J Cancer Res Clin Oncol, 1999. 125(8-9): p. 520-4. 
 
39. Crone, S.A., et al., ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med, 2002. 
8(5): p. 459-65. 
 
40. Ozcelik, C., et al., Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to 
dilated cardiomyopathy. Proc Natl Acad Sci U S A, 2002. 99(13): p. 8880-5. 
 
41. Garcia-Rivello, H., et al., Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J 
Physiol Heart Circ Physiol, 2005. 289(3): p. H1153-60. 
 
42. Zhai, P., et al., An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor 
transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res, 2006. 99(5): p. 
528-36. 
 
43. Howes, A.L., et al., Galphaq expression activates EGFR and induces Akt mediated cardiomyocyte 
survival: dissociation from Galphaq mediated hypertrophy. J Mol Cell Cardiol, 2006. 40(5): p. 597-
604. 
 
44. Chan, H.W., et al., Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte 
hypertrophy. J Recept Signal Transduct Res, 2006. 26(5-6): p. 659-77. 
 
45. Chan, H.W., et al., Tackling the EGFR in pathological tissue remodelling. Pulm Pharmacol Ther, 
2006. 19(1): p. 74-8. 
 
46. Pareja, M., et al., Activated epidermal growth factor receptor (ErbB1) protects the heart against 
stress-induced injury in mice. Am J Physiol Regul Integr Comp Physiol, 2003. 285(2): p. R455-62. 
 
47. Wissner, A., et al., Synthesis and structure-activity relationships of 6,7-disubstituted 4-
anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine 
kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth 
factor receptor-2 (HER-2). J Med Chem, 2003. 46(1): p. 49-63. 
 
48. Erlichman, C., et al., Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth 
factor receptor, in patients with advanced solid tumors. J Clin Oncol, 2006. 24(15): p. 2252-60. 
 
49. Ellis, A.G., et al., Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule 
inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol, 2006. 71(10): p. 1422-34. 
 
50. Partik, G., et al., Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins 
A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J Cancer Res 
Clin Oncol, 1999. 125(7): p. 379-88. 
 
51. Lenferink, A.E., et al., Blockade of the epidermal growth factor receptor tyrosine kinase suppresses 
tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci U S A, 2000. 
97(17): p. 9609-14. 
 
129 
 
52. Zhu, X.F., et al., EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell 
cycle in nasopharyngeal carcinoma cells. Cancer Lett, 2001. 169(1): p. 27-32. 
 
53. Dietrich, W.F., et al., Genetic identification of Mom-1, a major modifier locus affecting Min-induced 
intestinal neoplasia in the mouse. Cell, 1993. 75(4): p. 631-9. 
 
54. Carson, F.L., Histotechnology: A self- Instructional text. 1990, Chicago, Ill: ASCP Press. pp226-227. 
55. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402-8. 
 
56. Torrance, C.J., et al., Combinatorial chemoprevention of intestinal neoplasia. Nat Med, 2000. 6(9): p. 
1024-8. 
 
57. Roberts, R.B., et al., Importance of epidermal growth factor receptor signaling in establishment of 
adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A, 
2002. 99(3): p. 1521-6. 
 
58. Rabinowits, G., et al., Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell 
lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs, 2003. 
14(8): p. 665-8. 
 
59. Drolet, M.C., et al., A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J 
Am Coll Cardiol, 2006. 47(4): p. 850-5. 
 
60. Yamamoto, N., et al., Phase I dose-finding and pharmacokinetic study of the oral epidermal growth 
factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. 
Cancer Chemother Pharmacol, 2007. 
 
61. Yoneda, K.Y., et al., Interstitial lung disease associated with epidermal growth factor receptor 
tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer, 2006. 8 Suppl 
1: p. S31-5. 
 
62. Cersosimo, R.J., Gefitinib: an adverse effects profile. Expert Opin Drug Saf, 2006. 5(3): p. 469-79. 
 
63. Stern, L.E., et al., Salivary epidermal growth factor and intestinal adaptation in male and female mice. 
Am J Physiol Gastrointest Liver Physiol, 2000. 278(6): p. G871-7. 
 
64. Lazar, L.M. and M. Blum, Regional distribution and developmental expression of epidermal growth 
factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease 
protection assay. J Neurosci, 1992. 12(5): p. 1688-97. 
 
65. Kwak, E.L., et al., Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to 
gefitinib. Proc Natl Acad Sci U S A, 2005. 102(21): p. 7665-70. 
 
66. Baselga, J., Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in 
the treatment of cancer? A mutation-driven question. J Clin Oncol, 2006. 24(15): p. 2225-6. 
 
67. Coussens, L., et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares 
chromosomal location with neu oncogene. Science, 1985. 230(4730): p. 1132-9. 
 
68. Arteaga, C.L., The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to 
therapeutic target in human neoplasia. J Clin Oncol, 2001. 19(18 Suppl): p. 32S-40S. 
 
69. Yamamoto, T., et al., Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth 
factor receptor. Nature, 1986. 319(6050): p. 230-4. 
 
130 
 
70. Levitzki, A. and A. Gazit, Tyrosine kinase inhibition: an approach to drug development. Science, 
1995. 267(5205): p. 1782-8. 
 
71. Grazette, L.P., et al., Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: 
implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol, 2004. 44(11): p. 2231-8. 
 
72. Brenner, H. and V. Arndt, Recent increase in cancer survival according to age: higher survival in all 
age groups, but widening age gradient. Cancer Causes Control, 2004. 15(9): p. 903-10. 
 
73. Browe, D.M. and C.M. Baumgarten, EGFR kinase regulates volume-sensitive chloride current elicited 
by integrin stretch via PI-3K and NADPH oxidase in ventricular myocytes. J Gen Physiol, 2006. 
127(3): p. 237-51. 
 
 
131 
 
CHAPTER 5 
GENETIC MODIFIER LOCUS AFFECTING LEFT VENTRICULAR 
HYPERTROPHY IN THE EGFR WA2 MOUSE MODEL OF AORTIC STENOSIS 
 
Abstract 
Left ventricular hypertrophy (LVH), or increased left ventricle (LV) mass, is 
recognized as an independent risk factor for cardiac-related morbidity and mortality. LVH is 
most commonly caused by cardiovascular diseases which chronically elevate afterload, such 
as aortic stenosis (AS). Increasing evidence suggests heritable components significantly 
modulate the development and severity of AS-related cardiac hypertrophy.  One approach to 
identify genes which modify disease outcome is to use mouse models that show distinct 
genetic variation of the disease phenotype.  Mice homozygous for a hypomorphic mutation in 
the epidermal growth factor receptor gene (Egfr wa2) were discovered to have congenitally 
enlarged aortic valves with mild AS on a mixed genetic background. By backcrossing the 
Egfr wa2 allele onto the C57BL/6J or 129S1/SvImJ inbred strains, we discovered significant 
strain and sex dependent variation in LVH and progression to heart failure, with male B6- 
Egfr wa2/wa2 mice having the most severe cardiac phenotype.  Using these two inbred strains, 
we created an F2-Egfr wa2/wa2 population to employ this genetically sensitized mouse model to 
map modifiers of LVH. Linkage analysis of F2-Egfr wa2/wa2 progeny identified one significant 
locus on chromosome 9 in males (LOD score ~4.82, p<0.05) and one suggestive locus on 
chromosome 16 in females (LOD score ~4.14, p<0.63) linked to heart weight. By applying 
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haplotype analysis, we were able to narrow the critical intervals for each locus.  
Identification of genetic modifiers using the Egfr wa2 disease model may provide novel 
mechanistic insights into the pathogenesis and progression of AS and LVH. Moreover, these 
studies are particularly timely, since therapies targeting the EGFR have been proposed as 
novel treatments for LVH and hypertension. 
Introduction 
Left ventricular hypertrophy (LVH), or increased left ventricle (LV) mass, is 
associated with many cardiovascular disorders and is recognized as an independent risk 
factor for cardiac-related morbidity and mortality [1-5].  Although it can be associated with 
mechanical stress, growth factors, catecholamines, cytokines and primary genetic 
abnormalities, LVH is most commonly caused by chronically elevated afterload, which 
increases LV stroke work. Aortic stenosis (AS) and essential hypertension (EH) are two 
prevalent cardiovascular diseases that induce LVH secondary to increased afterload. Clinical 
presentation, onset of symptoms, disease progression and mortality associated with these 
diseases is highly variable [6-22]. Although several clinical risk factors have been elucidated, 
increasing evidence from clinical and experimental studies suggests heritable components 
significantly modulate the development and severity of AS and EH-related LVH, as well as 
LVH regression with therapy [11, 14, 23-28].  Thus, elucidating genetic factors underlying 
the pathogenesis of LVH is pivotal to the successful clinical management of these common 
cardiovascular diseases. 
Surgical transverse aortic constriction (TAC) is an accepted experimental model for 
human cardiac response to chronic pressure overload, since it causes chronic LV pressure 
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overload, progressive LVH remodeling and subsequent cardiac failure in mice [29-34]. 
Recently, we reported that C57BL/6J (B6)TAC mice had decreased survival, LVH, 
significant pathological cardiac remodeling and earlier progression to heart failure compared 
to 129S1/SvImJ (129S1) or F1 (B6x129S1) TAC mice (see Chapter 2).  Since all mice shared 
similar environmental conditions, this strongly suggested that genetic background 
significantly modified the cardiac response to increased afterload. However this model is not 
ideal for genetic mapping studies, since the degree of constriction, and thus induced load, can 
fluctuate [35, 36] and technical expertise is required for consistent results. Therefore, to 
dissect quantitative trait locus (QTL) that modify the hypertrophic response, we took 
advantage of a genetic model of pressure-overload induced LVH.   
The waved-2 allele (Egfr wa2) encodes a single base pair mutation in the epidermal 
growth factor receptor (Egfr/Erbb1) gene, resulting in an up to 90% reduction in receptor 
activity [37].  When maintained on a mixed genetic background, Egfr wa2/wa2 mice had 
hyperplastic aortic valves and mild to moderate AS, but otherwise were viable and fertile, 
with minor coat and eye phenotypes [38]. However, when this mutation was backcrossed 
onto the B6 and 129S1 genetic backgrounds, significant strain-dependent variability was 
detected in cardiac phenotypes.  While both B6 and 129S1-Egfr wa2/wa2 mice had similar 
congenital valve defects (consistent with previous reports), only B6-Egfr wa2/wa2 had 
significant cardiac hypertrophy, congestive heart failure and severe AS. Since F1-Egfr wa2/wa2 
(B6-Egfr wa2/+ X 129S1-Egfr wa2/wa2) offspring were protected from cardiac hypertrophy and 
had normal lifespans, we hypothesized that 129S1 genetic modifiers were protective and 
dominant to B6 modifiers in the cardiac response to chronic pressure overload.   Therefore, 
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we created an F2-Egfr wa2/wa2 population in order to map genes modifying the development of 
LVH.   
Materials and Methods 
Generation of congenic lines.  Stock B6EiC3H-a/A-Egfrwa2 Wnt 3avt   mice were obtained 
from The Jackson Laboratory (Bar Harbor, Maine). The Egfrwa2 allele was backcrossed to the 
inbred strains 129S1/SvImJ (129S1) and C57BL/6J (B6). Greater than ten backcross 
generations were performed by crossing Egfrwa2 allele carriers at each generation to the 
respective inbred strain. After ten generations, animals carrying the Egfrwa2 allele were freely 
intercrossed. Segregation and loss of the Wnt3avt mutation, which resides approximately 20 
cM distal to Egfr on chromosome 11 and which is maintained in cis with Egfrwa2 in the 
progenitor stocks, was verified by PCR genotyping. The F1-Egfr wa2/wa2 population was 
created by outcrossing B6-Egfrwa2/+ females to 129S1-Egfrwa2/wa2 males. Heterozygous mice 
were identified by PCR genotyping, while homozygous mice were identified by their curly 
whisker phenotype , with confirmation by PCR [39]. Four male and four female F1 Egfr 
wa2/wa2 mice were randomly intercrossed to generate 190 F2 offspring. An additional 32 N2 
mice were generated by crossing F1-Egfr wa2/wa2 females to B6-Egfr wa2/wa2 males. All crosses 
involved females between the ages of 2-10 months and males between the ages of 2-12 
months. Since significant post-natal lethality had been observed in the B6-Egfr wa2/wa2 mice 
(described in Chapter 3) cages were checked daily for the presence of newborn pups and 
litter size was recorded.  
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Phenotyping.  A total of 190 F2-Egfr wa2/wa2 mice were sacrificed at three months of age. 
Body weights and gross heart weights were recorded at this time. Tail and liver biopsies were 
flash frozen in liquid nitrogen for future analyses. 
Genome-wide Scan. A whole genome scan was performed on fifty-six progeny from the F2 
(F1xF1) intercross, chosen because their phenotypic values were greater than 0.5 standard 
deviations from the mean. Genomic DNA was prepared from mouse tails by using the 
PUREGENE Purification Kit for cells and tissue (Gentra Systems, Minneapolis, Minnesota).  
Genotyping  was performed by the Mouse SNP Genotyping Service of the  Mutation 
Mapping and Developmental Analysis Project (MMDAP; Brigham and Women’s Hospital, 
Harvard Medical School), using Sequenom MassARRAY technology employing 482 
informative SNPs between B6 and 129S1 inbred strains markers [40]. All physical positions 
of markers are based on the Ensembl v31 of the NCBI m33 mouse genome assembly. Table 
5-1 lists the informative markers and their physical and genetic positions, with marker 
coverage spanning 19 autosomes.  Markers were excluded on the basis of: (1) failure to 
recognize the three possible genotypes in B6, 129S1 and F1 controls (2) the presence of 
impossible genotypes and (3) genotypes that created impossible recombinations between 
closely linked markers. On average, markers were spaced every 3.4 cM (range 0-27cM). 
Linkage analysis. Genetic distances of informative SNPs included in this analysis were 
inferred using closely linked microsatellite markers for which the genetic distance from the 
centromere was determined previously [41]. We used heart weight (HW), normalized heart 
weight (H:BW), and body weight (BW) as the phenotypes for QTL mapping. Similar results 
were obtained when average HW or H:BW was used.  Since HW and H:BW were not 
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normally distributed, these values were log transformed prior to analysis. Linkage analyses 
were performed using  a parametric model within the R/qtl software program [42].  
Haplotype analysis. The haplotypes of regions within a 1.5 LOD interval surrounding each 
QTL were compared using The Jackson Laboratory’s Mouse Phenome Database SNP 
collection (http://www.jax.org/phenome/snp.html). All SNPs are mapped to NCBI mouse 
genome build 36.1 reference assembly (C57BL/6J). The C57BL/6J strain was used as the 
reference strain compared to 129S1/SvImJ strain. 
Results 
Cardiac hypertrophy in Egfr wa2/wa2 mice is modified by genetic background. Distinct 
strain-dependent differences were found in heart and body weights by three-months of age in 
Egfr wa2/wa2 mice.  As seen in Figure 5-1 A, heart weight (HW) was significantly increased in 
B6 compared to F1 and 129S1-Egfr wa2/wa2 mice (284.50±22.63 mg B6, 138.00±4.71 mg F1, 
130.27±5.62 mg 129S1, p<0.0001) and B6-Egfr wa2/+ littermates (see Chapter 3). Reduced 
EGFR activity also led to variable decreases in body weight (BW) in adult homozygous mice 
compared to heterozygous littermates. For example, three month-old 129S1-Egfr wa2/wa2 mice 
weighed approximately 15% less than heterozygous littermates, compared to only a 3.8% and 
4.6% decreased body weight in F1 and B6-Egfr wa2/wa2 mice relative to respective littermate 
controls. Despite the variable BW (Figure 5-1 B, p<0.01), normalized HW did not differ 
between F1 and 129S1-Egfr wa2/wa2 mice but remained higher in B6-Egfr wa2/wa2 mice 
(11.28±0.75 mg:g B6, 5.38±0.15 mg:g F1, 6.52±0.49 mg:g 129S1, p<0.0001, Figure 5-1 C).  
These data demonstrated that the severity of the cardiac phenotype was strongly dependent 
on genetic background, since environmental conditions were similar. Due to the distinct 
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strain-dependent differences, coupled with ease of measurement, we chose heart and body 
weights as our phenotypic endpoints for subsequent analyses. 
Sexual dimorphism exists in the temporal development of cardiac hypertrophy and 
heart failure in B6-Egfr wa2/wa2mice. While the hearts of B6-Egfr wa2/wa2 mice of both 
genders were consistently heavier than those of B6-Egfr wa2/+ littermates at all timepoints 
analyzed, comparison of B6-Egfr wa2/wa2 heart weights by gender and age revealed sexual 
dimorphism in survival and temporal development of severe cardiac hypertrophy. By three 
months of age, approximately 40% of B6-Egfrwa2/wa2 of male mice but only one female B6-
Egfrwa2/wa2 mouse (10%) (n=43 Egfr wa2 littermates) died, most likely from congestive heart 
failure. Although there were no significant differences by gender in heart or lung weights in 
surviving three-month-old B6-Egfr wa2/wa2 littermates, by 4-5 months the hearts of B6-Egfr 
wa2/wa2 male mice were significantly larger than those of female B6-Egfr wa2/wa2 mice (Figure 
5-1 D and Table 5-2). Despite increased mortality in B6-Egfr wa2/wa2 male mice, cardiac 
function as assessed by echocardiography was more severely depressed in female B6-Egfr 
wa2/wa2 mice (25.75±2.93 %FS B6-Egfr wa2/wa2 females, 31.35±1.26 % FS B6-Egfr wa2/wa2 
males, Table 5-3). However, these differences may have reflected the exclusion of the most 
severely affected males from echocardiography studies due to significant mortality.   
Sexual dimorphism was also noted with other cardiovascular endpoints.  For example 
mean arterial pressure (MAP) (data not shown), mean aortic peak velocity, and average peak 
systolic pressure gradients were all lower in B6-Egfr wa2/wa2 female mice compared to B6-
Egfr wa2/wa2 male mice (Table 5-3). Although these differences did not reach significance, 
these data suggested that B6-Egfr wa2/wa2 female mice experienced lower afterload compared 
to B6-Egfr wa2/wa2 male mice.  By 9 months of age, the hearts of B6-Egfr wa2/wa2 female mice 
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were significantly larger hearts than B6-Egfr wa2/wa2 male mice of all ages (Figure 5-1 D), 
suggesting either females survived longer with hypertrophy or there was a temporal delay in 
the development of severe hypertrophy. Consistent with previous findings in surgical models 
of pressure overload in B6 mice[43], these data suggested that female sex conferred a 
protective effect for cardiac hypertrophy and heart failure secondary to congenitally-induced 
pressure overload.   
Cardiac phenotype of F2 Egfr wa2/wa2 progeny. To further assess the effects of genetic 
background on cardiac hypertrophy, we intercrossed F1-Egfr wa2/wa2 mice to generate F2-Egfr 
wa2/wa2 progeny. Because B6-Egfr wa2/wa2 homozygous females exhibited variable lactation 
defects, while B6-Egfr wa2/wa2 male mice had early mortality, F1 progeny were derived by 
crossing B6-Egfr wa2/+ dams to 129S1-Egfr wa2/wa2 sires. Since F1-Egfr wa2/wa2 female mice 
successfully supported large litters, F1-Egfr wa2/wa2 mice were subsequently intercrossed to 
produce 190 F2 offspring.  At necropsy (three months of age), both sexes were equally 
represented in our F2 panel (48.5% female, 51.5% male), ruling out obvious gender bias in 
survival.  However, there was evidence of sexual dimorphism in the cardiac phenotypes of 
these mice. A histogram of total distribution of gross HW from our F2 panel is depicted in 
Figure 5- 2 A, while scatterplots comparing HW by gender in parental, F1 and F2-Egfr wa2/wa2 
mice is shown in Figure 5-2 B.  Arrows demark the heaviest heart weight from 129S1-Egfr 
wa2/wa2 mice (180 mg, blue arrow) and the lightest heart weight from the B6-Egfr wa2/wa2 mice 
(220 mg, red arrow) as reference points.  As expected, mean HW of B6 parental mice was 
significantly higher than all other groups (Figure 5-2 B, ANOVA p<0.0001), consistent with 
the hypothesis of dominant 129S1 protective modifiers of cardiac hypertrophy. 
Approximately 18% of the F2 panel had a HW > 220 mg, yet within this subset of severely 
139 
 
affected mice, over 75% were male mice. Similar results were obtained when using H:BW as 
the phenotypic endpoint (data not shown). Since by three months of age, the hearts of both 
male and female B6-Egfr wa2/wa2 mice are enlarged, we concluded that protective 129S1 
genetic modifiers must have interacted strongly with female gender in the F2 population. 
   Body weight was normally distributed (Figure 5- 2 C), but showed greater variability 
than in parental Egfr wa2 lines or F1 progeny (Figure 5- 2 D).  In male mice, BW differed 
significantly by genetic backgrounds, with the highest mean BW in F2 mice (29±4g F2 Egfr 
wa2/wa2 versus 27 ±0.25g B6-Egfr wa2/wa2 versus 28±3g F1-Egfr wa2/wa2 versus 24 ±4g 129S1 
Egfr wa2/wa2, p<0.005). The mean BW of F2 female mice fell within the BW range of parental 
and F1 female mice.  Normalized HW showed a distribution similar to HW (data not shown); 
moreover, there was little correlation between HW and BW (Figure 5-2 E, R2=0.10).  
Comparison of echocardiographic parameters, heart weights and histological sections 
in three-month-old F2-Egfr wa2/wa2 littermates revealed remarkable variation in cardiac 
hypertrophy, aortic valve size, fibrosis, and cardiac function (Table 5-4, and Figure 5-3). 
Since these mice were age and sex-matched littermates, sharing the same cage and uterine 
environment, this highlights the significant contribution of genetic modifiers to phenotypic 
expression. Among these littermates, the most severely affected mouse (# 61) had the 
heaviest heart weight, depressed systolic function, enlarged LV chamber, affected valves, 
and cardiac fibrosis, replicating the phenotype of the B6-Egfr wa2/wa2 parental line. 
Interestingly, mouse #60 had normal aortic valves. Since aortic valves were consistently 
enlarged in B6 and 129S1-Egfr wa2/wa2 congenic lines and F1 Egfr wa2/wa2 offspring, this 
suggests that some combination of B6 and 129S1 genetic modifiers was able to compensate 
for reduced EGFR activity during valvular development.  
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Mapping modifiers of cardiac hypertrophy. To map the genes that modify cardiac 
hypertrophy, progeny from the F2 intercross were used in a genome-wide scan for linkage. 
Four hundred and eighty two (482) informative SNPs were chosen with an average spacing 
of 3.4 cM to detect QTLs linked to HW, H:BW and BW.  For the F2 intercross, the initial 
genome screen included 56 progeny chosen from the extreme high and low ends of the heart 
weight distribution curve (>0.5 STD).  No markers reached suggestive or significant 
thresholds when the entire cohort was analyzed using HW, H:BW or BW as the phenotypic 
endpoint. However, when gender was used as a covariate, two loci were suggestively linked 
to heart weight (Figure 5-4, marker 9.033.451 on chromosome 9, and marker rs3686531, 
chromosome 16, p<0.63).    By partitioning the panel by sex, we determined that the QTL on 
chromosome 9 was significantly associated with male heart weight (p<0.05), while the 
marker on chromosome 16 was suggestively associated with female heart weight (p<0.63, 
summarized in Table 5-4). An additional marker on chromosome 12 (rs3686531, p<0.63) 
was suggestively linked to male heart weight. Two markers in male mice were also 
suggestively linked to BW (rs8254399, chromosome 9 and rs1348167, chromosome 12, 
p<0.63).   
An overlay of single marker association tests for all three endpoints in male F2 
progeny (Figure 5-5 A) demonstrated that QTLs for HW and H:BW were identical, but did 
not overlap BW QTLs. To show a relationship between phenotype and genotype, log HW 
was plotted against genotype at the marker at the chromosome 9 and chromosome 12 loci 
that had the highest LOD score (marker 9.033.451 and  marker rs3686531, Figures 5-5 B and 
C respectively).   A homozygous B6 genotype (B6/B6) at the chromosome 9 locus was more 
often associated with a higher HW than a heterozygous (B6/129S1) or homozygous 
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(129S1/129S1) genotype in male mice.  Conversely, the locus on chromosome 12 appeared 
to contain 129S1 susceptibility modifier(s), as a homozygous 129S1 genotype 
(129S1/129S1) was more often associated with a higher HW.  When single marker 
association tests were repeated on the male cohort using BW as a covariate, the LOD score 
on for the QTL on chromosome 9 increased to 6.39 (p<0.01), and an additional QTL on 
chromosome 1 was identified (gnf01.132.831, LOD 3.23, p<0.63) suggesting BW dependent 
effects for these loci (Figure 5-6). Two markers in F2 male mice were also independently 
linked to BW (Figure 5-7).  Interestingly, a homozygous 129S1 genotype was more often 
associated with higher BW in F2 male mice at both loci, an unexpected result given the 
significantly lower BW in male 129S1 Egfr wa2/wa2 mice relative to heterozygous controls and 
B6 and F1 Egfr wa2/wa2 male mice.  An overlay of single marker association tests in the female 
cohort is shown in Figure 5-8 A, identifying a single QTL on chromosome 16. To show a 
relationship between phenotype and genotype, log HW was plotted against genotype at the 
marker at the chromosome 16 locus that had the highest LOD score (marker 4220927, Figure 
5-8 B). A homozygous B6 genotype (B6/B6) at the chromosome 16 locus was more often 
associated with a higher heart weight than a heterozygous (B6/129S1) or homozygous 
(129S1/129S1) genotype in female mice. The LOD score for the QTL on chromosome 16 
showed little difference when analyzed using BW as a covariate, suggesting BW independent 
effects (Table 5-5). The discovery that disparate loci modulate the same phenotype (cardiac 
hypertrophy) in male and female F2 mice supports the observed sexual dimorphism in the 
cardiac phenotype.   
In order to identify additional QTLs whose effects might have been masked by 
dominant modifier loci, we performed covariate scans (using the QTL on chromosome 9 and 
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the QTL on chromosome 16) on the entire mapping panel. Additional modifiers of heart 
weight were identified on chromosome 1 (rs3711079, LOD 7.32, p<0.05), chromosome 15 
(rs13482485, LOD 4.72, p<0.63) and chromosome 19 (rs1348389, LOD 5.37, p<0.63). 
SNPs density and polymorphism for C57BL/6J versus 129S1/SvImJ strains within 
candidate QTL regions. Polymorphisms (the difference in genome sequences in each strain) 
can be used to map QTL regions because these variations correlate with phenotypic traits 
[44, 45]. Using the SNP collection from the Jackson Laboratory  Mouse Phenome database 
(MPD), which contains ~10 million SNP locations, we compared haplotypes between 
C57BL/6J and 129S1/SvImJ genomes in regions near QTLs identified on chromosome 9 and 
16 linked to cardiac hypertrophy. Regions spanning a 1.5 LOD score confidence interval 
around each locus are depicted in Figure 9.  For the region near the chromosome 9 QTL (A) 
there is a major region (spanning approximately 4 Mb) with high SNP diversity between B6 
and 129S1. The marker with the highest LOD score (9.0233.451, LOD 4.49) is located at 
32.67 Mb, approximately at the start of this highly variable region. Approximately thirteen 
genes map to this region, all of which have SNPs that differ between B6 and 129S1 strains 
within non-coding regions.  Four of these genes have known SNP variation within coding 
regions: kin of IRRE like 3 (Kirrel3), ST3 beta-galactoside alpha-2,3-sialyltransferase 4 
(St3gal4), CAM-related/down-regulated by oncogenes (Cdon), STT3, subunit of the 
oligosaccharyltransferase complex, homolog A (Stt3a), and fasciculation and elongation 
protein zeta 1(zygin I) (Fez1).  
There are two regions surrounding the QTL located on chromosome 16 with high 
SNP variability, spanning 5 or 6 Mb (Figure 5-8 B).  The marker with the highest LOD score 
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on chromosome 16 (rs4220927, LOD 4.14) is located at 95.31 Mb, falling within the more 
proximal high variability SNP region. Approximately thirty-one known genes are mapped to 
this region. All but five have SNP variation within the non-coding regions of the gene, while 
fifteen have variation within the coding regions. However, since other genes within this 
region may have SNP variation that has not been detected, examined or reported at this time, 
we cannot exclude gene candidates based on haplotype comparison. 
Discussion 
Using a genetically sensitized disease model, we identified modifier loci located on 
chromosomes 9 and 16 associated with cardiac hypertrophy arising from chronic pressure 
overload. Interestingly, these loci individually modulated the hypertrophic response in male 
(chromosome 9 QTL) or female (chromosome 16 QTL) F2-Egfr wa2/wa2 mice, consistent with 
sexual dimorphism in the cardiac phenotypes of the F2 progeny and B6 parental congenic 
line. The phenotype/genotype relationships (Figures 5-5 B and 5-8 B) also supported our 
hypothesis that the 129S1 inbred strain contributed a dominant resistance allele to the cardiac 
hypertrophy phenotype in this model.  
Since collectively these modifiers did not account for 100% of the phenotypic 
variance, by holding these loci constant, we detected three additional modifiers of heart 
weight on chromosomes 1, 15 and 19. Because the observed effects are continuous, we 
assume that the interaction of additional modifiers with weaker effects may be at work but 
fall below the threshold for detection. It should also be noted that there was considerable 
variation of the cardiac phenotype within the parental B6-Egfr wa2/wa2mice, suggesting that 
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subtle environmental effects, experimental error, and/or stochastic events also contribute to 
the variance.  
Comparison of the B6 and 129S1 haplotypes revealed one region of high SNP 
variability within the 1.5 CI for the chromosome 9 QTL, and two regions of high SNP 
variability within the 1.5 CI for the chromosome 16 QTL. Within these highly variable 
regions, there are a large number of genes that are reported to influence EGFR activity, 
inflammation, or cardiac development based on literature review. We anticipate that 
inclusion of the entire F2-Egfr wa2/wa2 mapping panel, allowing detection of additional 
recombination events within these regions, will further refine the loci.  Future studies include 
comparative analysis of cardiac gene expression and protein levels in B6 and 129S1-Egfr 
wa2/wa2 mice, which we expect will narrow the list of potential candidate genes.  
It is unclear if the major modifiers identified herein influence resistance to aortic 
valve disease or altered cardiomyocyte response to chronic pressure overload. Aortic leaflet 
size was highly correlated with heart weight and peak systolic pressure gradients in B6-Egfr 
wa2/wa2 mice. Additionally, pathological changes unique to the B6-Egfr wa2/wa2 aortic valves, 
coupled with progressively elevated peak aortic velocities, mimicked calcific degenerative 
aortic stenosis. In the etiology of this common valvular disease, calcification and other 
pathological changes gradually restrict systolic valve opening, and symptoms and LVH 
rarely occur until valve opening is decreased by seventy-five percent [46, 47]. Since the 
cardiac valves of F2-Egfr wa2/wa2 littermates varied in size, dominant 129S1 modifiers may 
have curtailed cardiac valve overgrowth in some mice, and in this manner prevented the 
pathophysiological responses observed in the B6 congenic mice.  In this scenario, other 
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129S1 modifiers would have played a supportive role by buttressing cardiac function with 
increased afterload. 
A limitation of this study is that we have not assessed EGFR activity, protein, or 
transcript levels in the hearts of F2-Egfr wa2/wa2 mice. However, previous experiments 
demonstrated that EGFR protein and transcript levels, and ligand-induced EGFR and 
ERK1/2 activity did not significantly differ by genetic background in the hearts and livers of 
Egfr wa2/wa2 mice (see Chapter 3).  All 56 mice selected for genotyping had characteristic 
curly coats and whiskers, and typed identically at markers in close proximity (~3Mb) to the 
Egfr waved-2 locus, confirming maintenance of a homozygous state in the F2 progeny. Thus, 
alterations in EGFR activity or expression would be due to a trans rather than a cis effect. 
GPCR agonist-induced transactivation of EGFR has recently been linked to 
pathological processes underlying common cardiovascular diseases, including cardiac 
hypertrophy, vascular smooth muscle proliferation, fibrosis and vasoconstriction [48-54]. 
Consequently, blocking EGFR transactivation (via metalloproteinase inhibition,  preventing 
conversion of EGF ligands into their active form) is proposed as a novel therapy for the 
treatment of hypertension and LVH [55] [56]. However, EGFR activity also provides 
significant cardioprotection against the detrimental effects of sustained beta-adrenergic 
stimulation and acute stress [57, 58].  Along with our studies, these data suggest that 
continuous pharmaceutical inhibition of EGFR in cardiac syndromes with increased afterload 
may exacerbate disease in some individuals; moreover the severity may be gender-
dependent. Identification of genetic modifiers using the Egfr wa2 model may help to further 
define the role of EGFR in the pathogenesis of common cardiac diseases.
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rs13475709 1 6.65693 
rs3703103 1 10.0838 
rs3655978 1 13.5322 
rs13475735 1 15.1699 
rs3711079 1 22.1371 
rs3711203 1 28.944 
rs13475794 1 32.3685 
01.035.266 1 34.7676 
rs3706514 1 38.7405 
rs3677272 1 40.8222 
rs13475845 1 45.3732 
rs13475881 1 58.6336 
rs6322485 1 63.4978 
rs6293581 1 64.9845 
rs3697638 1 68.0919 
mCV22884877 1 77.8988 
rs13475955 1 83.5477 
01.087.139 1 86.8537 
rs13475960 1 89.115 
rs13475985 1 92.8572 
rs13476005 1 98.2719 
CEL-1_102831225 1 102.816 
gnf01.107.327 1 107.388 
rs13476049 1 110.137 
01.118.639 1 115.842 
rs13476079 1 119.241 
rs13476086 1 122.097 
gnf01.124.355 1 124.564 
gnf01.126.387 1 126.608 
rs13459051 1 130.755 
gnf01.132.831 1 133.12 
rs6194543 1 155.704 
rs3661305 1 161.482 
UT_1_175.440616 1 171.553 
rs13476259 1 177.236 
rs13476288 1 185.763 
rs13476300 1 189.831 
01.193.155 1 192.148 
rs3680350 2 3.88002 
rs6331390 2 5.89134 
rs13476334 2 7.31452 
rs3719255 2 10.6948 
rs3699934 2 36.109 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-1. Informative markers used for SNP genotyping. 
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rs13476448 2 39.8218 
rs3658919 2 54.1598 
rs3672719 2 58.1903 
rs13476535 2 61.6873 
rs6367022 2 73.9189 
rs3694656 2 97.0492 
rs3674361 2 99.9858 
rs3143810 2 103.135 
rs6318808 2 109.841 
02.113.755 2 112.066 
rs13476739 2 121.108 
rs8251635 2 125.043 
rs13476765 2 128.215 
rs4223510 2 131.595 
rs13476785 2 134.502 
02.140.785 2 138.844 
UT_2_156.443943 2 155.56 
rs3691210 2 157.736 
rs3664408 2 161.121 
rs3712766 2 165.751 
rs3714936 2 168.88 
rs3668691 2 172.482 
rs8238755 2 174.163 
rs6187766 2 180.024 
rs6402916 2 182.308 
rs6345660 3 16.8672 
rs3677150 3 20.7694 
rs6373308 3 26.0093 
rs13477048 3 32.895 
rs3714497 3 39.71 
rs13477144 3 61.4248 
rs3722255 3 63.4826 
rs3674810 3 68.2438 
rs6351657 3 72.7604 
rs3686804 3 79.4384 
rs3699123 3 82.5009 
rs3670634 3 87.3056 
03.090.273 3 89.2967 
rs3708085 3 93.1366 
rs3671622 3 102.176 
rs6188615 3 104.812 
rs13477320 3 108.837 
rs6406405 3 112.047 
rs3718783 3 120.545 
rs13477384 3 124.645 
03.131.780 3 130.962 
rs13477421 3 134.033 
rs13477451 3 140.604 
rs6258013 3 142.785 
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rs3710548 3 146.168 
gnf03.151.421 3 147.861 
rs3656403 3 153.818 
03.157.668 3 156.856 
04.003.476 4 3.47653 
rs13477542 4 6.63814 
rs13477549 4 8.73086 
rs13477554 4 9.87607 
rs13477566 4 13.031 
04.017.889 4 18.2352 
gnf04.018.158 4 21.4202 
rs13477612 4 24.7825 
04.032.692 4 32.8548 
rs3702229 4 39.295 
rs13477681 4 46.1892 
rs13477699 4 50.6966 
04.060.127 4 62.1567 
rs3023981 4 69.5328 
rs13477785 4 75.5327 
rs3700579 4 83.343 
rs3707373 4 86.3369 
rs13477832 4 88.5409 
rs4136370 4 90.7473 
rs3663299 4 93.825 
rs3705454 4 98.3418 
04.106.358 4 107.736 
rs3659850 4 110.671 
rs13477920 4 113.677 
gnf04.117.102 4 120.837 
gnf04.119.329 4 123.444 
rs3661158 4 129.375 
rs3680937 4 133.631 
rs4136314 4 144.458 
rs6230717 4 146.889 
rs3697097 4 149.387 
rs3696703 4 154.215 
rs6245801 5 7.49898 
rs3714258 5 11.8519 
rs13478120 5 17.3349 
05.020.074 5 20.9777 
rs13478142 5 22.6867 
rs13478151 5 25.2363 
rs6196732 5 32.3251 
rs3703261 5 38.9604 
rs3656439 5 44.1853 
rs3023045 5 49.9486 
CEL-5_52953963 5 53.6994 
rs6339023 5 57.5404 
rs3090667 5 59.5946 
149 
 
rs6187409 5 62.1651 
rs3656989 5 65.5703 
rs6409508 5 72.5031 
rs3153753 5 76.0782 
rs13478349 5 79.8294 
rs3678577 5 84.5716 
rs3667067 5 88.1744 
rs13478390 5 91.3025 
CEL-5_93945748 5 95.8521 
rs6245715 5 97.1918 
rs3721248 5 100.573 
rs13478476 5 114.813 
rs3653889 5 118.742 
rs13478500 5 122.809 
rs3711495 5 125.381 
rs13478536 5 131.492 
rs3711751 5 135.889 
rs13478605 6 4.41233 
rs13478612 6 6.51136 
CEL-6_10519419 6 10.7529 
rs13478640 6 15.7343 
06.016.811 6 16.9081 
06.026.095 6 26.1231 
rs13478687 6 29.8932 
rs3678887 6 32.2382 
rs3696518 6 43.9976 
rs3718512 6 50.3202 
rs13478758 6 53.0796 
CEL-6_56528034 6 56.5317 
rs3710429 6 75.5541 
rs13478845 6 79.0147 
rs3152159 6 82.7691 
06.086.443 6 86.0185 
rs3671004 6 88.7749 
rs3683775 6 91.328 
gnf06.093.201 6 94.3935 
UT_6_102.533298 6 100.958 
rs3722170 6 104.979 
gnf06.106.186 6 107.467 
rs3723352 6 111.513 
mCV24115224 6 114.667 
rs3716551 6 118.495 
UT_6_123.37228 6 121.704 
rs3688358 6 131.701 
rs6400392 6 139.362 
rs3705112 6 144.206 
rs13479087 6 145.872 
07.003.727 7 3.9089 
rs13479119 7 8.88062 
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CEL-7_6264134 7 10.9586 
rs6361142 7 15.3037 
rs3726684 7 16.7142 
rs3724397 7 20.9873 
rs3156053 7 25.2359 
rs13479186 7 31.2881 
rs3720735 7 33.6747 
rs8255275 7 42.3432 
rs3680765 7 45.6178 
rs13479251 7 48.6384 
rs3663313 7 52.3752 
rs3719301 7 60.1547 
07.056.991 7 64.7128 
rs3683475 7 66.4322 
rs3716002 7 69.978 
rs3671471 7 72.289 
rs3700384 7 76.504 
07.074.764 7 82.2714 
rs3658777 7 85.551 
07.080.264 7 87.8297 
rs3717027 7 99.9414 
rs3711721 7 103.122 
rs3726501 7 107.744 
rs13479471 7 111.049 
rs6277857 7 114.275 
rs6322316 7 116.616 
rs3682038 7 122.437 
07.121.767 7 129.276 
rs3663988 7 135.733 
rs13479567 7 140.273 
CEL-8_7689226 8 7.66771 
rs6343961 8 14.4544 
08.020.650 8 20.578 
gnf08.021.719 8 22.0073 
rs3702973 8 25.198 
rs13479678 8 29.4664 
rs13479702 8 34.9055 
rs13479731 8 41.9157 
rs13479741 8 45.879 
rs13479748 8 48.2907 
CEL-8_51734273 8 51.3331 
rs13479784 8 57.1494 
08.068.088 8 66.5381 
rs3722665 8 71.0682 
rs13479840 8 73.9517 
rs3667484 8 82.005 
rs3724111 8 86.4835 
rs13479916 8 90.0343 
mCV23424042 8 101.132 
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rs6180306 8 105.241 
gnf08.109.993 8 107.369 
gnf08.119.598 8 116.994 
rs13480019 8 120.28 
rs3693295 8 121.589 
rs3667341 8 127.183 
09.016.217 9 16.2174 
09.019.168 9 19.1827 
rs6181976 9 23.8556 
rs13480120 9 30.3768 
09.033.451 9 32.6568 
rs13480142 9 37.066 
rs13480151 9 40.0571 
rs13480192 9 51.9285 
rs6206488 9 54.9415 
09.059.359 9 57.2807 
rs6358810 9 60.5322 
rs3664533 9 65.8425 
09.068.487 9 68.2968 
rs3721056 9 71.0668 
rs6292345 9 75.3386 
09.081.324 9 81.0607 
rs13480312 9 83.8923 
rs3698443 9 87.1572 
rs3693091 9 90.0332 
rs3657346 9 102.885 
rs6375364 9 106.149 
09.114.032 9 113.607 
rs6320810 9 114.807 
rs8254399 9 123.748 
10.003.693 10 6.5385 
rs3664101 10 9.30896 
rs3678286 10 17.7465 
rs13459119 10 20.0503 
rs3679120 10 22.678 
rs13480579 10 35.978 
rs13480605 10 45.6246 
rs3696307 10 53.5612 
rs6326263 10 69.3636 
rs13480652 10 74.2681 
rs13480657 10 76.3677 
rs6331511 10 92.8158 
10.097.478 10 97.5105 
rs13480736 10 102.486 
rs13480757 10 107.823 
CEL-10_113177617 10 112.906 
rs13480777 10 115.64 
mCV25429984 10 118.721 
rs3680343 10 126.385 
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rs3676330 10 127.712 
rs13480836 11 3.5062 
rs13480853 11 7.36709 
gnf11.006.472 11 8.98622 
rs13480871 11 11.5095 
rs13480881 11 14.3308 
rs13480889 11 17.4168 
rs3708339 11 21.8094 
rs4139111 11 37.2544 
rs6317915 11 40.37 
rs13480996 11 43.5097 
rs13481011 11 46.8852 
rs3698063 11 54.2785 
rs3024185 11 63.1785 
rs3694522 11 70.7883 
rs3701609 11 73.3452 
rs3705751 11 75.7884 
rs13481126 11 83.3534 
gnf11.093.966 11 87.4335 
rs3697441 11 89.6498 
rs13481185 11 99.8439 
rs3723163 11 104.089 
rs3669823 11 108.073 
13.084.759i 11 110.713 
11.114.529 11 113.765 
rs13481245 11 115.719 
rs3661724 11 117.795 
12.003.413 12 3.46528 
rs13481285 12 6.96789 
rs3717933 12 11.1401 
rs13481308 12 13.3891 
rs3717860 12 22.5655 
rs13481355 12 24.4093 
rs13481367 12 26.8325 
rs13481380 12 29.937 
C12.033.955 12 33.3512 
rs13481412 12 39.4976 
rs3671614 12 44.9341 
rs13481452 12 50.1111 
rs3705833 12 55.8877 
rs13481500 12 62.4094 
rs6383133 12 67.1023 
CEL-12_66272019 12 68.9488 
rs3655558 12 72.6811 
mCV23169261 12 74.9238 
CEL-12_85059563 12 87.9484 
rs13481601 12 94.2983 
rs3666004 12 96.9617 
CEL-12_108727612 12 111.45 
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rs3023711 12 113.911 
rs3686531 12 117.516 
rs3695486 13 4.04572 
rs13481672 13 5.284 
rs13481680 13 8.30161 
rs6348604 13 14.7799 
rs6345767 13 18.7634 
rs8267056 13 23.0666 
rs3710348 13 30.6389 
gnf13.035.637 13 36.9378 
rs13481775 13 39.6243 
rs13481788 13 43.0729 
gnf13.045.330 13 46.7262 
rs3683883 13 54.1935 
rs3690198 13 59.8269 
rs6220659 13 62.0257 
rs13481863 13 66.1198 
rs3680075 13 71.2797 
rs3679222 13 74.4116 
rs13481908 13 79.1053 
CEL-13_85525049 13 85.9409 
rs13481944 13 90.0658 
rs4229988 13 92.581 
rs3090371 13 99.8353 
rs13481998 13 104.265 
rs6316705 13 113.107 
rs6397687 13 116.6 
rs3710916 14 5.82962 
rs13482048 14 6.8277 
rs6352512 14 9.0142 
gnf14.007.267 14 12.4077 
rs6339205 14 14.9744 
rs3687889 14 17.3472 
rs6175633 14 19.8518 
rs3682880 14 23.0124 
rs13482117 14 26.9072 
rs13482132 14 31.7632 
rs3689402 14 41.0937 
14.040.618 14 44.5906 
rs13482177 14 45.9768 
rs13482191 14 49.5132 
rs3699179 14 56.6365 
rs3719672 14 62.387 
rs4230463 14 65.2486 
rs13482259 14 71.3111 
rs3665356 14 73.2453 
rs6379772 14 93.9578 
rs6179144 14 95.6553 
rs4230545 14 98.9074 
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rs3678059 14 100.841 
rs4139535 14 103.989 
rs13482374 14 105.949 
rs3671398 14 111.44 
CEL-14_110783830 14 112.865 
rs13459176 15 3.10499 
rs13482423 15 8.7464 
CEL-15_15919629 15 16.0696 
rs3696823 15 19.1654 
rs3714169 15 21.871 
rs13482485 15 25.5535 
rs13482507 15 31.5535 
rs8267917 15 33.3591 
15.037.853 15 37.9183 
rs4230714 15 44.4202 
rs4222076 15 54.8993 
rs13482602 15 61.4964 
rs6213684 15 67.9314 
rs3696311 15 71.2359 
rs3682805 15 78.2732 
rs3721372 15 80.4901 
CEL-15_83750824 15 83.4774 
rs3707587 15 88.1807 
rs13482722 15 94.854 
rs13482738 15 99.7796 
16.005.872 16 6.05262 
rs4158165 16 7.31967 
rs4161857 16 11.0539 
rs4165081 16 19.4331 
rs4167574 16 29.3403 
rs4179715 16 44.1695 
rs4184315 16 48.4268 
rs3682166 16 57.2872 
rs3693190 16 65.2716 
rs4201385 16 72.141 
rs4205586 16 75.6071 
rs3703235 16 78.5948 
rs4211772 16 84.1393 
rs4213876 16 87.154 
rs4215932 16 88.9837 
rs4220927 16 95.3101 
rs3696981 16 97.7769 
rs3721166 17 3.24696 
rs13482893 17 13.979 
rs6384940 17 27.2417 
17.037.607 17 36.0121 
rs3702604 17 38.9955 
rs13482994 17 41.5491 
rs3709891 17 47.1107 
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rs6191282 17 50.2134 
rs3714819 17 53.5104 
rs4231558 17 55.2074 
17.059.952 17 59.747 
rs13483068 17 62.2362 
rs3727008 17 66.0056 
rs6155172 17 69.9337 
rs6280326 17 72.0723 
rs3656948 17 74.7631 
rs3718983 17 77.5827 
rs13483133 17 81.3665 
rs6336971 17 85.0605 
rs3698948 17 87.0856 
rs6313030 17 88.8606 
rs6312389 18 6.80617 
rs3660245 18 9.47735 
gnf18.010.030 18 13.1482 
rs6358426 18 16.775 
rs6303064 18 19.9716 
rs13483251 18 23.1631 
rs3662641 18 25.8729 
rs3723870 18 33.9455 
rs13483314 18 40.3204 
rs13483326 18 43.1267 
CEL-18_46082735 18 46.0159 
rs3722312 18 52.7245 
rs13483368 18 54.8335 
rs3705107 18 57.8132 
CEL-18_60377359 18 60.251 
rs13483398 18 63.4765 
18.067.071 18 67.0452 
rs13483427 18 70.8616 
rs3715003 18 79.0183 
18.081.133 18 81.0613 
rs13483561 19 20.8292 
rs6291559 19 27.2732 
rs13483591 19 30.514 
rs6185741 19 38.5364 
rs3655407 19 40.1534 
rs13483643 19 45.2086 
rs3023496 19 48.0383 
rs13483662 19 50.7111 
gnf19.052.359 19 53.0789 
rs3654713 19 54.9332 
rs13483689 19 57.3624 
19.060.549 19 60.6807 
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Table 5-2. Organ weights of three-to-five month old Egfr wa2 littermates. BW, body weight; HW, heart weight; H:BW, normalized 
heart weight, LuW, lung weight;  LiW, liver weight; Lu:BW, normalized lung weight; Li:BW, normalized liver weight. 
Comparison by genotype to sex matched littermates*p<0.05 **, p<0.01***,p<0.001. 
 
 
B6 
 
F1 
 
129S1 
 wa2/+ wa2/wa2 wa2/+ wa2/wa2 wa2/+ wa2/wa2 
Sex F M F M F M F M F M F M 
N 6 10 6 10 8 5 8 5 10 7 10 7 
BW (g) 26.2±1.3 30.6±0.9 24.7±0.5 29±1.4 24.6±0.9 27.8±0.7 24.7±0.7 27.6±1.0 25.0±1.2 30.3±1.9 20.9±1.0* 26.5±1.9 
HW 135.4±3.9 153.5±6.5 261.0±9.7*** 339.8±29.2*** 112.6±1.3 131.4±8.4 167.5±27.9* 169.8±26.1 143.9±6.2 155.3±8.1 124.8±5.1 154.8±6.4 
H:BW 5.5±0.2 5.04±0.19 10.1±0.5** 11.3±0.9*** 4.6±0.2 4.7±0.3 6.8±1.1 6.2±1.0 5.8±0.3 5.2±0.3 6.1±0.3 5.9±0.3 
N 3 3 3 3 4 4 4 4 3 3 3 3 
LuW 149.3±1.9 149.8±0.3 174.0±2.0* 170.5±2.2* 130.3±9.9 158.0±40 155.3±12.8 162.5±2.5 146.6±15 135.0±5.0 142.00±4.0 128.07±4.37 
LiW 1150.3±22.1 1283.4±15.7 1322.0±148.0 1372.3±145.6 969.7±33.8 973.0±27.0 1141.8±60.8* 976.5±26.5 967.7±56.3 1001.5±1.5 836.0±29.0 658.5±45.7* 
Lu:BW 6.2±0.3 5.5±0.1 6.9±0.4* 6.4±0.3* 5.2±0.1 5.8±1.8 5.6±0.6 5.3±0.1 5.9±0.6 4.4±0.2 7.2±0.4 5.8±0.2 
Li:BW 47.9±1.6 47.4±1.6 52.8±3.7 51.7 ±3.5 40.0±1.9 35.1±1.0 40.4±3.1 31.7±1.1 39.3±2.8 32.6±0.1 42.4±0.4 29.8±1.8 
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Table 5-3. Echocardiographic parameters in three-to five month old Egfr wa2 littermates. LVED,d, left ventricular end diastolic 
diameter; LVED,s, left end systolic diameter; LVPW,d, left ventricular posterior diastolic wall thickness; LVPW,s, left ventricular 
systolic wall thickness; % FS, percent fractional shortening; RWT, relative wall thickness; HW, heart rate; AoVelocity, peak 
systolic velocity. Comparison by genotype to sex matched littermates *p<0.05,**p<0.01, ***p<0.001 
 
 
 
 
B6 
 
F1 
 
129S1 
           Genotype  wa2/+ wa2/wa2  wa2/+ wa2/wa2  wa2/+ wa2/wa2 
Sex F M F M F M F M F M F M 
N 7 5 7 5 4 4 4 4 8 10 8 10 
LVED, d (mm) 3.48±0.07 3.60±0.05 5.25±0.20*** 4.67±0.17*** 3.72±0.12 3.85±0.05 3.76±0.05 3.70±0.11 3.69±0.11 3.74±0.05 3.16±0.11** 3.52±0.09 
LVED, s (mm) 2.08±0.11 2.16±0.10 3.82±0.30** 3.20±0.10** 2.33±0.13 2.25±0.21 2.55±0.02 2.25±0.09 2.16±0.14 2.18±0.07 1.76±0.15 2.01±0.10 
LVPW, d (mm) 0.90±0.06 1.14±0.17 1.56±0.16* 1.50±0.09* 0.84±0.04 0.81±0.03 0.63±0.02* 0.77±0.03 0.86±0.04 0.83±0.05 0.79±0.07 0.67±0.03 
LVPW, s (mm) 1.27±0.06 1.52±0.20 2.12±0.18** 2.17±0.14** 1.12±0.02 1.06±0.02 0.93±0.01* 1.11±0.06 1.27±0.03 1.13±0.06 1.24±0.10 0.88±0.12 
% FS 40.30±2.31 40.05±2.45 25.75±2.93* 31.35±1.26** 37.59±1.55 41.77±4.63 34.06±1.24 39.32±1.33 41.76±2.45 41.84±1.32 45.10±2.96 42.79±2.78 
RWT 0.52±0.05 0.64±0.10 0.60±0.08 0.65±0.05 0.45±0.23 0.42±0.01 0.34±0.01* 0.42±0.02 0.47±0.03 0.44±0.03 0.52±0/06 0.38±0.01 
HR (BPM) 437±14 450±11 475±20 430±9 461±15 425±12 470±17 445±13 434±10 460±17 449±9 465±9 
N 4 4 4 4 2 2 2 2 4 4 4 3 
Mean Peak 
AoVelocity(cm/s) 106±24 136±26 283±59 357±30 110±9.8 95±6.5 170±8.7 190±15.7 85±1.8 109±2.5 197±30 237±29 
Pressure 
gradient 6.5±3.5 2.5±2.0 17.5±6.5 40.5±13.1 3.5±4.4 3.70±2.80 10±5.7 12±7.7 -2±3.04 1±4.49 8±0.87 15±2.05 
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Figure 5-1. Comparison of mean heart weight (HW,milligrams, mg) (A) mean body weight 
(BW,grams,g) (B) and normalized heart weight (H:BW, mg:g) (C) by genetic background in 
three month-old Egfr wa2/wa2 mice, n=3 mice of each gender. Distribution of heart weight by 
age (in months) in B6-Egfr wa2/wa2 male (solid circle) and female (open circle) mice (D). 
*p<0.05,**p<0.01, ****p<0.0001 
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Figure 5-2 A. Distribution of heart weight in F2 progeny. B. Scatter plot of HW in B6, F1 
(B6x129S1), 129S1 and F2 Egfr wa2/wa2 mice. C) Distribution of body weight (BW) in F2 
progeny. D. Scatter plot of BW in B6, F1 (B6x129S1), 129S1, and F2 Egfr wa2/wa2 mice. E. 
Correlation between HW and BW in F2 Egfr wa2/wa2 mice. Blue arrow point to highest values 
from 129S1 Egfr wa2/wa2 parentals and red arrow to lowest value from B6-Egfr wa2/wa2 
parentals.  
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Table 5-4. Representative echocardiographic parameters and organ weights from F2 -Egfr 
wa2/wa2 mice. 
 
  F2 Egfr wa2/wa2 
Mouse # 60 62 61 
HW (mg) 176.9 190.1 332 
H:BW (mg:g) 5.31 6.62 10.31 
BW (g) 33.3 28.7 32.2 
LVED, d (mm) 3.65±0.08 3.92±0.13 5.05±0.05 
LVED, s (mm) 2.32±0.02 2.37±0.07 3.26±0.30 
LVPW, d (mm) 0.75±0.08 1.09±0.06 0.79±0.16 
LVPW, s (mm) 0.90±0.02 1.48±0.11 1.24±0.02 
% FS 36.80±1.70 39.6±0.27 27.04±3.84 
HR (BPM) 447±5 452±2 475±10 
161 
 
Figure 5-3. Representative histological sections from F2 Egfr wa2/wa2 three-month old 
littermates. Arrows point to aortic (AV) and pulmonary (PV) valves. A fibrotic region (FIB) 
near the apex of the most severely affected heart is also indicated. Magnification=1.6x. 
PV 
AV 
PV 
FIB 
AV 
AV 
#60                #62 #61
162 
 
 
Figure 5-4. Single marker association tests for a whole genome scan performed on F2 
progeny, using sex as a covariate. Two suggestive QTLs were identified. 
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Figure 5-5. Single marker association tests for a whole genome scan performed on F2 male 
progeny (A). Interval mapping of the Chromosome 9 locus in F2 male mice and plot showing 
the relationship between cardiac weight and genotype at the 9.033.451 marker in F2 progeny 
(B). Interval mapping of the Chromosome 12 locus in F2 male mice and plot showing the 
relationship between cardiac weight and genotype at the rs3686531 marker in F2 (F1XF1) 
progeny (C). 
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Figure 5-6. Single marker association test for heart weight (HW) in F2 male mice using body 
weight (BW) as a covariate identified an additional QTL located on Chromosome 1 (near 
marker Gnf01.132) Suggestive (37.0%) significant (95.0%) and highly significant (99.0%) 
thresholds are indicated (A). Interval mapping and plot showing the relationship between 
HW and genotype at the Gnf01.132.831 marker in F2 male progeny (B). Suggestive threshold 
is shown as a dotted line. 
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Figure 5-7. Interval mapping and plot showing the relationship between body weight 
(BW) and genotype at the rs8254399 marker on chromosome 9 (A) and rs13481367 
markers on 12 (B) in F2 male progeny. 
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B. Chromosome 16
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Figure 5-8. Single marker association test results for a whole genome scan performed on 
F2 female mice. Each bar represents a single SNP marker (A). Interval mapping of 
chromosome 16 and plot showing the relationship between normalized cardiac weight and 
genotype at the chromosome 16 rs4220927 marker in F2 female progeny (B). Suggestive 
threshold is represented as a dotted line. 
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Figure 5-9. 1.5 LOD CI for QTLs on chromosome 9 (A) and 16 (B) linked to cardiac 
hypertrophy in male and female mice, respectively. Parenthesis denotes regions of high SNP 
variability between B6 and 129S1 strains. Grey bars represent the total number of SNPS 
genotyped per bin, while the red bars represent the number of SNPs per bin that differ 
between the specified strains. 
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Table 5-5. Summary of modifier locus identified using the F2-Egfr wa2/wa2 panel. 
Panel Phenotype Chr Marker 
Peak 
position 
(cM) 
Peak 
position 
(Mgb) 
COVARIATE ANALYSIS 
None Sex BW Chr 9 and 16 QTLS 
LOD p< LOD p< LOD p< LOD p< 
Total 
 
HW 
 
1 rs3711079 6.12 22.14 _ _ 
_ _ _ _ 
7.32 0.05 
9 9.033.451 18.49 32.67 _ _ 4.40 0.63 
_ _ _ _ 
15 rs13482485 9.05 25.55 
_ _ _ _ _ _ 
4.72 0.63 
16 rs4220927 46.45 95.31 
_ _ 
4.43 0.63 
_ _ _ _ 
19 rs1348389 48.97 57.36 
_ _ _ _ _ _ 
5.37 0.63 
Male 
 
 
 
HW 
1 Gnf01.132.831 52.04 113.12 
_ _ _ _ 
3.23 0.63 
_ _ 
9 9.033.451 18.49 32.67 4.82 0.05 
_ _ 
6.31 0.01 
_ _ 
12 rs3686531 82.40 117.52 3.03 0.63 
_ _ _ _ _ _ 
BW 
9 rs8254399 86.37 123.75 3.29 0.63 
_ _ _ _ _ _ 
12 rs13481367 17.73 26.83 3.81 0.63 
_ _ _ _ _ _ 
Female HW 16 rs4220927 46.45 95.31 4.14 0.63 
_ _ 
4.31 ns 
_ _ 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
EGFR activity is essential for proper tissue development, maintenance and repair in 
most organ systems. Conversely, EGFR overexpression or overactivation, particularly in 
epithelial tissues, promotes disease processes such as carcinogenesis.  Thus, a continuous 
balance of EGFR signaling is required for overall fitness and health.   A role for EGFR 
activity in adult tissue homeostasis is typically associated with organ systems that have high 
EGFR expression and retain proliferative or regenerative capacity, such as the skin, gut and 
liver.  Since the ERBBs are expressed at relatively low levels in adult heart, and 
cardiomyocytes are terminally differentiated, the significant and lethal cardiomyopathy 
resulting from targeted inhibition of ERBB2/HER2 activity in cancer clinical trials was 
unexpected [1]. Assisted by genetically engineered mouse models, research has since 
advanced understanding about ERBB2 receptor signaling in cardiac homeostasis and disease, 
leading to  the recent proposal to enhance ERBB2 activity via NRG1 stimulation as a 
strategy for treatment of heart failure and cardiotoxicity [2, 3]. Similarly, by using genetic 
and pharmaceutical models, the work presented herein explored the consequences of 
chronically suppressed EGFR/ERBB1 signaling on cardiac development and homeostasis. 
This effort is particularly timely for several reasons. First, due to innovations in cancer 
therapy and detection, cancer is frequently perceived and treated as a chronic disease [4]. As 
more patients are exposed to EGFR targeted therapies for longer duration, toxicities may 
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pose a greater health risk than predicted in short-term clinical trials, and adverse reactions 
associated with uncommon genetic polymorphisms may be uncovered. Secondly, inhibition 
of EGFR signaling has been proposed as a novel treatment for hypertension and LVH, 
meaning that patients with compromised cardiovascular function may also be chronically 
exposed to these drugs [5-7].  
Since other EGFR-related phenotypes showed strain-dependent penetrance and 
severity [8, 9], we first asked if EGFR-related cardiovascular phenotypes are modulated by 
genetic background. Using congenic B6 and 129S11 Egfr wa2 lines and their F1 Egfr wa2 
offspring, we found significant genetic-background dependent variation in cardiac 
phenotypes, including congenital cardiomyocyte defects, LVH, and development of 
degenerative calcific AS, confirming our hypothesis.  Since physiological studies suggested 
that B6 and 129S1 Egfr wa2 mice had variable pressure differentials across the aortic valve, 
indicating differences in AS severity and load, we next asked if genetic background modified 
the cardiac response to afterload. By constricting the ascending aorta (TAC), we applied a 
similar afterload on the LV of adult wild type B6, 129S1 and F1 male mice. We found 
significant genetic-background dependent variation in cardiac response to TAC, with B6 
genetic modifiers promoting more rapid progression to heart failure accompanied by severe 
pathological responses. Although the duration of the pressure overload was shorter in the 
surgical model, and the cardiomyocytes of 129S1 mice did manifest a hypertrophic response, 
results of this study suggested that resistant 129S1 modifiers sustaining cardiomyocyte 
survival and function contributed to the variable cardiac phenotype.   In order to partition 
EGFR congenital defects from effects on adult cardiac function, we conducted studies where 
adult B6 wild-type mice were chronically exposed to EGFR small molecule inhibitors.  Left 
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ventricular wall thinning, depressed cardiac contractility and increased cardiac cell apoptosis, 
parameters which profoundly impact cardiac function, were observed with pharmaceutical 
inhibition of EGFR activity.  Finally, we employed a genetic mapping study using an F2 
intercross strategy to broadly localize QTLs which modulated EGFR-related cardiac 
phenotypes. Consistent with observed sexual dimorphism in genetic and pharmaceutical 
studies, two QTLs were identified which were independently associated with cardiac 
hypertrophy in male and female F2-Egfr wa2/wa2 mice, respectively. 
Ultimately, we hope that our studies will contribute to understanding EGFR function 
in cardiac biology, as well as provide improved mouse models of common cardiac diseases.  
Growing evidence implies that mitogenic signals activated by EGFR which induce 
proliferation in other cell types trigger a hypertrophic response in terminally differentiated 
cardiomyocytes.  Consistent with other organ systems whose development is dependent upon 
EGFR, our observations suggest a balance of EGFR signaling is also important in 
cardiomyocyte homeostasis, where too much activity instigates a hypertrophic response, 
while too little activity compromises cardiomyocyte survival. During developmental 
timepoints prior to valve formation, we observed defective trabeculation and thinned 
chamber walls in B6 Egfr wa2/wa2 embryos and increased cardiomyocyte apoptosis in B6 Egfr 
wa2/wa2 neonatal pups, comparable to the congenital cardiomyocyte defects in Erbb2 -/- 
embryos [10]. The cardiac phenotype observed with chronic dietary exposure to EGFR 
inhibitors (which probably also target ERBB2) had similarities to the dilated cardiomyopathy 
observed in mice with ventricular-specific ablation of Erbb2 [11, 12].  Taken together, these 
observations suggest that signaling through EGFR/ERBB2 heterodimers or EGFR 
homodimers may also contribute to cardiomyocyte development and survival.  In cancer 
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cells, EGFR/ERBB2 heterodimers generate potent mitogenic and cell survival signals and 
have prolonged signaling compared to EGFR homodimers because of differences in rate of 
receptor endocytosis [13, 14]. If signaling through EGFR/ERBB2 heterodimers is similarly 
prolonged in cardiomyocytes, the relative contribution from ERGFR/ERBB2 heterodimers 
could alter cardiomyocyte apoptosis or hypertrophy. One way to address this question might 
be through primary Egfr wa2cardiomyocyte cultures.   A specific Erbb2 inhibitor, such as 
Herceptin/trastuzumab, could be applied to cultures of Egfr wa2/wa2 and Egfr wa2/+ 
cardiomyocytes and effects on apoptosis, AKT activity and levels of phosphorylated pro and 
anti-apoptotic proteins assessed. Alternatively, Egfr wa2/wa2 mice could be crossed to Erbb2 
cardiac restricted knock-out mice to test the consequences in vivo of reduced EGFR activity 
on the Erbb2 cardiac phenotype.  Given the development of dual inhibitors targeting both 
EGFR and ERBB2 signaling [15, 16], and the recent proposal to target ERBB signaling for 
the treatment of cardiovascular diseases where cardiomyocyte function may be impaired, it 
follows that the relative contributions of ERBB members to cardiac survival should be 
investigated. 
A requirement for EGFR signaling in cardiac valve development has consistently 
been reported [17, 18]. Our studies extend these observations, suggesting that EGFR 
signaling may prevent degenerative pathological processes associated with valvular disease.  
Since we found evidence of significant valvular interstitial cell proliferation and altered 
extracellular matrix (ECM) composition in adult B6 Egfr wa2/wa2 mice, we hypothesize that 
EGFR signaling normally checks valve cellular proliferation and may also play a role in 
ECM stratification or organization during valve remodeling stages. Decreased EGFR 
signaling delays wound healing and exacerbates inflammation in several injury models [19-
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22] and misregulation of these processes may worsen or accelerate valvular disease on the 
sensitive B6 genetic background. Initial results from pharmaceutical studies appeared to 
reinforce our hypothesis, as 100% of the EKB-569 inhibitor treated mice had evidence of 
calcification, compared to 38% of the controls; in addition mean thickness of aortic valve 
leaflets was associated with diet. However, valve thickening was seen in mice fed both 
treated and control diets compared to mice receiving normal chow, while calcification was 
present in valves from all mice fed the control diet in later experiments. Repeating these 
experiments with a different base diet or inbred strain, and performing histological analysis 
of calcification, ECM composition and cellular proliferation would be important in light of 
the Egfr wa2 developmental and post-natal cardiac valve phenotypes. Additionally, the chick 
embryo cardiac cushion explant system might be useful to determine if EGFR inhibitors 
enhance calcification, VIC proliferation or ECM composition in a more controlled 
environment. In addition, by using lower drug concentrations, these in vitro studies would 
reduce off-target effects.  
A conditional Egfr allele (Egfr flox) using a LoxP strategy has been developed in the 
lab, making inactivation of Egfr in specific cell types possible. By crossing the Egfr flox   line 
to lines with cardiomyocyte-restricted Cre recombinase expression, we can obtain mice with 
cardiomyocyte-specific deletion of Egfr. This strategy should allow us to discriminate Egfr-
related effects on cardiac muscle from secondary effects due to congenital valve 
enlargement.  Preliminary characterization of Egfr flox/flox mice that express Cre recombinase 
under the control of the myosin light chain 2v locus (MLC2v Cre/+) has revealed no significant 
differences in survival, baseline cardiac function or cardiac or other organ weights compared 
to Egfr flox/flox or Egfr flox/+ MLC2v Cre/+ controls. However, these mice are on mixed B6/129S1 
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genetic background and recombination efficiency has not been assessed.  Additionally, it is 
possible that cardiac phenotypes arising from cardiomyocyte specific EGFR inactivity may 
be subtle without challenge. Currently, we have B6 Egfr flox congenic lines (N10) and have 
ongoing crosses to both MLC2v and -cardiac myosin heavy chain (αMHC) Cre mice. 
Characterization of cardiac phenotypes of these mice at baseline, and in response to stimuli 
such as pressure overload induced by aortic banding or β-adrenergic stimulation via 
isoprotenol exposure, would further define the role of EGFR signaling in cardiomyocyte 
function and survival. 
A significant portion of interindividual variability in both tumor response to EGFR 
targeted therapies and toxicities appears to be the result of genetic variations both in the 
individual and in the neoplasia [23-25]. Positive response and skin toxicity have been 
connected to germline EGFR polymorphisms within intron 1 that alter its expression 
(Veronese, 2005[26, 27].  Polymorphisms correlating to low EGFR expression and tumor 
resistance to EGFR targeted therapy are found more frequently in persons of Asian ethnicity 
[28, 29]. A rare, but potentially fatal complication of EGFR inhibitor therapy is interstitial 
lung disease, and Japanese patients appear to be at a higher risk for this rare toxicity than 
patients from other nationalities [30]. Sexual dimorphism in EGFR somatic mutations, 
clinical outcome and toxicities with EGFR targeted therapies has also been reported [31]. 
Females more often experience tumor response and positive outcome in cancer clinical trials 
using the EGFR TKI Iressa/Gefinitib for the treatment of non-small lung cell cancer [32-34].  
Since phenotypes of mice with reduced or absent EGFR are highly dependent upon genetic 
background and mimic patient toxicities observed with EGFR targeted therapies, these 
mouse models may prove useful in identifying genetic modifiers of EGFR activity [35].  
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Preliminary studies are underway profiling expression of genes residing within the identical 
by descent (IBD) region of the Chromosome 9 QTL in Egfr wa2/wa2 LV and aortic outflow 
tracts.  Our laboratory has also backcrossed the Egfr wa2 mutation onto the A/J and BTBR T+ 
tf/J genetic backgrounds. Comparison of cardiac phenotypes of these mice coupled with 
haplotype analysis may narrow the candidate region even further.  Transgenic bacterial 
artificial chromosomes (BAC) mice harboring overlapping candidate regions of 129S1 
chromosome 9 QTL on the B6 genetic background could be created and crossed to B6 Egfr 
wa2/wa2 mice. Amelioration of cardiac hypertrophy in Egfr wa2/wa2 mice would provide strong 
evidence of protective 129S1 modifiers. Successful identification of genes modulating the 
Egfr wa2 cardiac phenotypes would advance understanding about the role of EGFR in cardiac 
development and homeostasis, may uncover novel targets for the treatment of common 
cardiac diseases, and assist prediction of cardiotoxicity in sensitive populations. 
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